MODULATION OF T CELL RESPONSE IN TUBERCULOSIS GRANULOMAS by Wong, Eileen
 










Eileen A. Wong 
B.S., University of California, Berkeley, 2008 










Submitted to the Graduate Faculty of 
School of Medicine in partial fulfillment  
of the requirements for the degree of 















UNIVERSITY OF PITTSBURGH 


















It was defended on 
May 15, 2018 
and approved by 
Jennifer Bomberger, PhD, Microbiology and Molecular Genetics 
Robert L. Hendricks, PhD, Microbiology and Molecular Genetics 
Dario A. Vignali, PhD, Immunology 
John V. Williams, MD, Pediatrics 









Tuberculosis (TB) remains a major threat to global health. When an individual is infected with 
M. tuberculosis (Mtb), the causative agent of TB, host immune cells form highly organized 
structures, granulomas, around the bacteria. Granulomas contain Mtb and prevent dissemination, 
but can also serve as a niche for persistence. While host control of Mtb infection involves an 
interplay of innate and adaptive immune cells in the granulomas, T cells have been demonstrated 
to be a critical component. The goal of this dissertation was to define facets of the host immune 
system that modulate the T cell cytokine response in TB granulomas and ways to alter the T cell 
cytokine responses to improve protection through vaccination, by using a non-human primate 
(NHP) model that recapitulates human TB disease and granuloma formation. In the first aim, the 
role of IL-10 in downregulating T cell responses in granulomas was investigated by 
neutralization of IL-10 in Mtb-infected NHPs. Although lack of IL-10 had a transiently increased 
the immune response early in Mtb infection (4 weeks), the presence or absence of IL-10 did not 
affect the overall inflammation, bacterial burden, or disease pathology up to 8 weeks post-
infection. The second aim examined T cell exhaustion in TB granulomas by characterizing 
expression of the inhibitory receptors PD-1, CTLA-4, and LAG-3 on T cells. Low levels of 
expression of the inhibitory receptors suggested few exhausted T cells in granulomas. Moreover, 
T cells expressing inhibitory receptors were still functional and capable of proliferation, 
indicating that these inhibitory receptors may not be a marker of exhaustion in TB. Finally, the 
third aim investigated vaccination strategies to alter granuloma T cell response and confer 
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protection from TB disease. While none of the experimental vaccination strategies were more 
protective than the current vaccine BCG, some of the strategies increased T cell cytokine 
response in granulomas. In summary, the factors investigated in this dissertation were not 
significant contributors to the modulation of T cell responses or Mtb control in TB granulomas, 
but these results further inform the field of the immune response to Mtb for potential future 
vaccines and therapeutics. 
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1.0  INTRODUCTION 
1.1 TUBERCULOSIS: A MAJOR GLOBAL HEALTH PROBLEM 
Tuberculosis, or TB, is one of the leading causes of death worldwide. In 2016 alone, 1.7 million 
people died from TB. While TB is found all over the world, it currently disproportionately 
affects low- to middle-income countries. The World Health Organization estimates that 87% of 
the new cases of TB arise within just 30 countries, and more than 95% of TB-related deaths 
occur in developing countries [1]. While the United States does not bear the majority of TB cases 
or death with a total of 9,272 cases reported to the Centers for Disease Control in 2016, complete 
elimination of TB in the U.S. or the world with current prevention and treatment strategies is not 
feasible within the foreseeable future [2]. Clinically, TB presents as primary active disease about 
4-14% of the time, characterized by coughing, chest pains, weight loss, weakness and night 
sweats. The remaining infected majority are considered to be “latently infected,” and contain 
their infection, are asymptomatic and non-infectious [1, 3, 4]. About 5-10% of those latently 
infected individuals reactivate at some point in their lifetime, and the risk is higher (~50%) in 
those who are immunosuppressed [5-7]. 
Despite the continuous obstacles presented by TB, the incidence of TB has fallen 
significantly over its long history, with an estimated decrease of 2% every year [1]. A global 
effort has emerged to eliminate TB, through the Stop TB Partnership established in 2000 and the 
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WHO End TB Strategy, adapted by the World Health Assembly in 2014. However, TB remains a 
major global health problem in spite of these renewed and continued efforts.  
There are many reasons for the difficulty in eliminating TB and reducing the morbidity 
and mortality. The addition of another major global health problem, HIV, greatly increases the 
mortality of TB. TB is the major cause of death in HIV+ individuals, accounting for ~40% of 
HIV deaths. 1.4 million new cases of TB were reported in HIV-positive populations in 2016 [1]. 
Furthermore, the emergence of drug resistant strains of Mycobacterium tuberculosis (Mtb), the 
causative agent of TB, has further complicated the problem of TB. Although drug-susceptible 
cases of TB can usually be treated with a 6-month multi-drug regimen consisting of isoniazid, 
rifampicin, pyrazinamide, and ethambutol, resistance to these drugs have emerged. Resistance to 
at least isoniazid and rifampicin (multidrug-resistant TB, MDR-TB) has been reported in nearly 
all countries, but mostly occurs within China, India, and the Russian Federation. MDR-TB that is 
also resistant to second-line TB drugs (extensively drug-resistant TB disease, XDR-TB) has also 
emerged, accounting for 6.2% of MDR-TB cases in 2016 [1]. Further compounding the burdens 
of TB, there is currently no fully protective TB vaccine. The only currently approved vaccine for 
TB, BCG (Bacille-Calmette Guérin), has efficacy as variable as 0-80%, with geographic and 
strain differences affecting efficacy [8].  
The difficulty in preventing or treating TB has been suggested to be a result of the long 
history of TB evolving along with humankind, the particular characteristics of the bacterium that 
causes TB, and the difficulties in elucidating immunological correlates of protection. These 
aspects of TB will be further expanded upon below. 
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1.1.1 A brief summary of the long history of TB 
TB has affected and evolved with mankind for millennia [9, 10]. Genomic evidence of TB in 
humans has been suggested to have started as early as 70,000 years ago, originating in Africa and 
expanding along with human migration patterns [11]. Global evidence of TB-related disease has 
been found in human cultures as varied and old as Egyptian mummies (2400BC), the writings of 
Ancient Greeks (~174AD), descriptions of TB in India and China, and pre-Columbian Peruvian 
mummies (~1000 AD) [9, 12]. TB remained a common affliction through the Middle Ages in 
Europe and well into the 19th century, causing devastating numbers of deaths across the 
continent, particularly among the younger population [9].  
Throughout history, TB has had numerous names, including phthisis, “the king’s touch,” 
and consumption, until Johann Lukas Schönlein first coined the current term “tuberculosis” in 
the mid-19th century [9]. During this time, physicians puzzled over many aspects of the disease, 
including the causes of the disease, with hereditary, moral, or spontaneous causes as the most 
common theories [10]. Additionally, the many pulmonary and extrapulmonary manifestations of 
TB caused confusion over whether TB was a single disease with multiple clinical symptoms or 
multiple diseases. René Théophile Hyacinthe Laennec was the first to unify the many different 
forms of TB under a single disease, describing the physical signs of pulmonary TB and 
establishing the modern concepts of TB in his book, D’Auscultation Mediate in 1819 [13].  
Although some conjectured that TB was caused by a particle of contagious nature early on, 
exemplified by Italy passing a law of quarantining anyone with symptoms of TB starting in 
1700s, the contagious nature of TB was not established until Jean-Antoine Villemin. In 1865, 
Villemin demonstrated the transmissibility of TB by inoculating a rabbit with an extract from a 
lesion from an infected patient [13].  
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In the 1880s, Robert Koch isolated the causative agent of TB, a rod-shaped bacterium 
that was very difficult to stain. He was able to cultivate the bacterium in animal serum and on 
solid culture media, and show that it indeed could reproduce the disease in guinea pigs when 
they were inoculated with his bacterial culture. By observing that these bacteria were in TB 
lesions only and not associated with other diseases; that these bacteria could be cultured in vitro 
outside of animal or man; and that these in vitro bacteria could be grown and then reinfect an 
uninfected animal and cause the same TB lesions, Robert Koch definitively showed 
Mycobacterium tuberculosis (Mtb) as the infectious cause of TB. The results were reported in his 
seminal paper to the Berlin Society of Physiology in 1882 [10]. With Koch’s work and 
conclusions, the idea that diseases could be caused by microscopic infectious agents was 
established, including the concept of Koch’s postulates. The era of research into ways to combat 
Mtb had begun. 
1.1.2 Transmission and detection of Mtb 
Mtb is primarily transmitted by inhalation of aerosolized droplets containing the bacteria 
produced by people with active TB disease coughing, sneezing, or spitting [14]. The airborne 
transmission of Mtb was confirmed in a series of experiments exposing susceptible guinea pigs 
to air from TB wards, which led to Mtb infection in the guinea pigs  [15-17]. Fennelly et al. 
observed 25% of their patients with pulmonary TB generated culture-positive cough aerosols, 
with most of the particle sizes within the respirable range [18]. Thus, there is a high chance of 
exposure to Mtb, particularly within enclosed spaces. A systematic review of all TB contact 
studies found 3.1% of exposed contacts had active TB, while 51.5% had latent infections [19]. In 
general, children tend to be at the most risk of Mtb infection from their contacts [20]. A meta-
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analysis of household contact studies concluded that children exposed to TB in their households 
were more likely to be infected than their community counterparts, and this was higher in 
children under 4 years of age compared to children 10-14 years [21]. However, the locations 
with the greatest risk of Mtb exposure may be age-dependent. For young adults, the majority of 
the transmission likely occur outside of the household, with 50% occurring in schools, and for 
people across all ages public transportation poses a significant risk for Mtb transmission [22, 23]. 
Andrews et al. estimated the annual risk of Mtb infection among daily commuters in South 
Africa to be 3.5-5% [24]. The risk of TB disease tends to be the greatest within the first year of 
Mtb exposure, but remains high for the next five years after exposure [19]. 
Classically, the disease outcomes of Mtb infection were separated into two major 
outcomes, active disease or latent infection, but increasingly a spectrum of TB disease has been 
recognized (Figure 1). Exposure to Mtb does not always lead to infection, as Mtb is less 
successful at establishing infection compared to other infectious microorganisms, but leads to 
much longer durations of infections. The infection could be quickly cleared by the innate or 
adaptive immune system, or could lead to latent infection, classified by positive tuberculin skin 
test (TST) but no clinical symptoms [25]. There is evidence in humans and animal models that 
within the clinical classification of latent TB, there is substantial heterogeneity, possibly 
influencing the risk of reactivation [26, 27]. At the other end of the spectrum, active TB presents 
with clinical symptoms, and in the absence of treatment, can lead to fatality in about 70% of 
active TB patients in approximately 3 years [28]. Between latent infection and active TB disease 
are the subclinical TB disease patients who may exhibit some symptoms of TB, but do not have 
overt illness [29]. Only those with subclinical or active TB disease are infectious, although 
because subclinical patients likely have lower bacterial burdens, they have lower risks of 
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transmission [25, 29]. Previous infections may also impart some protection against Mtb 
reinfection [4, 30]. 
Mtb infection is primarily confirmed by tuberculin skin tests (TST), which consists of an 
intradermal injection of a purified protein derivative (PPD) of mycobacteria. Mtb-infected 
individuals with a cell-mediated immune response to Mtb can then be identified by a delayed-
type hypersensitivity reaction that occurs between 48 and 72 hours after test placement. 
However, BCG vaccination or NTM exposure can confound the results. An alternative to TSTs 
are blood tests, such as the Interferon Gamma Release Assay (IGRA), which measures the 
cellular immune response in blood to antigens from the RD-1 region of Mtb, which is not present 
in BCG or most NTMs. Both TSTs and IGRAs have reduced sensitivity in immunocompromised 
patients and have low predictive value for whether a patient may be latently infected or their 
likelihood to develop active TB [14, 25].  
Active TB disease is defined by clinical symptoms and confirmed by microbiological 
assays. Initial screening for active TB can consist of chest X-rays or CT imaging. Since 
abnormalities on chest x-rays are non-specific, microbiological assays are still needed to 
confirm. Sputum smear microscopy is one of the most common methods to confirm the disease 
state of an individual, although cultures of samples are the gold standard. However, sputum 
smears are not always accurate as patients do not always have Mtb present in their sputum, or in 
sufficient quantities, and culturing of samples takes weeks before a result. Countries are 
increasingly using molecular based assays, such as Xpert MTB/RIF, to more accurately diagnose 
patients [14, 25]. By nucleic acid amplification of sputum samples, Xpert MTB/RIF is not only 
more accurate and rapid than sputum smear microscopy, it also detects the HIV-positive 
individuals that are typically missed by sputum assays and quickly identifies drug-resistant Mtb 
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strains. However, it is more expensive and requires more technical expertise [31, 32]. More 
research has also been devoted to finding biomarkers that distinguish between the different 
clinical outcomes of Mtb infection, especially to predict those with latent or subclinical 
infections that may progress to active disease [33, 34]. These improved detection methods may 
help identify high-risk patients for treatment and prevent further transmission. 
 
 
Figure 1. Spectrum of outcomes during Mtb infections.  
Exposure to Mtb can lead to many different outcomes, from complete elimination of the 
infection by the innate and/or adaptive immune response to fully active TB disease with clinical 
symptoms. Adapted by permission from Springer Nature: Springer Nature, Nature Reviews 
Disease Primers, Tuberculosis, Pai et al., 2016 [25]. 
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1.2 M. TUBERCULOSIS: THE CAUSATIVE AGENT OF TB 
Mtb is an aerobic, facultative intracellular, non-motile and non-spore forming bacillus that grows 
best in high oxygen environments, such as the lungs. The unique lipid-rich cell wall composed of 
mycolic acids makes Mtb less permeable relative to other bacteria, which makes drug treatment 
more challenging. Mtb is not considered to be Gram-positive or Gram-negative, but is 
categorized as acid-fast because of its impermeability to basic dyes. Mtb also replicates slowly, 
dividing only every ~24 hours, making drug treatments longer in duration [35]. Mtb is a human 
obligate pathogen with no known environmental reservoirs [11]. 
Mtb is one species within the larger Mtb complex of mycobacteria, which includes M. 
africanum, M. bovis, M. microti, and M. canetti. All species of the Mtb complex can cause 
human disease [35]. Genomic studies have shown that Mtb and M. bovis (the progenitor of BCG 
vaccine) evolved into separate lineages, and that the deletion of one sequence TbD1 in modern 
Mtb strains suggests a major bottleneck occurred approximately 15,000-20,000 years ago before 
spreading around the world [36]. Mtb has been distinguished by genomic data into six main 
geographical lineages that are closely associated with specific human populations [37]. While the 
differences between these Mtb strains are still being studied, some of the strains, particularly the 
Beijing strain that originated in Asia, have shown distinct characteristics of increased virulence, 
mortality, and drug resistance [38]. 
There are approximately 4000 genes in the Mtb genome [39]. Mtb secretes approximately 
200 proteins during culturing process, which are collectively referred to as culture filtrate 
proteins (CFP) [40]. CFP contains proteins, particularly the critical virulence factors ESAT-6 and 
CFP-10, that stimulate host immune responses [41, 42]. ESAT-6 and CFP-10 are part of and 
secreted by the ESX-1 system of mycobacteria, a type VII secretion system [43]. Notably, the 
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genes for ESAT-6 and CFP-10 and the rest of the ESX-1 proteins lie in the RD1 deletion region, 
which is found in all virulent Mtb and M. bovis strains, but not in the TB vaccine BCG, which 
suggests its role in the virulence of Mtb [36]. Indeed, deletion of the RD1 region from virulent 
Mtb resulted in attenuated virulence, while complementation of the RD1 region in BCG 
increased virulence during infections in mice [44, 45]. The mechanism of ESAT-6 and CFP-10 
virulence have not been determined, but ESAT-6 has been demonstrated to restrict TLR 
responses in innate cells and assist in dissemination by promoting cell lysis and pore formation 
[46-48]. While Mtb has many more virulence factors that have been identified, not all of their 
mechanisms and immunogenic properties have been characterized, however some of the more 
immunogenic ones have been incorporated into diagnostics and vaccines [49]. 
1.3 THE HOST IMMUNE RESPONSE TO M. TUBERCULOSIS 
1.3.1 Initial events in Mtb infection: bacterial containment and persistence in granulomas 
When aerosolized droplets containing Mtb are inhaled, alveolar macrophages phagocytose Mtb 
in the lung alveoli before invading the epithelial layer. The host innate immune system brings in 
the first Mtb responders: macrophages, including epithelioid macrophages, giant cells, and 
foamy macrophages, myeloid dendritic cells and neutrophils [50]. Within the first 4 weeks of 
infection, a complex orchestration of all of the various innate immune cells occur within the 
lungs, with their individual roles and contributions to the containment and control of Mtb [51-
53]. Macrophages have been shown to be particularly crucial for containing mycobacteria during 
the initial days of infection [54]. Dendritic cells, however, are the crucial infected cell subset to 
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transport Mtb to the lymph nodes, and without their trafficking of live Mtb to the mediastinal 
lymph nodes, the T cell response to Mtb is not initiated [53, 55].  The adaptive immune response 
cells, CD4 and CD8 T cells and B cells, are recruited to the cluster of infected and uninfected 
cells in the lung. Delayed measurable T cell responses by TSTs in humans (6-8 weeks post-
infection) and NHPs (4-6 weeks post-infection) or in the lungs of mice (2-3 weeks post-
infection) suggest that the adaptive T cell response is quite slow [55-57].  
As more cells are recruited to the site of infection, a granuloma, the hallmark of Mtb 
infection, is formed. Typically, TB granulomas are highly structured, with the center of a 
granuloma containing caseous necrosis, surrounded by a ring of epithelioid macrophages, and an 
outer ring of lymphocytes and macrophages, sometimes with a fibrotic cuff (Figure 2) [58-60]. 
As demonstrated in the NHP model, the onset of the adaptive immune response in the 
granulomas assists with Mtb killing and clearance between 4 and 11 weeks of infection [61]. 
The granuloma serves to contain Mtb, but may be advantageous for the bacterium to 
shield itself from host defense mechanisms. Mtb has been suggested to manipulate the 
granuloma environment to promote subsistence [50]. Studies from the zebrafish model of 
mycobacterial granulomas has indicated that infected macrophages recruited to early granulomas 
by mycobacteria are also motile and may assist in dissemination [54, 62]. Mtb also persists 
within macrophages by blocking phagosome maturation and phagolysosomal fusion [63, 64]. 
Mtb can also alter the macrophage balance of LXA4 and PGE2 signals to promote necrosis and 
impede dendritic cell cross-priming of T cells [65]. Mtb infection may actively inhibit dendritic 
cell maturation [66]. Additionally, Wolf et al. found that Mtb-infected dendritic cells in a mouse 
model may actively inhibit MHC II antigen presentation to CD4 T cells [53]. T cell priming in 
the lymph nodes may also be delayed because of Mtb-specific expansion of regulatory T cell 
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populations [67]. The early events in Mtb infection are critical to the outcome of infection, yet 
are difficult to study, particularly in humans [68]. 
Although the clinical manifestations are strikingly different between active disease and 
latent infection, there is much overlap in granuloma pathology and bacterial burden per 
granuloma between the disease states [61, 69]. On the individual granuloma level, in Mtb-
infected NHPs, mineralized and caseous granulomas are found in across the spectrum of 
infection outcomes [69]. Both sterile and non-sterile granulomas are found in active TB, 
subclinical TB, and latent infection, but there are usually more granulomas and complex 
pathologies with higher overall bacterial burden in the lungs and lymph nodes in active TB [61].  
The differences in the immune responses that lead to controlled infections versus active 
disease are not known. Much of the evidence thus far supports that T cell responses are a crucial 
factor in the control and clearance of Mtb, particularly from the extreme susceptibility of murine 
knock-out animals and humans with T cell deficiencies [70-73]. Human studies of active and 
latent TB have also shown significant differences in their Th1 responses [74-76].  Despite its 
critical role in the progression of TB, much about the granuloma remains unknown due to 
technical and logistical challenges. It is challenging to obtain granulomas from Mtb-infected 
patients, the commonly used mouse models do not form granulomas that accurately resemble 
human granulomas, and there are fewer immunological reagents available to study them in 
rabbits and guinea pigs [59]. Instead, much of what is known and researched in the granuloma is 
in the M. marinum-infected zebrafish and Mtb-infected non-human primate (NHP) model, as the 




Figure 2. Classic caseous granuloma structure.  
(A) Hematoxylin and eosin stained section of necrotic lung granuloma with caseous necrosis 
(10x magnification) and (B) immunohistochemical staining of necrotic lung granuloma with a 
dark center of caseous necrosis with no visible cell nuclei (blue). CD68+ macrophages (green) 
line the edge of the necrosis and CD3+ T cells (red) form lymphocytic cuff (20x magnification). 
Other clusters of CD68+ (green) macrophages are in the outer edge of the granuloma and in the 
surrounding tissue. Reproduced by permission from John Wiley and Sons, Immunological 
Reviews, Immunology studies in non-human primate models of tuberculosis, Flynn et al., 2015 
[78]. 
 
1.3.2 The adaptive immune response to Mtb 
The primary adaptive immune actors in Mtb infections are T cells. Both CD4 and CD8 T cells 
are involved in the host adaptive immune response to Mtb infections, but the CD4 response to 
Mtb has been studied more extensively [79]. The necessity of CD4 T cells has been illustrated by 
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the increased susceptibility in HIV patients [80, 81]. The importance of CD4 T cells has also 
been demonstrated in murine and NHP models of TB [82-84]. An important component in 
control of Mtb infection is the inflammatory response, mediated by Th1 cells which produce 
cytokines like IFN- TNF, and IL-2 [85]. The importance of IFN- has been illustrated with 
IFN deficient mice, which are extremely susceptible to even low doses of Mtb [72, 86]. 
Humans with genetic defects in their Th1 IFN--and IL-12 signaling pathways (Mendelian 
susceptibility to mycobacterial diseases, MSMD) also are more susceptible to mycobacterial 
infections [71]. TNF is essential for control of Mtb infection, as mice, NHPs, and patients with 
rheumatoid arthritis treated with anti-TNF antibodies have increased risk of TB [73, 87, 88]. The 
role of IL-2 in Mtb infections is more contentious, but IL-2 may have an interplay with IFN- 
and higher levels of IL-2 are associated with better disease outcome [89, 90]. Mtb infections 
induce IL-17 production in humans and mice, but the function of IL-17 during Mtb infections 
less clear [91-93]. CD8 T cells in Mtb infections have been shown to be crucial for protection 
from TB, as knock-outs of the MHCI pathway in mice and CD8 depletion in NHPs result in 
increased lung pathology and decreased control of Mtb [94-96].  
Although most studies have focused on the effect of the immune response on the whole 
animal disease outcome, there is evidence of the importance of the local T cell response on 
granuloma formation at the local site of infection. The loss of CD4 T cells, IFN- and TNF can 
cause dysfunctional granulomas [85, 97]. Mice and humans with defects in IFN- or TNF 
pathways have disseminated disease [71, 86]. Neutralization of TNF in NHPs results in poor 
control of initial infection and increased reactivation of latent TB [88, 98]. Furthermore, studies 
in mice without TNF have deficiencies in granuloma formation, excessive neutrophil infiltration 
and tissue destruction [73, 99, 100]. TNF may be necessary for chemokine expression and cell 
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recruitment in granuloma formation and maintenance [101]. A balanced T cell response in 
granulomas, such as inhibitory IL-10 and a pro-inflammatory cytokine, is associated with 
increased bacterial killing in lung granulomas [102]. 
Since Mtb is an intracellular pathogen, much of the research in the adaptive immune 
response has emphasized the cellular response, rather than the humoral response. Thus, much 
less is known about B cells than T cells during Mtb infection. Activated B cells have been 
characterized in clusters within the lymphocytic cuff of TB granulomas in a NHP model, with 
higher concentrations of Mtb-specific IgG in granulomas as opposed to uninfected tissue samples 
[103]. The presence of inducible lymphoid follicles, or inducible BALT (iBALT), in lungs is 
associated with better disease outcomes [104]. Furthermore, antibody signatures may be distinct 
between patients with latent Mtb infections compared to active disease. The antibodies from 
latently infected patients also induced more macrophage activation and killing of Mtb, 
suggesting that antibodies may be critical for bacterial control [105]. B cell-deficient mice had 
more immunopathology and susceptibility when challenged with Mtb, but B cell-depleted NHPs 
had similar disease outcomes and bacterial loads compared to controls after Mtb challenge, 
although they had altered granuloma cytokine responses [106]. Although the humoral response 
may not be critical for host control of Mtb infection, other studies have shown that B cells and 
antibodies may be adjunctive or synergistic for Mtb control by interacting and enhancing other 
immune cells [107]. 
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1.4 MODULATORS OF THE T CELL RESPONSE IN TB GRANULOMAS 
As reviewed above, many different immune cell types contribute to the containment and control 
of Mtb during infection, with the T cell response noted as a crucial component. Besides the local 
inflammatory response, an effective immune response requires a balance between pro- and anti-
inflammatory factors, as an imbalance will provoke excessive tissue damage or ineffective 
bacterial clearance. Several modulators of pro-inflammatory T cell responses have been 
suggested and investigated as potentially significant in Mtb infections, including regulatory T 
cells (Tregs), immunoregulatory cytokines, and exhausted T cells.  
1.4.1 Regulatory T cells 
Tregs may have an immunosuppressive role in TB; mice depleted of Foxp3-expressing 
Tregs and infected with Mtb had significantly lower bacterial burden, although they also had 
multi-organ inflammation [108]. Tregs have been suggested to migrate to the local sites of Mtb 
infection, with Tregs accumulating in the lungs of mice, and frequencies of peripheral Tregs 
decreasing during early Mtb infection in humans and NHPs, but increasing in the airways of 
Mtb-infected NHPs [108-110]. Treg populations also expand in response to Mtb antigens, and 
may inhibit the priming of effector T cells in the lymph nodes [67]. A study in the PBMCs of 
TST reactors found that Treg expansion in the presence of Mtb also required the expression of 
PD-1 [111]. Tregs can suppress other immune cells through inhibitory cytokines, cytolysis, 
metabolic disruption, or modulation of dendritic cells. In particular, the inhibitory cytokines IL-
10 and TGF- are induced by Tregs as one of their main mechanisms of suppression, which will 
be discussed in further detail below [112]. Interestingly, Tregs have been known to express 
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inhibitory receptors CTLA-4 and LAG-3, and there is growing evidence that they may also 
express PD-1 [111-114]. These inhibitory receptors in the context of T cell exhaustion will also 
be further discussed below. 
 
1.4.2 Inhibitory cytokines: IL-10 and TGF- 
Levels of IL-10 and TGF- are higher in active TB patients, suggesting these inhibitory 
cytokines may be associated with increased disease [115-118]. Fewer studies of TGF- in TB are 
available, but TGF- exacerbated pulmonary TB through T cell suppression in guinea pigs [119], 
and inhibition of TGF- during BCG vaccination enhanced immune response [120]. In human 
studies, higher levels of TGF- associated with active TB, and suppressed lymphocyte 
proliferation and IFN- production in vitro [118, 121]. A study suggested IL-10 and TGF- 
together have synergistic immunosuppressive effects on Mtb-infected cells [117].  
The more well-studied of the two cytokines, IL-10, still has a debated role during Mtb 
infections. In addition to being produced by Tregs, IL-10 is produced by nearly all immune cells, 
including monocytes, macrophages, dendritic cells, B cells, NK cells, mast cells, and nearly all T 
cell subsets [122]. IL-10 downregulates Th1 responses by inhibiting antigen presentation from 
macrophages and DCs and IL-12 production [123-125]. IL-10 can also inhibit macrophage 
function, reducing macrophage killing, and nitric oxide and TNF production [125]. The balance 
of IL-10 response during infections and autoinflammatory conditions is critical, as it is 
associated with many negative disease outcomes [125-127]. In patients with TB disease, IL-10 is 
elevated and may downregulate the Th1 response [115, 128-131]. The downregulation of 
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beneficial Th1 responses by IL-10 during Mtb infection is further supported by mouse studies, in 
which eliminating IL-10 enhances protection, IFN- production, and T cell recruitment without 
negatively increasing pathology [132-136]. Conversely, excessive IL-10 in the murine model 
increased bacterial burden and exacerbation of the disease [137, 138]. However, other studies in 
mice found loss of IL-10 increased IFN- production and inflammatory responses, but had a 
negative or no effect on protection from TB [139-142]. Although the available studies do not 
definitively demonstrate that IL-10 detrimentally downregulates Th1 responses or prevents 
immunopathology during Mtb infections, recent studies suggest that IL-10 may have more 
specific roles during particular points of Mtb infection. In mice, lack of IL-10 early in Mtb 
infection, during the first month of infection had significant improved the long-term control of 
Mtb infection [136], while blocking IL-10 later in Mtb infection, after 3 months, only partially 
reduced bacterial loads [134]. Additionally, in NHPs, at the local site of infection (granulomas), 
IL-10 expressed in the same granuloma as a pro-inflammatory cytokine was associated with 
increased sterilization [102]. Thus, the role of IL-10 within Mtb infections is unsettled, and will 
be clarified through the studies described in Chapter 2. 
1.4.3 Exhaustion of T cells during chronic diseases 
T cell exhaustion has been characterized in other chronic infections, such as HIV, LCMV, and 
hepatitis B, and in cancer, in which T cells lose functionality and proliferation capabilities in 
response to chronic antigenic stimulation [143-148]. Considering that Mtb can persist in humans 
for years until death and antigen load (bacterial burden) was associated with decreased T cell 
responses in patients, T cell exhaustion has also been hypothesized to contribute to the immune 
response during TB [75]. Exhausted T cells are characterized by low cytokine production, low 
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proliferation, and expression of one or more inhibitory receptors, including PD-1, CTLA-4, and 
LAG-3. These inhibitory receptors interact with their corresponding ligands on antigen 
presenting cells to activate negative regulatory pathways [149, 150]. While T cell exhaustion in 
CD8 T cells has been well studied in a variety of disease models, the phenomenon of exhaustion 
in CD4 T cells has more recently emerged, although exhausted CD8 and CD4 T cells appear to 
differ transcriptionally [151, 152]. As demonstrated in other diseases, blocking inhibitory 
receptors rescues T cell function and may lead to improved disease outcomes [153-158]. 
However, although inhibitory receptors and their regulatory pathways may help prevent chronic 
inflammation and tissue destruction, they may also prevent necessary T cell functions for 
complete clearance of infections or tumor cells. 
The question of whether T cell exhaustion occurs or is important during Mtb infection 
has been examined by characterization of the inhibitory receptors PD-1, CTLA-4, and LAG-3. 
TB patients had increased PD-1 expressing T cells in their peripheral blood mononuclear cells 
(PBMC) compared to healthy controls, and blockade of inhibitory receptors in vitro enhanced T 
cell function [159-161]. In a mouse model, PD-1+ T cells accumulated in the lungs and lymph 
nodes during Mtb infection [162]. Relatedly, the ligand for PD-1, PD-L1, has also been shown to 
be upregulated on neutrophils in active TB patients, and downregulated after TB treatment [163]. 
Dendritic cells from chronic (10 week) liver granulomas in a mouse model of mycobacterial 
infection also tended to express higher levels of PD-L1 than in acute (3 week) liver granulomas 
[164]. CTLA-4 has been less well-characterized in Mtb, but two studies in different populations 
indicate that polymorphisms in gene for CTLA-4 may be associated with more pulmonary TB or 
more severe pulmonary TB [165, 166]. A study in PBMCs of active TB patients associated 
CTLA-4 expression with activation in T cells [115]. In a murine model, blockade of CTLA-4 
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during mycobacterial infection increased lymphocyte proliferation and IFN- production in 
lymph nodes, but did not reduce the bacterial loads or lung pathology [167]. LAG-3 on T cells in 
a NHP model was associated with active or reactivated TB compared to clinically latent NHPs 
[168]. Although studies use these inhibitory receptors, especially PD-1, as markers of T cell 
exhaustion, and thus reduction in protective T cell activity, some mouse studies have suggested 
that T cells expressing PD-1 may be necessary to maintain antigen-specific effector T cells 
during Mtb infections [169, 170]. Importantly, mice developed extreme inflammation and poor 
outcome in the absence of PD-1 during Mtb infection [171-173]. When Einarsdottir et al. 
specifically blocked PD-1 and PD-L1 during chronic Mtb infection in mice, they found no 
detectable change in T cell function or bacterial load [162]. 
The majority of the current published literature on T cell exhaustion in TB have identified 
exhausted T cells based on the expression of a single inhibitory receptor. However, inhibitory 
receptors can also be upregulated during activation, and T cells can simultaneously express both 
inhibitory and activation markers [150, 174-177]. Since increasing co-expression of multiple 
inhibitory receptors on T cells may reveal increasing T cell exhaustion, characterization of 
inhibitory receptor co-expression may be more accurate [178]. T cells co-expressing inhibitory 
receptors during Mtb infections have not been studied as thoroughly, although PD-1 expression 
was found to correlate with CTLA-4 expression on CD4+ T cells from tissues of Mtb-infected 
NHPs [179]. Gideon et al. found low frequencies of PD-1+ T cells co-expressing CTLA-4, with 
significantly higher PD-1+CTLA-4- T cells [102]. Mtb infections in mice increased the 
expression of PD-1 and LAG-3 as the infection progressed, and this was associated with 
increased T cell impairment. However, PD-1+ T cells co-expressing TIM-3, another inhibitory 
receptor, had an even more dysfunctional exhausted phenotype during Mtb infection [180]. 
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These PD-1+TIM-3+ cells also had upregulation of genes associated with other inhibitory 
receptors, including TIGIT, Blimp1, LAG-3. And CTLA-4. While there are other inhibitory 
receptors that may mark T cell exhaustion, the study presented in Chapter 3 will focus on the 
expression of PD-1, CTLA-4, and LAG-3. 
1.5 MODULATION OF IMMUNE RESPONSES IN TB BY VACCINATION 
Since correlates of protection against TB are currently still unknown, development of an 
effective vaccine has been stymied for the past century, almost since the initial identification and 
isolation of Mtb by Robert Koch. Initially, in 1890, Koch claimed to have isolated a substance 
from Mtb that when injected could treat tuberculosis. This substance, which was subsequently 
named tuberculin, was soon proved to be ineffective as a treatment and actually harmful in some 
cases, but it became useful as a diagnostic tool for infection and the basis for the current 
standardized test for Mtb. Following tuberculin, in 1921, Albert Calmette and Camille Guérin 
introduced their vaccine, BCG (Bacille Calmette-Guérin) to combat TB. BCG was eventually 
widely accepted, and has been and continues to be the only licensed vaccine for TB in the world 
[13]. As further described below, BCG has its drawbacks with variable efficacy, but a new and 
more effective vaccine has yet to be developed. 
1.5.1 History and current status of BCG 
Initially, attempts to make a vaccine against TB by boiling or chemically treating Mtb failed. 
Although tuberculin was not effective as a vaccine against TB, Albert Calmette suspected that 
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the sensitivity following injection was a sign of an immune reaction. Combined with the 
previous observation that patients with tuberculous glands in their necks tended to not also have 
pulmonary tuberculosis, Calmette began a long journey in 1900 to find a live, avirulent vaccine 
that would artificially stimulate the immune response to Mtb and prevent TB. He and Camille 
Guérin, they first began culturing tubercle bacilli on glycerin and potato media, but because they 
could not create a homogeneous suspension of the bacteria, they added ox bile to their media to 
reduce clumping. After realizing the addition of ox bile during subculturing reduced the 
virulence of the bacteria, they began serially subculturing a virulent bovine strain related to Mtb, 
M. bovis in 1908. Calmette and Guérin continued to subculture even through World War I, 
despite the difficulty of acquiring the supplies necessary to make the medium. Finally, in 1919, 
after over 200 subcultures over 11 years, their culture did not cause progressive tuberculosis in 
guinea pigs or other animal models. They named their culture Bacille Calmette-Guérin (BCG) 
[8, 13, 181, 182].  
The first trial of BCG in humans was in 1921, when BCG was administered by oral route 
to an infant born to a tuberculous mother with no complications. By 1928, over 100,000 doses of 
BCG were given to infants and it began to be administered to infants in other European 
countries. Although Calmette and Guérin published a reduction in infant mortality from TB after 
BCG vaccination, it was still met with skepticism in other parts of the world, with strong 
criticisms of their claims [8, 182, 183]. In 1930, an accidental contamination of the BCG vaccine 
with virulent Mtb that was administered to over 200 children in “the Lubeck disaster” caused a 
further setback in the confidence in BCG. However, when World War II caused epidemics of TB 
throughout Europe and Asia, BCG began to be used on a global scale [8, 182]. Under the 
International Tuberculosis Campaign, nearly 30 million people were tested for TB, and almost 
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14 million were vaccinated in 22 countries by 1951 [184]. Despite the increased global use of 
BCG, the United States resisted adoption of BCG vaccination, citing low levels of TB in the 
U.S., the benefits of tuberculin testing, and prophylactic chemotherapy of tuberculin-positive 
patients to be sufficient to prevent TB in the U.S. [185, 186]. 
Even during the early decades of BCG vaccinations, there were contradictory reports in 
the efficacy of BCG. Most reports agree that BCG has been shown to be protective in infants 
against severe TB disease, preventing TB meningitis and military disease, however, the efficacy 
of BCG against pulmonary TB remains inconsistent [187-189]. Protection against pulmonary TB 
varies from 0-80%, depending on the clinical trial [188, 190-194]. One potential cause is the 
variability in immunogenicity between the strains of BCG currently in use worldwide, with 
phenotypic and molecular differences between the strains, likely due to divergence in production 
methods over the years [8, 195]. Geographical differences and exposure to other non-tuberculous 
mycobacteria NTM) is widely believed to affect BCG vaccine efficacy, called the North-South 
effect [8, 188, 194]. Further confusing the benefits of BCG, the administration of BCG has been 
suggested to prevent infant mortality beyond simply protecting from TB, continuing the need for 
administration of BCG in endemic areas despite doubts of its efficacy against pulmonary TB 
[196].   
The mechanisms by which BCG provides protection are currently unknown. Genomic 
studies have shown many regions of difference (RD) between virulent Mtb and BCG, where 
genes present in Mtb are no longer in the present passage of BCG [197]. Notably, these genomic 
changes may affect T cell epitopes in BCG compared to Mtb [198]. Vaccination with BCG has 
been shown to induce robust T cell response from both CD4 and CD8 T cells [199-201]. 
However, these responses have been shown to be mostly of the effector T cell type, primarily 
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producing IFN-, rather than of a long-lived central memory T cell. The peak BCG T cell 
response is typically within 10 weeks of vaccination, and protection appeared to wane over time, 
likely due to the lack of central memory T cell response [200, 202, 203]. Additionally, 
comprehensive studies of infants vaccinated with BCG failed to identify any immunological 
correlates of risk for developing TB disease [204, 205]. The unidentified factors of BCG that 
confer partial protection to TB have made it difficult to improve upon BCG and to produce a 
fully protective vaccine. 
1.5.2 Strategies for protective TB vaccines 
Considering the waning immune response to BCG, the simplest strategy of extending protection 
is by revaccination using BCG. Unfortunately, repeated vaccination with BCG has not shown 
substantial additional protection [206-208]. By studying the variability in response to 
revaccination depending on the geographical site (19% in Salvador vs. 1% in Manaus), Barreto 
et al. proposed that exposure to NTM before BCG vaccination may block the protection 
conferred by BCG, and may be overcome or bypassed by new TB vaccines [208]. Novel 
vaccines strategies aim to protect against TB at three stages of disease: pre-exposure to Mtb to 
prevent infection or TB disease, post-exposure to Mtb to prevent TB disease, and therapeutic to 
cure TB disease. The underlying mechanism of the current proposed vaccines is to induce and 
alter the T cell response, particularly of memory T cells that produce IFN-, TNF, and IL-2, 
since the T cell response has been shown to be crucial for protection [209].  
Currently, 12 new vaccine candidates have been developed and are in various stages of 
pre-clinical and clinical trials [14]. These vaccines arise from two main approaches – to either 
improve BCG by genetic recombination or by boosting BCG through additional subunit vaccines 
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using protein or viral vectors [210]. Of the vaccines currently in clinical trials, MTBVAC and 
VPM1002 are live mycobacterial vaccines designed to replace BCG [14]. MTBVAC is a live 
clinical isolate of Mtb containing deletions of phoP and fadD26 genes, which encode two genes 
that control major virulence factors [211]. On the other hand, VPM1002 is a live recombinant 
BCG vaccine that contains the listeriolysin encoding gene from Listeria monocytogenes to 
promote rapid phagosome acidification and phagolysosome fusion [212]. RUTI, Vaccae, and 
DAR-901 are all inactivated vaccines derived from whole or fragmented mycobacteria. RUTI 
and Vaccae were designed as therapeutic vaccines to shorten TB drug treatment [14]. RUTI 
consists of detoxified and liposomed cellular fragments of Mtb, while Vaccae consists of a 
nonpathogenic NTM vector, M. vaccae, expressing a 19kDa fragment of Mtb to stimulate T cell 
responses [213, 214]. DAR-901 is the scalable vaccine based on SRL172, an inactivated, whole-
cell vaccine from NTM that is meant to boost BCG vaccine responses [215]. 
Subunit vaccines consist of one or more immunogenic antigens expressed by a viral 
vector or formulated in an antigen designed to boost the efficacy of BCG [210]. Ag85A, a 
mycolyl transferase in mycobacteria that contains several CD4 and CD8 T cell epitopes, has 
been incorporated into multiple vaccines, including the viral vectored vaccines Ad5 85A 
(adenovirus), ChAdOx185A-MVA85A (adenovirus and vaccinia virus), and TB/FLU-04L 
(influenza virus) [14, 210, 216]. MVA85A, modified vaccinia Ankara-expressing Ag85A, had 
formerly been the most advanced vaccine in the TB vaccine pipeline, until it was shown to lack 
any efficacy against TB or Mtb infection in a randomized, placebo-controlled phase 2b trial 
[217]. Alternatively, TB subunit vaccines with non-viral adjuvants currently in clinical trials are 
H56:IC31, H4:IC31, ID93+GLA-SE, and M72/AS01E [14]. H4, which is designed for pre-
exposure vaccination includes antigens produced by Mtb during active replication, while H56, 
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ID93, and M72 incorporate larger combinations of antigens to cover all stages of Mtb infection 
for post-exposure use [210]. ID93, which consists of the mycobacterial antigens associated with 
virulence, Rv2608, Rv3619, Rv3620, and latency, Rv1813, combined with a stable oil-in-water-
emulsion adjuvant GLA-SE has been shown to induce Th1 responses [218]. M72 is a 
recombinant fusion protein vaccine composed of Mtb32A and Mtb39A proteins in a liposomal 
adjuvant containing TLR4 ligand 3-O-desacyl-4’-monophosphoryl lipid A (MPL) and 
immunostimulant Quillaja saponaria fraction 1 (QS21) to promote antigen-specific CD4 T cells 
[219]. H56 and H4 fusion protein vaccines in clinical trials are administered via IC31, an 
adjuvant that combines immunostimulatory oligodeoxynucleotide containing deoxy-
Inosine/deoxy-Cytosine (ODN1a) and the antimicrobial peptide KLKL5KLK, which signals 
through the TLR9 pathway to induce Th1 and humoral responses [220]. Protein subunit 
vaccines, including H56, will be discussed in further detail below. 
1.5.2.1 Protein subunit vaccines with liposomal adjuvants 
Subunit vaccine H4 and H56 are protein fusion vaccines currently in clinical trials that 
have shown a strong immune response and protection in animal models and were developed by 
our collaborators at the Statens Serum Institute (SSI) [221, 222]. Both H4 and H56 contain 
Ag85B, an abundant and strongly immunogenic protein part of the Ag85 protein complex of 
mycolyl transferases [221, 223]. Ag85B, which is produced in Mtb and BCG, is recognized by 
Th1 cells and triggers strong cytokine responses, including IL-2, IFN-, and TNF [224, 225]. 
Besides Ag85B, H4 also contains the immunodominant Mtb antigen, Mtb10.4, which is also 
present in Mtb and BCG, and stimulated the greatest responses of its subfamily within the esat-6 
gene family [223, 226]. In H56, in addition to Ag85B, the protein vaccine also includes ESAT-6, 
a highly immunogenic protein secreted by Mtb but not BCG or environmental mycobacteria, and 
 26 
Rv2660c, a latency associated protein up-regulated by Mtb under nutrient starved and hypoxic 
conditions to mimic antigen from Mtb entering the persistent stage of infection in vivo [221, 222, 
227, 228]. H56 induced vaccine-specific immune responses in mice, non-human primates 
(NHPs), and humans, and reduced bacterial burden in mice, while preventing reactivation in 
NHPs [221, 222, 229, 230]. Additionally, SSI has since developed a new related fusion protein 
vaccine, H74. H74 is composed of the strongly immunogenic Mtb antigens ESAT-6, Rv3881c 
(EspB), Rv3614c (EspD), Rv3615c (EspC), Rv3616c (EspA), and Rv3849 (EspR), which are co-
regulated and secreted through the ESX-1 secretion system of Mtb throughout the course of Mtb 
infection [231-241]. H74 has been demonstrated to cause strong immunogenic response and 
decrease bacterial burden in the mouse model of Mtb infection (SSI, data not published).  
These vaccines have also been tested with a variety of adjuvants to try to induce the 
protective immune response, even though the parameters of this immune response, especially at 
the local level, is still unclear, but are suspected to include a strong Th1/Th17 cytokine response, 
particularly IFN-. Besides IC31, which is currently being used with H4 and H56 in clinical 
trials, SSI has formulated a series of novel liposome-based cationic adjuvant formulations (CAF) 
[14, 242], including CAF09 and CAF01. CAF09 is composed of monomycoloyl glycerol 
(MMG)-1, a synthetic analogue of a mycobacterial cell wall lipid, and Poly(I:C), a synthetic 
dsRNA and TLR3 agonist, and demonstrated to induce robust CD4 and CD8 T cell responses 
[243, 244]. In contrast, CAF01 has trehalose 6,6-dibehenate (TDB) glycolipids, a synthetic 
variant of a mycobacterial cell wall cord factor, as a stabilizer and immunomodulatory, and has 
been demonstrated to trigger long-lasting Th1 and Th17 immune responses [242, 245-248]. 
Chapter 4 of this dissertation will investigate the efficacy of the H56 and H74 protein fusion 
vaccines with the adjuvants CAF01 and CAF09. 
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1.5.2.2 Vaccination routes 
The route of vaccination can also greatly affect the modulation of immune response by vaccines. 
For example, BCG, which was originally given as an oral vaccination, but is currently given as 
an intradermal injection, can have very different immunogenic effects and levels of protection 
depending on the route of vaccination. Mouse studies have suggested that aerosolized BCG may 
confer the most protection compared to oral or intradermal administration [249]. Similarly, 
Lagranderie et al. also found improved protection to Mtb challenge in aerosol vaccinated guinea 
pigs compared to intradermal vaccinated animals [250]. Although systemic intravenous 
vaccination of BCG in mice led to higher levels of BCG and CD4 T cells in tissues, Mittrucker et 
al. found that these higher immune responses in intravenous vaccination did not improve 
protection against Mtb challenge compared to oral BCG vaccination [251].  Surprisingly, 
intravenous administered BCG in rhesus macaques vastly improved protection during Mtb 
challenge compared to intradermal vaccination [252-254]. Thus, vaccination routes can greatly 
affect the efficacy of a vaccine and may need to be optimized for each vaccine. As BCG boosting 
protein subunit vaccines must be used in conjunction with current intradermal vaccination 
practices, optimization of the vaccination route and strategy of these novel vaccines must be 
tested with BCG [14, 255-257]. 
Since TB primarily is a pulmonary disease, vaccination that targets the site of infection 
for a mucosal pathogen, such as Mtb may increase the efficacy of a TB vaccine [258-263]. 
Additionally, studies have shown that booster vaccines given simultaneously as BCG toward the 
same draining lymph node can boost immune response [264]. The studies described in Chapter 4 
will investigate whether various routes and strategies of protein subunit boost vaccination 
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improve protection from TB, particularly focusing on the administration of vaccines via the 
mucosal route. 
1.6 NON-HUMAN PRIMATE MODEL OF TB 
Many animal models have been adapted for TB studies. The earliest landmark studies of TB 
transmission used the highly susceptible models of rabbits and guinea pigs. A variety of strains 
of mice are commonly used for TB, and although they are a tractable model of TB, mice are 
relatively resistant to Mtb and they do not reproduce the same type of disease as in humans, with 
high levels of bacterial burden and uncircumscribed lung granulomas. In contrast, NHPs are 
naturally susceptible to Mtb, develop TB that resembles that of humans, have similar immune 
responses to Mtb, and have similar levels of protection with BCG vaccination. However, they are 
more expensive, and more difficult to maintain under Biosafety Level 3 conditions, and are 
outbred, leading to substantial variability in infection outcome and immune responses, similar to 
humans [265, 266]. 
Our lab previously developed a low dose ( 25 CFU) cynomolgus macaque (Macacca 
fasicularis) model that recapitulates the spectrum of human Mtb infection in both disease 
progression (clinically active disease to latent infection) and pathology (granuloma formation 
and more complex pathologies) [57, 77, 267, 268]. In particular, the histopathology of 
granulomas in the NHP model fully represents the range of granulomas in human disease, with 
identifiable caseous, non-necrotizing, suppurative, fibrotic, and mineralized granulomas, and TB 
pneumonia [57, 77]. A number of immunological and physical monitoring tools have also been 
developed along with the NHP model to further track disease progression and address specific 
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questions about Mtb infection, including PET-CT imaging and intracellular cytokine staining of 
tissues, including granulomas and lymph nodes [77, 269, 270]. Our NHP model has several 
advantages: (1) recapitulates the spectrum of human TB; (2) ability to modulate immune 
responses with vaccinations, including adjuvants, host-directed therapies, or antibodies; (3) 
ability to manipulate timing of infection and observe the earliest events of infection; (4) ability to 
extract and characterize individual lung granulomas by bacterial burden, pathology, and 
immunology; (5) ability to track Mtb infection in lung and lymph nodes non-invasively by using 
18F-FDG in PET-CT imaging [78]. Thus, the NHP model of TB serves as the ideal model to 
examine the modulation of immune responses at the local site of Mtb infection, within individual 
granulomas, while also observing the relation of the local response on the overall disease 
outcomes and bacterial loads within animals. 
1.7 STATEMENT OF THE PROBLEM 
Each year, TB is responsible for well over a million deaths around the world. Despite continued 
efforts to reduce the global burden of TB and nearly a century of vaccination with the TB 
vaccine BCG, an additional 10.4 million people become infected every year [14]. Part of the 
roadblock to TB eradication is that the immune response during Mtb infections is not fully 
understood, and thus immune correlates of protection have not been identified. Additionally, the 
only available vaccine for TB, BCG, has variable efficacy, particularly in preventing pulmonary 
TB in adolescents and adults. While the host immune response involves many innate and 
adaptive immune cells working in concert, T cells have been identified as a crucial component in 
the control of Mtb. Gideon et al. demonstrated a balance of pro- and anti-inflammatory T cell 
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cytokines in the granulomas is associated with bacterial clearance. Despite this need for a 
balanced T cell response in the granulomas, low frequencies of pro-inflammatory cytokine 
response (IFN-, IL-2, TNF, IL-17) in T cells from TB granulomas were observed [102]. These 
low cytokine responses in T cells may be caused by a variety of factors, including (1) high levels 
of immunomodulatory soluble factors and regulatory cells, such as anti-inflammatory cytokines 
IL-10, TGF-or regulatory T cells; (2) decreased response from increased numbers of 
exhausted T cells during chronic antigen exposure; (3) influx of non-specific T cells; or (4) 
downregulation of T cell response by Mtb. This dissertation aimed to address two of these 
potential causes – the anti-inflammatory cytokine, IL-10 and T cell exhaustion. Due to the 
difficulty of isolating individual lung granulomas in patients and most animal models, much of 
the known aspects of the T cell response during Mtb infections originate from studies of the 
systemic (blood) response rather than the local (granuloma) response. This dissertation uses the 
NHP model of TB, which recapitulates the spectrum of disease, granuloma structure and 
formation, and immune response observed in humans. Using the NHP model, the goals of this 
dissertation were to answer the questions: (1) Does IL-10 downregulate the T cell response in TB 
granulomas? (2) Does T cell exhaustion contribute to the modulation of T cell response in TB 
granulomas? (3) Can different vaccination strategies alter the T cell response in TB granulomas 
for increased control and overall better disease outcomes?  
These data will contribute to the understanding of the factors modulating T cell response 
in TB granulomas to take a step toward identifying the correlates of protection needed for 
successful prevention of TB disease. 
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2.0  THE ROLE OF IL-10 DURING EARLY MTB INFECTION IN A NHP MODEL 
2.1 ABSTRACT 
Tuberculosis (TB), caused by the bacterium M. tuberculosis (Mtb), continues to be a major 
global health problem. Lung granulomas, organized structures of host immune cells to contain 
Mtb, are the pathologic hallmark of TB. The host cytokine response plays a major role in 
containment of Mtb infection within these granulomas. While the importance of pro-
inflammatory cytokines IFN- and TNF in controlling Mtb infections has been established, the 
effects of immunomodulatory cytokines, such as IL-10, in Mtb infections are less well 
understood. We used cynomolgus macaques, a non-human primate (NHP) model that 
recapitulates human TB to investigate the role of IL-10 early in Mtb infection. A cross-reactive, 
rhesus recombinant anti-IL-10 antibody was used to neutralize IL-10 in vivo in NHPs prior to 
and during the early course of Mtb infection. Disease progression was monitored by PET-CT 
scans, and local immune responses in the granulomas and lymph nodes assessed at necropsy. Our 
data indicate transient differences in innate cell response early in infection between anti-IL-10-
treated and control animals. Surprisingly, there was less inflammation and more fibrosis in lung 
granulomas and earlier lymph node effacement from IL-10 neutralized animals at 3-4 weeks 
post-infection, compared to control animals. Overall, this unique dataset provides important 
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insight into the contribution of IL-10 to the immunological balance necessary for granulomas to 
control bacterial burden and disease pathology in Mtb infections. 
2.2 INTRODUCTION 
Tuberculosis (TB) continues to be a major cause of death worldwide, with 1.7 million deaths 
from TB in 2016 alone [1]. Despite decades of research, the nuances of the complex relationship 
between the host response and the bacterial cause of TB, M. tuberculosis (Mtb), remains unclear. 
For the best-case scenario, host immune cells coordinate their responses to contain the bacteria, 
in a delicate balance of halting bacterial spread without causing excessive disease pathology. 
When Mtb bacilli are initially inhaled, they are phagocytosed by alveolar macrophages, followed 
by an influx of other innate immune cells, such as neutrophils and dendritic cells, to the site of 
infection to assist in containment of Mtb. Later in infection, the adaptive immune response, 
including T cells and B cells, arrive to assist innate immune responses. Together, these host 
immune cells form the organized structure of a granuloma around the Mtb to contain the bacteria 
and prevent further bacterial spread. Both innate and adaptive immune cells and their cytokine 
responses have been established to be critical for control and clearance of Mtb (reviewed in [60, 
68, 85, 271]).  
These events and the host immune response early in infection are critical for the disease 
outcome. Subjects infected with Mtb have early initial inflammatory response and lymph node 
involvement, usually within the first two months of infection (reviewed in [68]). Studies in non-
human primates (NHPs) have also indicated the importance of these early immune events on the 
eventual disease outcome [61, 270]. As reviewed by Cadena et al. [68], many host immune cells 
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and their cytokine responses are necessary for clearance of the bacteria. In particular, pro-
inflammatory cytokines such as IFN-, TNF, and IL-17 have been shown in humans, non-human 
primates (NHPs), and mice to be critical for optimal control of Mtb [60, 71-73, 85, 86, 88, 92, 
93, 98, 100, 101, 272, 273]. However, uncontrolled inflammatory cytokine response from these 
immune cells can also cause damage to the tissues. 
The immune response has many checks and balances to counter a pro-inflammatory 
response and prevent damage. One major factor that can prevent tissue damage is IL-10, a 
cytokine that has been identified with anti-inflammatory properties. IL-10 can be produced by 
nearly all immune cells, including monocytes, macrophages, dendritic cells, B cells, NK cells, 
mast cells, and nearly all T cell subsets [122]. Dysregulation of IL-10 (increase or decrease) has 
been associated with many negative disease outcomes, including against bacterial and viral 
infections and autoimmune or inflammatory diseases [125-127].  
Many studies have investigated the role of IL-10 in Mtb infections, but the cumulative 
results have been inconclusive. Elevated levels of IL-10 in patients have been suggested to be 
associated with more active or severe cases of TB [130, 131, 274]. In patients with Mtb 
infections, Th1 function increased when IL-10 was blocked during in vitro PBMC studies [115]. 
In the murine model, IL-10 has been observed to prevent control of the bacteria. Mice with IL-10 
function blocked or knocked-out are better at controlling their bacterial burdens and enhancing 
survival during Mtb infections [132-136]. Overexpressing IL-10 in the murine model increased 
bacterial burden and exacerbation of the disease [137, 138]. In contrast, other studies using the 
murine model of TB indicated that IL-10 had insignificant effects on the bacterial burden during 
Mtb infections, with sometimes detrimental immunopathology and decreased survival [139-142]. 
While many of these studies indicate that IL-10 during Mtb infection may be decreasing Th1 
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function and preventing a sufficient immune response to reduce bacterial burden, some of these 
studies also implicate IL-10 in preventing immunopathology. Further contributing to these 
contradictory results, some studies suggest the timing of IL-10 may have differential effects 
during the course of Mtb infection. While blocking IL-10 later in infection (after 3 months) 
partially reduced bacterial burden [134], transiently blocking IL-10 during the first month of 
infection had even greater effects on the long-term control of Mtb infection [136]. Most of these 
studies were based on whole organ or whole animal outcomes, there are fewer studies of 
individual TB granulomas. By computational modeling of TB granulomas, IL-10 within the 
granulomas was necessary to reduce bacterial loads [275]. Granulomas from NHP-infected 
macaques expressing IL-10 in conjunction with pro-inflammatory cytokines, such as IL-17, were 
associated with better clearance [102].  
To conclusively address the role of IL-10 during Mtb infections for the host immune 
response to contain Mtb, we used our NHP model and a macaque-specific anti-IL-10 neutralizing 
antibody to manipulate the levels of IL-10 in vivo during Mtb infection. Our NHP model 
recapitulates the spectrum of disease and pathology in human Mtb infections. Since we have the 
advantage of knowing exactly when the NHPs are infected, we can address the role of IL-10 at 
critical, early time points after infection, as the immune cells establish in the lungs and form 
granulomas. Using our NHP model, we can examine the effect of IL-10 on TB outcome on a 
systemic level, as well as probe the effects in the individual TB granulomas. When IL-10 was 
neutralized in our model, certain cytokine responses in lung granulomas and thoracic lymph 
nodes increased early on, 4 weeks after the onset of Mtb infection. However, by 8 weeks post-
infection, these effects on lung granulomas and lymph nodes decreased or stabilized. Our study 
indicated that while IL-10 impairs the cytokine response in lung granulomas and lymph nodes 
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early in infection, IL-10 does not affect the short-term overall bacterial burden or disease 
outcome during Mtb infection. 
2.3 RESULTS 
2.3.1 Anti-IL-10 antibody neutralizes activity of macaque IL-10 
The role of IL-10 in Mtb infections has been difficult to discern due to model variability and 
technical difficulties in studying IL-10 at the local sites of infection in TB patients. To better 
understand IL-10 at the primary site of infection, TB lung granulomas, we used our NHP 
cynomolgus macaque model of Mtb infections, which recapitulates the granuloma structure and 
disease pathology observed in humans. While TB granulomas are independent entities, and not 
all have detectable levels of IL-10, we aimed to understand how those granulomas with IL-10 
differed in their control of the bacterial burden and disease pathology from those lacking IL-10. 
Collaborators at MassBiologics (Dr. Keith Reimann, University of Massachusetts 
Medical School) created an antibody to specifically bind to macaque IL-10, which neutralizes 
active IL-10 activity (Figure 3A). D36 mouse mast cells are IL-10 dependent, thus the addition 
of 20ng/ml rhesus macaque IL-10 increased cell proliferation. The anti-macaque-IL-10 antibody 
was added at varying concentrations to the rhesus macaque IL-10, and reduced D36 mast cell 
proliferation to baseline levels. This demonstrated neutralization of macaque IL-10 by this 
antibody. We used this anti-IL-10 antibody in the rest of this study to investigate whether IL-10 
had an effect on T cell function in TB granulomas.  
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Using excised and homogenized TB granulomas from Mtb-infected cynomolgus 
macaques, we treated one half of a granuloma sample with the anti-IL-10 antibody, while 
treating the other half as a media control, and then looked at the effects of neutralizing IL-10 on 
cytokines by flow cytometry. In TB granulomas with detectable levels of IL-10 by ELISA, 
treatment of TB granuloma T cells with anti-IL-10 antibody increased the frequency of CD3 T 
cells producing IL-2 compared to the media control (i.e., delta IL-2% = anti-IL-10 IL-2% – 
media IL-2% > 0). Granulomas with detectable levels of IL-10 had greater increase in IL-2 
response after anti-IL-10 antibody treatment (Figure 3B), suggesting that IL-10 in TB 







Figure 3. Anti-IL-10 antibody neutralizes macaque IL-10.  
(A) D36 mouse mast cells are IL-10 dependent for cell proliferation. Mast cells supplemented 
with 20ng/ml rhesus IL-10 proliferate, while mast cells and rhesus IL-10, plus varying 
concentrations of anti-IL-10 antibody have reduced proliferation, as measured by tritiated-
thymidine levels. (B) Changes in frequency of T cells (comparing ex vivo anti-IL-10-antibody-
treated to the same untreated excised granulomas) producing IFN- (Delta IFN-%), IL-2 (Delta 
IL-2%), and IL-17 (Delta 1L-17%) by flow cytometry according to whether there were 
detectable levels of IL-10 in the granulomas. IL-10- indicates granulomas with no detectable IL-
10 by ELISA, IL-10+ indicates granulomas with detectable IL-10 by ELISA.  
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2.3.2 In vivo assessment of IL-10 effects on M. tuberculosis infection 
Immune responses in individual granulomas, even from the same macaque, are extremely 
variable. This was true of IL-10 levels in granulomas as well (Figure 3B) [102]. Although not 
every TB granuloma has detectable levels of IL-10, those that do are more likely to experience 
IL-10 modulation. Previously, we have observed that granulomas with strong T cell-mediated 
IL-10 production balanced with a pro-inflammatory cytokine response, such as IL-17, are 
associated with sterilization [102]. However, the timing of the IL-10 response in TB granulomas 
is not well understood [134, 136, 137]. To examine whether IL-10 in TB granulomas early in 
infection may prevent a robust T cell response and thus sterilization, we planned an in vivo IL-10 
depletion study (Figure 4). The adaptive immune response to Mtb is initiated between 3-4 weeks 
post-infection, but robust bacterial killing in granulomas is only observed after 8 weeks. This 
study looked specifically at 4 weeks and 8 weeks post-infection, with IL-10 depletion throughout 
the course of infection, beginning one day before Mtb infection. We maintained IL-10 depletion 
throughout the study by infusions with the anti-IL-10 antibody approximately every 10 days. A 
dose of 15mg/kg was chosen based on unpublished data from a similar human antibody in 
cynomolgus macaques, which indicated effectiveness without side effects. Lack of IL-10 has 
been shown to cause intestinal inflammation and colitis in both human genetic studies and 
animal models [276-278]. Our collaborators confirmed that this dose of anti-IL-10 antibody in 
our cynomolgus macaque model did not cause adverse side effects and colitis in uninfected 
cynomolgus macaques (data not shown).  
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Figure 4. Experimental setup for study of IL-10 neutralization in vivo in cynomolgus 
macaques for 4 weeks and 8 weeks.  
In each study, anti-IL-10 antibody infusions began one day before Mtb infection and continued 
throughout the course of infection, for every 10 days (+/-3 days). 
 
2.3.3 Early peripheral and tissue-specific response to IL-10 neutralization 
During the course of the study, we tracked the peripheral effects of IL-10 neutralization on the 
immune response to Mtb infection. Since IL-10 can affect many immune cell types in addition to 
lymphocytes, we tested the peripheral immune cell response to Mtb by stimulating whole blood 
from critical time points during the course of infection (Figure 5A) and measuring IL-10 by 
multiplex immunoassay (Luminex). Since this assay does not distinguish between active and 
inactive IL-10, the cytokines detected could be bound by the anti-IL-10 antibody. While 
unstimulated (media only) whole blood cells had undetectable levels of IL-10 throughout the 
Mtb infection, the neutralization of IL-10 led to sustained peripheral IL-10 responses to Mtb 
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stimulation in whole blood through 4 weeks. In comparison, control animals peaked in their 
response to Mtb at 2 weeks. This suggests the host immune response produces IL-10 in response 
to Mtb early in infection (2 weeks), and in the absence of functional IL-10, this response may 
continue for an additional 2 weeks before additional immune response factors compensate for 
IL-10 by 8 weeks post-infection. 
We also followed the inflammatory response in the lungs over the course of Mtb 
infection using PET-CT imaging of 18F-FDG uptake as a marker of inflammation. Overall lung 
inflammation was similar between the anti-IL-10 treated animals and the saline control animals 
(Figure 5B). But when we further examined the FDG avidity within individual granulomas, we 
found a subset of granulomas in anti-IL-10 treated animals had much lower levels of 
inflammation, particularly early in infection, at 3 and 4 weeks post-infection (Figure 5C). 
Although there was a range of FDG activity in granulomas in both groups, a subset of the 
granulomas from IL-10 neutralized animals were extremely low, which was not seen in saline-
treated animals. Granulomas from anti-IL-10 treated animals tended to have low inflammation 
through the 8 weeks of infection, while granulomas from saline animals started with higher 
inflammation, peaking at 4 weeks post-infection, and then decreasing to similar levels as anti-IL-
10 granulomas by 8 weeks. The reduction in inflammation after neutralizing an anti-
inflammatory cytokine, IL-10, in TB granulomas was a surprising result. Since 18F-FDG is a 
marker of metabolic activity, and a general indicator of inflammation, these results suggest that 




Figure 5. Early peripheral and lung response to anti-IL-10 treatment.  
(A) Whole blood IL-10 response to gamma-irradiated Mtb over the course of Mtb infection (p = 
0.02 at 4 Weeks post-infection, Mann-Whitney test). Each dotted line/color indicates a NHP, 
solid black line indicates average of anti-IL-10 NHPs, solid gray line indicates average of control 
NHPs. (B) Total lung inflammation (total 18F-FDG uptake) during the course of infection, anti-
IL-10 treated and saline control. Each color indicates a NHP. Gray points indicate historical 
controls. (C) 18F-FDG-uptake in individual lung granulomas during the course of infection, as 
measured by standard uptake value normalized to muscle (SUV) Each point is a granuloma 
identified from PET-CT scans, each color is a NHP. Lines at medians. Numbers indicate p-
values from Mann-Whitney test. 
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2.3.4 Neutralization of IL-10 does not affect early disease outcome 
The differences in early peripheral response and granuloma inflammation did not translate to 
overall disease outcome. Anti-IL-10 treated animals had similar disease pathology at the end of 4 
and 8 weeks of infection as untreated animals (Figure 6). Their total thoracic (lung plus lymph 
node) bacterial burden, as well as bacterial burden within individual granulomas, was also 
similar between the two groups at both 4 and 8 weeks post-infection. Few animals had evidence 
of extrapulmonary disease, and there were no differences between the anti-IL-10 and control 
groups (data not shown).  Lower inflammation in granulomas at 4 weeks did not seem to lead to 




Figure 6. Disease pathology and bacterial burdens.  
Similar disease outcomes between anti-IL-10 treated animals compared to untreated animals at 
(A) 4 weeks and (B) 8 weeks post-infection. Disease pathology quantified by necropsy scores, 
which measures amount of disease pathology in lungs, lymph nodes, and extrapulmonary sites. 
Bacterial burden measured by colony forming units (CFU) in all lung and lymph node samples 
for total bacterial burden, and in individual excised granulomas for bacteria in granulomas. Each 
point/color in disease pathology and total bacterial burden graphs indicate a NHP, gray indicates 
historical controls. Each point in bacteria in granulomas graph indicate a granuloma, each color 
indicates a monkey, gray indicates samples from historical controls. Lines at medians. 
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2.3.5 IL-10 neutralization does not affect lung granuloma cell composition or T cell 
function 
To further assess the effects of anti-IL-10 treatment on the immune cells in lung granulomas and 
granuloma clusters, we looked at the frequencies of cell populations by flow cytometry (Figure 
7). Although some granulomas in anti-IL-10 treated animals had higher frequencies of some cell 
populations than granulomas from saline controls, overall the cell populations within granulomas 
were similar between the two groups at 4 and 8 weeks post-infection (Figure 8A and 8B). We 
further investigated T cell populations in unstimulated granulomas by flow cytometry, looking at 
regulatory T cell populations (CD4+FOXP3+), activated T cells (CD69+), and Th1 cells (IFN-
+TNF+) (Figure 9). We could not discern a difference in T cell populations between the anti-IL-
10-treated and untreated animals.  
Since we observed neutralization of IL-10 in TB granulomas ex vivo increased IL-2 
response, we asked whether the anti-IL-10 antibody infusions in vivo also increased T cell IL-2 
responses. As we had observed ex vivo, some of the granulomas from anti-IL-10 treated animals 
had higher IL-2 responses from the T cells compared to granulomas from the saline control 
animals, but it was not consistent (Figure 9). Perhaps only a subset of the granulomas in the anti-
IL-10 animals were IL-10 responsive, and thus had differential response with IL-10 
neutralization. 
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Figure 7. Flow cytometry gating strategy for cell populations.  
Gating strategy from representative lung granuloma used to distinguish different cell 
populations, using CD3 as a T cell marker, CD20 as a B cell marker, CD11b and CD163 as 
macrophage markers, and CD11b and calprotectin as neutrophil makers. CD3 T cell population 
further separated into CD4+ and CD4- populations, with CD4- cells used to approximate the 




Figure 8. Immune cell populations in lung granulomas and lung clusters. 
Similar frequencies of immune cell populations in lung granulomas and granuloma clusters 
between anti-IL-10 treated and untreated animals at (A) 4 weeks and (B) 8 weeks of infection. 
CD3 is used as a marker of T cells, CD4 is used as a marker of CD4 T cells, CD4- is used as an 
approximation of CD8 T cells, CD20 is used as a marker of B cells, CD11b+CD163+ is used as 
a marker of macrophages, CD11b+Calprotectin+ is used as a marker of neutrophils. Each point 
represents a lung granuloma or cluster of granulomas, each color is a NHP. Lines are at medians. 
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Figure 9. T cell populations in lung granulomas and granuloma clusters.  
Similar T cell population frequencies between anti-IL-10 treated and untreated controls at (A) 4 
weeks and (B) 8 weeks of infection. CD4+FOXP3+ is used as a marker of regulatory T cells, 
CD3+CD69+ is used as a marker of T cell activation, CD3+IFN-g+TNF+ is used as a marker of 
Th1 cells, and CD3+IL-2+ is used as a marker of T cells producing IL-2. Each point represents a 
lung granuloma or cluster of granulomas, each color is a NHP. Lines are at medians. 
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2.3.6 IL-10 receptor is most commonly expressed on non-T cells in TB granulomas 
Since we did not observe many differences in the T cell populations or their cytokine responses 
in lung granulomas despite our initial results ex vivo IL-10 neutralization results (Figure 3B), we 
sought to measure the number and types of cells in TB granulomas that would be responsive to 
IL-10. By immunohistochemistry, we determined that the majority of cells in TB granulomas 
expressing IL-10 receptor (IL-10R) were not CD3+ at either 4 weeks or 8 weeks (Figure 10A 
and 10B). Instead, IL-10R co-localized more with CD11c+ macrophage clusters on the outer 
edge of the granuloma macrophage region and with CD20+ B cells in the lymphocyte cuff 
(Figure 10B and 10C). A few CD3 cells co-expressed IL-10R, but most of the IL-10R signal was 
not on CD3 cells (Figure 10 insets). Although IL-10 has immunosuppressive effects on T cells 
(which may be indirect), perhaps the T cells in TB granulomas were not as affected by the 
absence of IL-10 during anti-IL-10 neutralization because they tend to be the minor IL-10R-
expressing immune cell in the granuloma. Thus, IL-10 neutralization may have a more 
significant role on the immune response of non-T cells in TB granulomas, such as macrophages 
and B cells. 
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Figure 10. IL-10R co-localizes with non-T cells in TB granulomas.  
(A) A representative granuloma from 4 weeks of Mtb infection has more co-localization of IL-
10R (red) with CD11c-expressing cells (blue) than CD3-expressing cells (green).  (B) A 
representative granuloma from 8 weeks of Mtb infection also has more IL-10R (red) co-
localization with CD11c cells (blue) than CD3 cells (green). (C) The same granuloma as in (B) 
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shows that the B cells (blue) are IL10R-positive (red), along with a few CD3 cells (green) also 
expressing IL-10R. Scale bar in DAPI indicates 500um. 
 
2.3.7  IL-10 neutralization increases innate cytokine response and fibrosis in lung 
granulomas 
While we did not discern differences in cell populations or their potential frequencies of cytokine 
response within lung granulomas and clusters of granulomas, total concentrations of certain 
cytokines in granulomas were different between anti-IL-10 treated and untreated control animals. 
Cytokines in supernatants of granuloma homogenates were measured using the multiplex 
immunoassay Luminex. At 4 weeks post-infection, anti-IL-10 treated animals had increased 
levels of IL-2, IL-13, IL-12p70, and IL-23 compared to granulomas from control animals (Figure 
11A). These cytokines are likely produced by innate cells, as well as T cells, but neutralization of 
IL-10 did not lead to increases in all cytokine responses. Anti-IL-10-treated animals had reduced 
IL-18 and IL-1beta in their granulomas compared to control granulomas (Figure 11A).  
By 8 weeks post-infection, most of the T cell inducing cytokines that were prominent at 4 
weeks post-infection were no longer detectable or were no longer significantly different in 
granulomas of anti-IL-10 and saline treated animals (Figure 11B). Instead, granulomas from anti-
IL-10 treated animals had lower levels of total IL-1beta, IL-1RA, IL-6, and IFN-beta compared 
to granulomas from untreated animals. IL-23, which was significantly increased at 4 weeks post-
infection in anti-IL-10 animals, tended to be lower in anti-IL-10 granulomas at 8 weeks post-
infection. IL-10 may reduce the innate and adaptive immune response in lung granulomas early 
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in infection at 4 weeks, but have a differential effect and increase innate cytokine response after 
8 weeks of Mtb infection. 
These differences in cytokine response in granulomas from anti-IL-10 animals may 
change the granuloma structure during Mtb infection. Blinded histopathological analysis of 
granulomas from both treatment groups revealed more evidence of fibrosis in granulomas from 
animals treated with anti-IL-10 at the time of necropsy compared to control animals (Figure 
12A). Nearly half of the granulomas analyzed from anti-IL-10 animals showed signs of fibrosis, 
which may suggest that IL-10 prevents healing-associated fibrosis in lung granulomas during 
Mtb infections. It is possible that the fibrosis in lung granulomas contributes to the lower levels 
of inflammation previously observed at 4 weeks of infection (Figure 5C and 12B), perhaps due 




Figure 11. Total cytokine response in lung granulomas and granuloma clusters.  
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Total cytokine response in lung granulomas and granuloma clusters are higher in anti-IL-10 
treated animals (A) at 4 weeks post-infection, but lower (B) at 8 weeks post-infection. Each point 
represents a lung granuloma or cluster of granulomas, each color is a NHP. Lines are at medians. 




Figure 12. Fibrosis in lung granulomas. 
More fibrotic granulomas from anti-IL-10 treated NHPs compared to untreated controls. (A) 
Numbers of granulomas with signs of fibrosis compared to non-fibrotic granulomas in the two 
treatment groups at time of necropsy, anti-IL-10 = 13 NHPs, control = 8 NHPs. P-value from 
Fisher’s exact test. (B) Comparison of 18F[FDG] uptake in lung granulomas at 4 weeks of 
infection to signs of fibrosis at the time of necropsy. P-value from Mann-Whitney test. 
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2.3.8 IL-10 inhibits cell recruitment and immune response in lymph nodes 
Considering the strong increase in T cell-promoting cytokines, such as IL-2 and IL-12p70, in the 
absence of IL-10 at 4 weeks post-infection by Luminex, we expected this increase to lead to 
more T cells or increased T cell function. However, as shown in Figures 8 and 9, there were no 
differences in frequencies of T cell populations in lung granulomas as assessed by flow 
cytometry at 4 weeks post-infection. Since thoracic lymph nodes are also infected in macaques, 
we investigated whether IL-10 neutralization affected the T cell response to Mtb infection in 
lymph nodes (LNs).  
 After 4 weeks of infection, the Mtb-infected LNs of anti-IL-10 treated animals had higher 
levels of bacterial burden compared to control animals (Figure 13A, anti-IL-10 median = 4.98log 
CFU, control median = 3.4log CFU). Along with the higher bacterial burden, these Mtb-infected 
LNs had skewed CD4+/CD4- T cell ratios by flow cytometry (Figure 13B). Because of limited 
space in flow cytometry panels, CD3+CD4- was used as a substitute for CD8 T cells, as previous 
data had shown that the majority of CD3+CD4- cells were CD3+CD8+ cells. By calculating the 
numbers of CD3+ T cells in the LNs, at 4 weeks post-infection, there were 4-fold more CD4- 
(likely CD8+) T cells in LNs of anti-IL-10 treated animals (median = 1.32x107 cells) compared 
to control animals (median = 3.62x106 cells), while numbers of CD4+ cells were similar between 
both groups (anti-IL-10 median = 6.35x106 cells, control median = 4.09x106 cells) (Figure 13C 
and 13D). Similar to the lung granulomas, the total cytokine concentrations in the Mtb-infected 
LN supernatants of the anti-IL-10 animals had higher levels of T cell-promoting cytokines IL-2 
and IL-12p70 compared to LNs of control animals. The Mtb-infected LNs of anti-IL-10 animals 
also had more IFN- and TNF compared to control animals. Interestingly, there were also 
increased levels of lymphocyte recruiting chemokines in the LNs of anti-IL-10 animals (Figure 
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13E). This suggests that during Mtb infection, IL-10 may normally prevent T cell proliferation 








Figure 13. Bacterial burden and immune response in LNs at 4 weeks post-infection. 
Neutralization of IL-10 leads to uncontrolled bacterial replication and skewed T cell responses in 
LNs at 4 weeks post-infection. (A) Bacterial burden is higher in Mtb-infected LNs at 4 weeks 
post-infection. (B) At 4 weeks post-infection, anti-IL-10 treated animals have skewed CD4/CD4- 
ratios of CD3+ T cells compared to control animals by flow cytometry. The numbers of CD3+ T 
cells that are (C) CD4 and (D) CD4- in LNs show that there are more CD4- cells in LNs of anti-
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IL-10 treated animals. E) At 4 weeks post-infection, LNs from anti-IL-10 treated animals have 
higher total cytokine and chemokine responses, particularly lymphocyte-inducing chemokines. 
Each point is a Mtb-infected LN, each color is a NHP, gray indicates historical control. P-values 
from Mann-Whitney tests. 
 
However, after an additional 4 weeks of Mtb infection, there was no longer a difference 
in the bacterial burden in Mtb-infected LNs between the two groups and the ratio of T cell 
subsets in anti-IL-10 animals reversed, with more CD4+ T cells relative to CD4- T cells 
(CD4/CD4-ratio median = 1.91) in the IL-10 neutralized group (Figure 14A and 14B). While the 
number of CD4+ T cells in Mtb-infected LNs were similar at 8 weeks to their numbers at 4 
weeks (anti-IL-10 median = 4.2x106 cells, control median = 1.112x106 cells), the elevated 
numbers of CD4- T cells observed in anti-IL-10 treated animals 4 weeks of Mtb infection greatly 
decreased by 8 weeks (median = 2.4x106 cells) (Figure 14C and 14D). Thus, after 8 weeks of 
Mtb infection, the numbers of CD4- T cells in the LNs of anti-IL-10 treated animals decreased, 
so that not only were there fewer CD4- T cells at 8 weeks relative to CD4+ T cells, but there 
were also much fewer CD4- T cells at 8 weeks compared to at 4 weeks post-infection. These 







Figure 14. Bacterial burden and immune response in LNs at 8 weeks post-infection. 
Neutralization of IL-10 leads to skewed T cell responses in LNs at 8 weeks post-infection. (A) 
Bacterial burden is similar in Mtb-infected LNs from both treatment groups at 8 weeks post-
infection. (B) At 8 weeks post-infection, anti-IL-10 treated animals have skewed CD4/CD4- 
ratios compared to control animals. The numbers of (C) CD4 and (D) CD4- cells in LNs show 
that there are more CD4- cells in LNs of anti-IL-10 treated animals. Each point is a Mtb-infected 
LN, each color is a NHP. P-values from Mann-Whitney tests. 
 
The increased bacterial burden, CD4- T cells, T cell-promoting cytokines, and 
lymphocyte recruiting chemokines at 4 weeks of Mtb infection in the absence of functional IL-10 
correlated with an increase in LN effacement (necrosis) compared to control animals (Figure 
15A). Along with the effacement, the Mtb-infected LNs from anti-IL-10 treated animals also had 
increased numbers of total immune cells compared to those from control animals (Figure 15B). 
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By 8 weeks, however, there are similar numbers of effaced LNs from anti-IL-10 treated and 
untreated animals, and the Mtb-infected LNs have similar numbers of immune cells (Figure 15C 
and 15D). Thus, anti-IL-10 treatment may cause earlier effacement of LNs compared to control 
animals. Taken together, these results suggest that during Mtb infection, IL-10 may help control 





Figure 15. LN effacement at 4 and 8 weeks post-infection. 
(A) Anti-IL-10 treatment in animals increases LN effacement early at 4 weeks post-infection, 
with (B) higher numbers of cells within LNs within anti-IL-10 treated animals. In anti-IL-10 
group, number of LNs analyzed per NHP ranged from 7-10. In control group, number of LNs 
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analyzed per NHP ranged from 7-11. (C) At 8 weeks post-infection, the number of effaced LNs 
are similar between anti-IL-10 and control animals, with (D) similar numbers of cells in LNs 
from both experimental groups. In anti-IL-10 group, number of LNs analyzed per NHP ranged 
from 8-11. In control group, number of LNs analyzed per NHP ranged from 8-12. Each point is a 
Mtb-infected LN, each color is a NHP, gray indicates historical control. P-values from Mann-
Whitney tests. 
2.4 DISCUSSION 
Nearly a third of the world’s population is infected with Mtb, yet the correlates of protection are 
still unknown. Although pro-inflammatory cytokines have been demonstrated to be necessary to 
control Mtb replication, the role of anti-inflammatory cytokines to counteract these tissue-
damaging cytokines have not been fully elucidated. Previous studies had contradictory 
conclusions about the beneficial or harmful role of IL-10 during Mtb infection [102, 132-142]. 
Some studies suggested that IL-10 may have differential roles during Mtb infection depending 
on stage of infection [134, 136]. We sought to clarify the role of IL-10 within TB lung 
granulomas using our NHP model of TB and an anti-IL-10 antibody that we demonstrated to 
neutralize macaque IL-10. Our preliminary ex vivo results suggested that IL-10 may 
downregulate the T cell cytokine response and that not all TB granulomas may be responsive to 
IL-10. Our in vivo study neutralizing the effects of IL-10 in a cohort of NHPs during early Mtb 
infection (4 and 8 weeks) demonstrated that IL-10 may be downregulating the cytokine response 
and increasing inflammation in lung granulomas and lymph nodes very early in Mtb infection (4 
weeks), but may have fewer effects by 8 weeks of Mtb infection. However, the presence or 
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absence of IL-10 does not ultimately influence the host control over bacterial burden or disease 
pathology, at least up to 8 weeks of infection. 
 The results from this study indicate that IL-10 has the greatest effect on the host immune 
response to Mtb infection early in infection, within the first 4 weeks of infection. Our peripheral 
data indicated that the circulating immune cells respond to Mtb by producing IL-10 early on in 
infection, after 2 weeks of infection, but this response was reduced by 4 weeks of infection. In 
the absence of IL-10, the peripheral immune cells from the anti-IL-10 treated animals continued 
to produce significantly higher levels of IL-10 in response to Mtb stimulation. Mtb is a well-
documented stimulator of IL-10 production [128, 279], but the neutralization of IL-10 response 
in anti-IL-10 treated animals seemed to sustain the IL-10 production by Mtb-responsive immune 
cells longer than control animals. It is possible that the lack of IL-10 prevented downstream 
mechanisms and downregulation of response to Mtb stimulation, or that lack of active IL-10 
interrupted a feedback loop of IL-10 regulation. 
The increase in cytokine response in lung granulomas and LNs at 4 weeks after anti-IL-
10 treatment was expected, particularly in the pro-inflammatory cytokines IL-23, IL-2, and IL-
12p70 in the lungs, and the Th1 cytokines (IFN-, IL-2, TNF) and IL-12p70 in the LNs. IL-10 
has been demonstrated to be anti-inflammatory, and the blockade or removal of IL-10 from in 
vitro and in vivo experimental models increased pro-inflammatory cytokine response, 
particularly in macrophages and T cells [125-127]. Our initial ex vivo experiments indicated that 
IL-10 neutralization affected the T cell IL-2 response. While our in vivo experiments showed 
increased T cell inducing cytokines and chemokines in the lung granulomas and LNs, we did not 
observe increased frequencies or numbers of T cells in the absence of functional IL-10. 
However, increased cytokines and chemokines, particularly in the LNs, may be increasing T cell 
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priming and functionality. Increased LN responses in the absence of IL-10 during Mtb infection 
were also observed in previous studies [132, 136]. Interestingly, unlike Redford et al., who 
observed increased numbers of CD4+ T cells in the draining LNs of IL-10 knock-out mice 
compared to controls [132], we observed increased numbers of CD4- (presumably CD8+) T 
cells, particularly at 4 weeks post-infection.  Our results were more similar to studies in acute 
LCMV infection, where blockade of IL-10 during acute LCMV infection increased CD8 T cells, 
particularly during the priming phase [280, 281]. IL-10 has also been shown to inhibit CD8 T 
cell responses in other models of infection, such as in listeria and HIV [282, 283]. However, the 
heightened LN T cell responses and recruitment did not necessarily translate into host control or 
clearance of Mtb infection, and seemed to only accelerate LN effacement. 
Many of the T cell promoting cytokines and chemokines that were produced in anti-IL-10 
treated animals are produced by myeloid cells. There were also lower concentrations of 
macrophage-produced cytokines (IL-1beta, IL-1RA, IL-18, IL-6) in lung granulomas of anti-IL-
10 treated animals at 8 weeks. In addition, as we and others have demonstrated, the receptor for 
IL-10 (IL-10R) is predominantly on non-T cells, especially in TB granulomas [138, 284, 285]. A 
study investigating overexpression of IL-10 during Mtb infections concluded that macrophage 
IL-10 was the most crucial aspect of controlling Mtb numbers [138]. Thus, although IL-10 can 
affect most immune cells, it may primarily affect myeloid cells in the context of Mtb infections. 
This also corresponds to the change in the immune response in anti-IL-10 treated animals 
between 4 and 8 weeks of Mtb infection. Since IL-10 may have the most influence on myeloid 
cells in Mtb infections, it is reasonable that it may cause the most changes during the initial 
stages of the infection, when the innate immune response dominates in the lungs and in priming, 
followed by smaller effects after the onset of the adaptive immune response around 6 weeks of 
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infection [68]. Thus, while we observed greater changes in the cytokine and chemokine response 
in anti-IL-10 animals after 4 weeks of infection, the adaptive immune response may counteract 
and minimize the influence of IL-10 by 8 weeks.  
The lack of functional IL-10 in this study increased fibrosis in lung granulomas at the 
time of necropsy (4 or 8 weeks). The role of fibrotic lesions in TB is unclear, but they tend to be 
associated with containment, drug treatment, and sterility [286, 287]. Fibrosis is a healing 
response that can result in pathology but can also limit spread of infection, and is not generally 
observed at early time points in Mtb infection, but is seen more at later time points. Early 
blockade of IL-10 during Mtb infection also led to fibrotic granuloma formation in the mouse 
model [136]. Higgins et al. also observed changes in granuloma structure of IL-10 knock-out 
mice [139]. While we did not observe the same levels of bacterial control in our NHP model, 
neutralization of IL-10 significantly increased the fibrosis and collagenization of lung 
granulomas. The significance of fibrosis in granulomas is currently unclear, but the fibrosis in 
lung granulomas may lead to improved bacterial containment and/or modified lung pathology in 
the long term beyond the scope of this study. 
Surprisingly, a subset of granulomas from the anti-IL-10 treated animals had very low 
levels of 18F-FDG uptake, a metabolic proxy for inflammation, especially during early Mtb 
infection. This also contrasted with the higher levels of pro-inflammatory cytokines, such as IL-
23, IL-2, IL-12p70 that we measured from lung granulomas. The increased fibrosis in the lung 
granulomas of anti-IL-10 treated animals could also decrease the amount of metabolically active 
cells in the granulomas. The measured inflammation could be more influenced by the lower 
concentrations of pro-inflammatory cytokine IL-18 and higher concentrations of anti-
inflammatory cytokine IL-13 we observed. However, because of the non-specificity of 18F-FDG, 
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other unmeasured factors or indirect effects could be causing the decrease in granuloma 
inflammation in the absence of functional IL-10.  
Although neutralization of IL-10 caused transient increase in cytokine and chemokine 
response, these increased immune responses did not affect the overall disease pathology or 
bacterial burden at either of the two time points investigated in this study. The absence of IL-10 
during Mtb infection did not decrease the bacterial load in the lungs (or individual granulomas) 
or lymph nodes as other studies had suggested [132, 134, 136], but it also did not cause increased 
disease pathology and decreased survival [139]. This could be the result of several possible 
reasons. First, IL-10 may not have a significant role in the host immune response to Mtb. Some 
previous studies have found that complete depletion of IL-10 or depletion of the primary T cell 
producers of IL-10 during Mtb infection had little to no effect on the bacterial load compared to 
wild-type mice [139-141, 288]. Second, not all granulomas may respond to IL-10 in the same 
manner. Previous studies from our lab have demonstrated the individuality of each granuloma, 
even from the same animal [102, 269]. Our ex vivo neutralization assays also suggest that 
granulomas may not all be producing or responding to IL-10 during Mtb infection. 
Third, other host factors may compensate for the lack of IL-10. Roach et al. also noticed 
a transient decrease in bacterial burden of IL-10 knock-out mice after 4 weeks of infection, but 
by 8 weeks post-infection, there was no difference in bacterial burden compared to wild-type 
mice [142]. In our study, IL-10 seemed to have the most effect on the host immune response at 4 
weeks post-infection. This could be due to the onset of the adaptive immune response by 
approximately 6 weeks post-infection counteracting the absence of IL-10 [68]. The observed 
increase in Th2 cytokine IL-13 with anti-IL-10 treatment at 4 weeks may have helped 
compensate for the lack of IL-10. Although we quantified FOXP3+ regulatory T cells in our 
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study, we did not measure the anti-inflammatory cytokine TGF-. Mtb can also stimulate the 
production of TGF-, and may compensate for the lack of IL-10 in these animals [285, 289]. 
Due to the limitations of this study, we may have not quantified the factor(s) that compensated 
for the actions of IL-10. 
Fourth, the role of IL-10 during Mtb infection could be timing-dependent. This study was 
restricted to look at the earliest time points of Mtb infection, at 4 and 8 weeks, during which we 
found the greatest peripheral response to Mtb stimulation. Turner et al. observed overexpression 
of IL-10 in the mouse model of Mtb infection had no effect on the bacterial load until much later 
in infection, approximately 5 months post-infection [137]. Other studies further dissecting the 
timing of IL-10 during Mtb infection found that IL-10 had the greatest effect on the host ability 
to control the bacterial burden starting at least 3 months post-infection [134, 136, 138]. However, 
computational modeling of IL-10 during the course of Mtb infections indicated that IL-10 
prevented clearance of bacteria during early infection [275]. While Moreira-Texeira et al. did not 
observe decreased bacterial loads within one month of infection, they did have significantly 
lower bacterial burdens in IL-10-depleted and Mtb-infected mice after two months [135]. 
Although our study looked at the effects of early neutralization during early Mtb infection only, 
these early neutralization events may set up the immune response for long-term control of 
bacterial loads outside the scope of this study, as previously showed by Cyktor et al. [136].  
Future studies should further investigate the role of IL-10 during more chronic infections. 
In summary, our studies of early Mtb infection in a NHP model in the presence or 
absence of functional IL-10 indicate that IL-10 primarily affects innate cells, namely 
macrophages, to downregulate T cell recruitment and proliferation in lung granulomas and 
draining LNs, to induce LN cell recruitment and effacement, and to decrease inflammation while 
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promoting fibrosis in lung granulomas. However, with the onset of the adaptive immune 
response at 6 weeks, many of these changes may be compensated for by other immune cells and 
host factors by 8 weeks of Mtb infection. Overall, these changes in the immune response without 
IL-10 do not affect the bacterial load or disease pathology during the first 8 weeks of Mtb 
infection. This study demonstrates that IL-10 may not have as significant of a role in Mtb 
infections as previously suggested. IL-10 likely works in more cooperation with other immune 
cells, and does not appear to be the sole anti-inflammatory response in Mtb to prevent tissue 
damage, with other cytokines to also compensate [285, 289, 290]. This study further 
demonstrates the need for a balance of immune responses within the locally affected tissues 
during Mtb infection, and the need to continue to identify other host factors that may be 
detrimentally preventing an effective immune response against Mtb. 
2.5 MATERIALS AND METHODS 
2.5.1 IL-10 neutralization in vitro and ex vivo assays 
D36 mouse mast cells (ATCC, Manassas, VA) were cultured in IMDM media (Sigma, United 
Kingdom) containing 10% FBS, 1% HEPES, 1mM sodium pyruvate, and 1% L-glutamine in the 
presence of 1ng/ml IL-3 and 1ng/ml IL-4. Cells were washed in PBS, counted by Trypan Blue 
exclusion, and resuspended in RPMI media (Sigma, United Kingdom) containing 1% HEPES 
and 1% L-glutamine before resting for 3 hours at room temperature. Following rest, cells were 
counted again by Trypan Blue exclusion and aliquoted in sterile 96 well flat bottom plates at 
100,000 cells/well in 100l. Rhesus macaque IL-10 (kindly provided by Dr. Francois Villinger) 
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was added to appropriate wells at a concentration of 20ng/ml. Macaque-IL-10-specific antibody 
(IL-10R1-LALA, MassBio, Cambridge, MA) was added to appropriate wells at varying 
concentrations (1-100g/ml). Samples were incubated for 18 hours at 37C. Tritiated thymidine 
(PerkinElmer, Waltham, MA) was diluted in AIM V media (Gibco, Gaithersburg, MD) to a 
concentration of 20Ci/ml and added to all samples before incubation for another 6 hours at 
37C. Cells were harvested onto glass fiber filters (PerkinElmer, Waltham, MA) before 
incorporated radioactivity was determined by liquid scintillation counting (TopCount, 
PerkinElmer, Waltham, MA). 
2.5.2 IL-10 neutralization in ex vivo assays 
Excised lung granulomas from cynomolgus macaques (Macaca fascicularis) designated for other 
studies were homogenized as previously described [267]. Single cell suspensions of lung 
granulomas were used for flow cytometry, while corresponding supernatants were stored at -
80C until ELISA as described below. Samples were resuspended in assay media (RPMI with 
1% HEPES, 1% L-Glutamine, and 10% human AB serum) and divided into 2 wells in a sterile 
96 well round bottom plate. Samples were washed with additional assay media. Sample halves 
designated for anti-IL-10 antibody neutralization treatment were resuspended in media 
containing anti-IL-10 antibody diluted in assay media for concentration of 10g/ml (IL-10R1-
LALA, MassBio, Cambridge, MA). Corresponding sample halves designated as media controls 
were resuspended in equal volumes of assay media. Samples were incubated overnight at 37C. 
Following overnight incubation, samples were stimulated with peptide pools of Mtb-specific 
antigens ESAT-6 and CFP-10 (10ug/ml of each peptide) and Brefeldin A (GolgiPlug, BD 
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Biosciences, San Jose, CA) for 3.5-4 hours at 37C. Samples were then stained for viability 
(Invitrogen), cell surface markers, and intracellular cytokine markers. Cells were identified as T 
cells, with antibodies against CD3 (clone SP34-2), CD4 (clone L200), and CD8 (clone SK1). 
Following permeabilization using Fixation/Permeabilization solution (BD Biosciences), cytokine 
and cellular response were identified using antibodies against IFN-g (clone B27), IL-2 (clone 
MQ1-17H12), TNF (clone MAB11), IL-17 (clone eBio64CAP17), IL-10 (clone JES3-9D7), and 
Ki67 (clone B56). Data acquisition was performed using a LSRII (BD) and analyzed using 
FlowJo Software v.9.7 (Treestar Inc, Ashland, OR). 
 Stored supernatants were thawed and filtered using 0.22m syringe filter into ~1ml 
aliquots immediately before assay to prevent freeze-thaw cycles. Concentrations of IL-10 were 
detected using a NHP-specific IL-10 enzyme-linked immunosorbent assay (ELISA) (U-Cytech, 
Utrecht, The Netherlands) according to manufacturer’s directions. Samples were measured at 
OD450 on a spectrophotometer (SpectraMax, Molecular Devices, San Jose, CA). 
2.5.3 Experimental animals, anti-IL-10 ab infusions, and infections 
Fourteen cynomolgus macaques (Macaca fascicularis) between 5.7 and 8 years of age, with 
starting weights of 3.9-6.9 kg (Valley Biosystems, Sacramento, CA) were housed within 
Biosafety Level 3 (BSL-3) facilities as previously described [57, 88, 291]. Additional historical 
control animals from a previous study of similar age and weight infected with Mtb and 
necropsied at 4 weeks were also used in this study.  
Starting 1 day prior to Mtb infection, macaques were sedated and given acetaminophen 
and diphenhydramine  30 minutes prior to infusion in both anti-IL-10 treatment and saline 
control groups. Macaques that were randomly designated for the anti-IL-10 treatment group were 
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then infused with anti-IL-10 antibody (IL-10R1-LALA, MassBio, Cambridge, MA) diluted in 
saline at 15mg/kg over the course of 20-30 minutes, with pre-dosing, interim, and post-dosing 
vitals recorded. Following the initial infusion, macaques were infused with 15mg/kg of antibody 
every 10 days (+/-3 days) using the same procedure methods until necropsy, 4-8 weeks after 
initial infusion). Macaques randomly designated for the control group were sedated and treated 
the same as the anti-IL-10 treatment group, except infusions with 50ml of saline over 20-30 
minutes. Three macaques were designated for the anti-IL-10 antibody treatment and 1 macaque 
was designated for the saline control group for the short 4 week study; 4 historical controls were 
included in the analysis. Five macaques were designated for the anti-IL-10 antibody treatment 
and 5 macaques were designated for the saline control group for the longer 8 week study. 
Animals were infected with 9-19 colony forming units (CFU) of Mtb Erdman strain to 
the lower lung lobe by bronchoscopic instillation. Infection was confirmed and serial clinical, 
immunologic, and radiographic examinations were conducted during the course of the study as 
previously described [57, 61, 267, 269, 270]. Specifically, blood was serially drawn immediately 
prior to infusions, and TB granuloma formation and progression were tracked by serial 18F-FDG 
PET-CT imaging, and their relative metabolic activity as a proxy for inflammation measured as 
18F-FDG standard uptake values normalized to muscle (SUV). 
2.5.4 Whole blood stimulation assay 
Blood drawn from NHPs at baseline and at serial intervals was centrifuged to remove plasma and 
washed with PBS twice. Plasma volume was then replaced with AIM V media and aliquoted in 
triplicate in flat bottom 96 well plates. Blood was then stimulated with gamma-irradiated Mtb 
diluted in AIM V media or unstimulated with AIM V media only for 72 hours at 37C. 
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Following stimulation, samples were centrifuged and supernatant fluids were collected into clean 
96 well round bottom plate, and repeated to minimize cell contamination of supernatant fluids. 
Samples were stored at -20C until time of assay. Total cytokine and chemokine levels in thawed 
samples were measured by multiplex immunoassays specific for NHPs (ProcartaPlex, 
ThermoFisher Scientific, Waltham, MA) according manufacturer’s instructions. Immunoassay 
results were collected and analyzed using BioRad Bio-Plex 200 (BioRad, Hercules, CA). 
2.5.5 Necropsy 
After 4 or 8 weeks of infection and infusions, necropsy of study animals was performed as 
previously described [57, 88, 267, 291, 292]. In summary, 1-3 days prior to necropsy, individual 
granulomas were identified by 18F-FDG PET-CT scans. At necropsy, NHPs were maximally bled 
and humanely sacrificed using pentobarbital and phenytoin (Beuthanasia, Schering-Plough, 
Kenilworth, NJ). Lymph nodes and PET-CT matched granulomas were excised for bacterial 
burden, immunological studies, and histological analyses. Representative sections were 
homogenized into single cell suspensions for bacterial quantification, flow cytometry, and 
multiplex immunoassays. Representative sections were formalin-fixed for 
immunohistochemistry and histology. 
2.5.5.1 Necropsy score 
During necropsy, gross disease pathology was quantified by a scoring system of number, size, 
and pattern of lung granulomas, and extent of disease involvement in lung lobes, mediastinal 
lymph nodes, and visceral organs, as previously described [57]. 
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2.5.5.2 Bacterial quantification 
Bacterial burden in individually excised granulomas, lymph nodes, representative lung lobe 
tissue, spleen, and liver were quantified by serial plating onto 7H11 medium and colony forming 
units (CFU) enumerated after 21 days of incubation at 37C. Total CFU from summation of all 
plated samples. 
2.5.5.3 Flow cytometry 
Single cell suspensions of homogenized tissues were incubated in the presence of Brefeldin A 
(GolgiPlug, BD Biosciences, San Jose, CA) with no additional stimulation for 2.5-3 hours at 
37C. Samples were washed with PBS, and stained for viability (Invitrogen), immune cell 
subsets, and intracellular cytokine markers. Cells were identified as T cells: CD3 (clone SP34-2), 
CD4 (clone L200), and CD8 (clone SK1); B cells: CD20 (clone 2H7); and macrophages and 
neutrophils: CD11b (clone ICRF44), CD163 (clone eBioGH1/61), calprotectin (clone 27E-10). 
Following permeabilization using FOXP3 staining kit (eBioscience), cytokine and cellular 
response were identified using antibodies against CD69 (clone TP1.55.3), IFN-g (clone B27), IL-
2 (clone MQ1-17H12), TNF (clone MAB11), IL-17 (clone eBio64CAP17), IL-10 (clone JES3-
9D7), IL-6 (clone MQ2-6A3) and FOXP3 (clone PCH101). Data acquisition was performed 
using a LSRII (BD) and analyzed using FlowJo Software v.9.7 (Treestar Inc, Ashland, OR). 
Only samples with greater than or equal to 100 cells of a population were included in data 
analysis of cytokine response. 
2.5.5.4 Immunohistochemistry of paraffin-embedded granulomas 
Formalin-fixed paraffin-embedded tissue sections from animals included in this study were 
deparaffinized in xylene, 100% ethanol, and 70% ethanol. Tissue sections were then incubated in 
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a pressure cooker containing Tris-EDTA (pH 9) antigen retrieval buffer for 6 minutes under 
pressure. Samples were then depressurized and allowed to cool slowly over 30 minutes before 
washing in PBS. Samples were incubated in blocking buffer (1%BSA in PBS) for 15-30 minutes 
in a dark humidified chamber before addition of primary antibody cocktails diluted in blocking 
buffer to sections for overnight incubation at 4C in a dark humidified chamber. Antibodies were 
against CD3 (clone CD3-12, 1:200 dilution, Abcam), CD11c (clone 5D11, 1:30 dilution, Leica 
Microsystems, Buffalo Grove, IL), CD20 (clone L26, 1:100 dilution, Dako), and IL-10R 
(polyclonal, 1:150 dilution, Millipore, Temecula, CA). After incubation with primary antibodies, 
sections were washed four times in PBS and incubated with secondary antibodies for 1 hour at 
room temperature in a dark humidified chamber. Secondary antibodies were purchased from 
Jackson ImmunoResearch Laboratories (West Grove, PA) or Invitrogen (Eugene, OR). 
Specificity of antibodies for IL-10R were confirmed using no-primary controls using the same 
staining and imaging protocol on serial sections. After secondary antibody incubation, slides 
were washed four times in PBS and mounted using ProLong Gold mounting medium with DAPI 
(Life Technologies, Eugene, OR). Slides were cured at room temperature for at least 24 hours 
and subsequently stored at -20C. Slides were imaged using a Nikon immunofluorescent 
microscope with a scanning stage and saved as TIFF-format images. 
2.5.5.5 Multiplex immunoassay 
Total cytokine concentrations in lung granulomas and LNs were quantified using multiplex 
immunoassays. Supernatants from homogenized excised tissues stored at -80C until time of 
assay. Supernatants were filtered using a 0.22m syringe filter into ~1ml aliquots immediately 
before storage at -80C or immediately before time of assay to minimize freeze-thaws. Cytokine 
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and chemokine levels in thawed samples were measured by multiplex immunoassays specific for 
NHPs (ProcartaPlex, ThermoFisher Scientific, Waltham, MA) according manufacturer’s 
instructions. Immunoassay results were collected and analyzed using BioRad Bio-Plex 200 
(BioRad, Hercules, CA). 
2.5.5.6 Histopathology of tissues 
A subset of tissues excised during necropsy, including lung granulomas and lymph nodes, were 
fixed in 10% neutral buffered formalin before placing in histology cassettes and paraffin-
embedding. Sections of 5m thick tissues were cut and mounted on SuperFrost Plus slides 
(ThermoFisher Scientific, Waltham, MA) and stained with hematoxylin and eosin by the 
University of Pittsburgh’s in situ histology laboratory. Structures of lung granulomas and extent 
of TB disease in LNs were examined and recorded by veterinary pathologist Edwin Klein, VMD, 
who was blinded to treatment groups. To quantify fibrosis in lung granulomas, granulomas 
described as containing “collagen”, “fibrosis”, or “fibroblasts” were scored as fibrotic. Excised 
lung granulomas that were not described as granulomas Dr. Klein were excluded from the 
analysis. To quantify LN effacement, LNs described as having “effacement” were scored as 
effaced. LNs had about 50% or more effacement. 
2.5.6 Statistical analysis 
Statistical analyses were conducted in GraphPad Prism 7 (GraphPad Software, San Diego, CA). 
Data were tested for normality by D’Agostino & Pearson Omnibus Normality Test. Since data 
analyzed in this study were not normally distributed, Mann-Whitney tests were used to compare 
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two groups. Fisher’s exact test was used to analyze contingency tables. P-values ≤ 0.05 were 
considered significant and noted in individual graphs. 
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3.0  LOW LEVELS OF T CELL EXHAUSTION IN TUBERCULOUS LUNG 
GRANULOMAS 
3.1 ABSTRACT 
The hallmarks of pulmonary Mycobacterium tuberculosis infection are lung granulomas.  These 
organized structures are composed of host immune cells whose purpose is to contain or clear 
infection, creating a complex hub of immune and bacterial cell activity, as well as limiting 
pathology in the lungs. Yet, given cellular activity and potential for frequent interactions 
between host immune cells and Mtb infected cells, we observed a surprisingly low quantity of 
cytokine producing T cells (<10% of granuloma T cells) in our recent study of Mtb infection 
within non-human primate (NHP) granulomas. Various mechanisms could limit T cell function, 
and one hypothesis is T cell exhaustion.  T cell exhaustion is proposed to result from continual 
antigen stimulation inducing them to enter a state characterized by low cytokine production, low 
proliferation and expression of a series of inhibitory receptors – the most common being PD-1, 
CTLA-4, and LAG-3. In this work, we characterized the expression of inhibitory receptors on T 
cells and functionality of these cells in TB lung granulomas. These experimental data were then 
used by our collaborators at the University of Michigan to calibrate and inform an agent-based 
computational model that captures environmental, cellular, and bacterial dynamics within 
granulomas in lungs during Mtb infection. Together, the results of the modeling and the 
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experimental work suggest that T cell exhaustion alone is not responsible for the low quantity of 
Mtb-responsive T cells observed within TB granulomas, and that the lack of exhaustion is likely 
an intrinsic property of granuloma structure.  
3.2 INTRODUCTION 
Tuberculosis (TB), caused by inhalation of the bacterium Mycobacterium tuberculosis (Mtb), 
continues to be a major global health problem. The World Health Organization estimates that 
more than 10 million people became ill with TB in 2016 alone, and 1.7 million deaths were 
caused by TB [1]. TB is a chronic pulmonary disease, with organized structures, called 
granulomas, forming within the lungs and thoracic lymph nodes. Granulomas are formed by the 
host immune response to Mtb. Due to substantial heterogeneity of granulomas, even within the 
same host, these structures can contain and kill Mtb but also can be a niche for bacterial survival, 
replication, and persistence [293]. The host immune cells and Mtb bacilli and antigens interact 
within the granulomas for the entire course of infection, which, during clinically latent TB, can 
last the lifetime of the host [27]. Macrophages are the primary host cell for infection, while 
CD4+ and CD8+ T cells have been shown to be critical for granuloma formation and 
maintenance through cytokine secretion and activation of other immune cells, including 
macrophages [294, 295]. Yet, even though the granuloma provides the potential for frequent 
interactions between host immune cells and Mtb bacilli, our previous data in a macaque model 
showed that less than 10% of T cells in a granuloma produce cytokines [102]. While various 
mechanisms could be limiting T cell function, one potential explanation for the low T cell 
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responses within granulomas is T-cell exhaustion occurring due to chronic antigen stimulation 
from Mtb-infected cells. 
In chronic viral infections and cancer, a subpopulation of T cells has been demonstrated 
to lose both functionality and proliferation capabilities over time in response to persistent antigen 
stimulation [143-148]. This subpopulation of T cells enters an “exhausted” state, characterized 
by low cytokine production, low proliferation, and expression of a series of inhibitory receptors. 
The most well-studied of these receptors include PD-1, CTLA-4, and LAG-3, which interact 
with a range of ligands to activate negative regulatory pathways [149, 150]. While these 
inhibitory receptors may balance an overly activated immune response that could lead to disease 
pathology, the receptors can also prevent an effective immune response from clearing infections 
and tumor cells. In cancer and some infectious diseases, blockade of these inhibitory receptors 
reverses exhaustion and rescues T cell functions [153-158].  
Since Mtb causes a chronic bacterial infection confined to a structured environment, it 
seems obvious that T cell exhaustion would occur within the critical site of granulomas.  Not 
surprisingly, the contribution of T cell exhaustion to TB has been the subject of several studies. 
Patients with active TB were shown to have significantly higher PD-1 expression on their 
peripheral blood mononuclear cells (PBMC) compared to healthy controls, and blockade of 
inhibitory receptors in vitro enhanced T cell function [159-161]. Additionally, increased antigen 
load was associated with decreased T cell responses in patients with high Mtb loads compared to 
patients with latent Mtb infections [75]. Rhesus macaques with active or reactivated TB 
expressed more LAG-3 on their CD3+ T cells in their lung tissue compared to clinically latent 
animals [168]. PD-1 expression significantly correlated with CTLA-4 expression on CD4+ T 
cells from tissues of Mtb-infected rhesus macaques [179]. Mtb infections in mice increased the 
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expression of PD-1 and LAG-3 as the infection progressed, and this was associated with 
increased T cell impairment [180]. However, murine studies also suggested that presence of 
these inhibitory receptors may be beneficial for overall TB disease pathology and bacterial 
control, and are necessary to maintain antigen-specific effector T cells during Mtb infections 
[169, 170], with detrimental outcomes when mice lacking PD-1 were infected with Mtb [171-
173]. While these studies examined T cell exhaustion in the periphery (patient studies) or in the 
whole lung (animal models), the frequency and role of exhausted T cells in individual 
granulomas is still unstudied and could provide important clues to overall infection dynamics as 
granulomas are the sites of infection in pulmonary TB. Confounding these data, the relationship 
between inhibitory markers and functional exhaustion is not abundantly clear. Recent studies 
have shown that inhibitory receptors can act as activation markers and that T cells can 
simultaneously express both inhibitory and activation markers [150, 174-177].  Therefore, it 
becomes difficult to distinguish T cell exhaustion using inhibitory receptors alone. 
We hypothesized T cell exhaustion could be contributing to the observed low frequencies 
of T cells producing cytokines in TB granulomas. We used a non-human primate (NHP) model 
of TB that recapitulates human granuloma structure and disease to assess the extent of exhausted 
T cells and their function in lung granulomas [296]. However, contrary to our hypothesis, we 
found low levels of inhibitory receptor expression, and those T cells expressing inhibitory 
receptors were often still functional. To further confirm and explore these findings, our 
collaborators at University of Michigan (Louis Joslyn, under the mentorship of Dr. Denise E. 
Kirschner) applied a computational modeling approach using GranSim, an agent-based model 
simulator of lung granulomas. The model predicted that the structure of granulomas may prevent 
T cell exhaustion, and we concluded that this mechanism is likely beneficial for the host because 
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granulomas can remain functional even after chronic containment of Mtb from months to years. 
Thus, our data combined with our collaborators’ data indicate that T cell exhaustion is limited in 
most tuberculous granulomas. 
 
3.3 RESULTS 
3.3.1 Few T cells in granulomas of Mtb-infected macaques co-express inhibitory receptors 
T cells from individual lung granulomas from of Mtb-infected macaques (6-31 weeks post-
infection) were characterized for expression of well-documented markers for T-cell exhaustion, 
namely the inhibitory receptors PD-1, CTLA-4, and LAG-3, using flow cytometry (Figure 16). 
PD-1 was expressed in higher frequencies (median = 16.55% of the CD3+ T cells), while the 
majority of the CD3+ T cells expressed very low frequencies of CTLA-4 (median = 2.02%) or 
LAG-3 (median = 1.53%) in granulomas (Figure 17A). Although exhaustion in CD8 T cells has 
been more commonly characterized, exhausted CD4 T cells also comprise a critical and distinct 
population of exhausted T cells [151]. In TB granulomas, inhibitory receptors tended to be 
expressed more frequently on CD4 T cells than on CD8 T cells, particularly in the expression 
PD-1 and CTLA-4. (Figure 17B). There was no significant difference in expression of LAG-3 on 
CD4 and CD8 T cells.  
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Figure 16. Gating strategy and positive control examples for flow cytometry antibodies 
against inhibitory receptors in single cell suspensions.  
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(A) Flow cytometry gating strategy example from TB pneumonia sample excised from Mtb-
infected cynomolgus macaque. (B) Testing of flow cytometry antibodies in PBMCs isolated 
from Mtb-infected cynomolgus macaque stimulated by PDBU & ionomycin for 3 hours at 37°C. 
 
Since these inhibitory receptors also have been characterized as markers of activation on 
T cells, co-expression of these inhibitory receptors has been demonstrated to be better indicators 
of exhaustion [178]. By flow cytometry, co-expression of inhibitory receptors on CD3+ T cells 
in any combination was rare (Figure 17C). There were very few CD3+ T cells that had co-
expression of these inhibitory receptors, with the medians less than 1% of CD3+ T cells. PD-1 
and CTLA-4 had the highest levels of co-expression in granulomas, but they were still very low 
(median: 0.6%; range: 0-3.46%). A fraction of granulomas had higher levels of PD-1 and LAG-3 
co-expression (0.82-5.51%). Even in more severe forms of disease pathology (i.e., clusters of 
granulomas and consolidations, where bacterial burden is often higher), expression of inhibitory 
receptors, including co-expression, was low, similar to that of individual granulomas (Figure 
17D). Notably, however, the most severe form of disease, TB pneumonia had the highest 
expression of LAG-3 and 6.4% of the T cells from the sample co-expressed PD-1 and LAG-3 
(diamond, Figure 17D).  
Thoracic lymph nodes infected with Mtb also had low levels of inhibitory receptor 
expression, including PD-1, of total CD3 populations (Figure 18A). Similar to the lung 
granulomas, there was very few cells co-expressing inhibitory receptors in the lymph nodes (PD-
1+CTLA-4+ median = 0.28%, PD-1+LAG-3+ median = 0.171%), suggesting low levels of 
exhaustion. PBMCs isolated from the blood, which presumably are not chronically stimulated by 
antigen, had even lower frequencies of inhibitory receptor expression. We found lower 
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frequencies of PD-1 expression (median = 2.2% vs. 16.55% of CD3 cells in lung granulomas), 
and similarly low frequencies of CTLA-4 (median = 0.888% vs. 2.02% of CD3 cells in lung 
granulomas) and LAG-3 (median = 0.442% vs. 1.53% of CD3 cells in lung granulomas) (Figure 










Figure 17. Few T cells in granulomas of Mtb-infected macaques co-express inhibitory 
receptors.  
(A) Frequency of cells expressing inhibitory receptors PD-1, CTLA-4, or LAG-3 in individual 
granulomas from Mtb-infected cynomolgus or rhesus macaques. (B) CD4 T cells express PD-1 
and CTLA-4 significantly more frequently than CD8 T cells. P-values indicated on figure, 
Wilcoxon matched-pairs signed rank test. (C) Frequency of co-expression of inhibitory receptors 
in granulomas. Each point indicates a granuloma (N = 34), each color corresponds to a NHP (12 
NHPs), circles indicate cynomolgus macaques, squares indicate rhesus macaques. (D) Clusters of 
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granulomas and TB pneumonia have similarly low frequencies of CTLA-4 and LAG3, and 
similarly high frequencies of PD-1 alone. There is low co-expression of inhibitory receptors in 
clusters of granulomas. Each point indicates a cluster, consolidation, or pneumonia lung sample 
(N = 8), each color corresponds to a NHP (6 NHPs), circles indicate cynomolgus macaque, 





Figure 18. Frequency of inhibitory receptor expression in thoracic lymph nodes infected 
with Mtb and PBMCs of Mtb-infected NHPs.  
(A) Mtb-infected lymph nodes defined as having positive CFU and/or granulomas present in 
histopathology at time of necropsy. Frequencies of expression of inhibitory receptors on CD3+ T 
cells from Mtb-infected lymph nodes. Each point indicates a lymph node (N = 15), each color 
corresponds to a NHP (12 NHPs), circles indicate cynomolgus macaque, squares indicate rhesus 
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macaques. Lines at medians. (B) Frequencies of expression of inhibitory receptor on PBMCs 
isolated from Mtb-infected NHPs at time of necropsy. Each point and color indicates a NHP (10 
NHPs), all are cynomolgus macaques. Lines at medians. 
 
3.3.2 Inhibitory receptors tend to be expressed on other immune cells in the granuloma 
To further characterize T cell exhaustion in TB granulomas, we used immunohistochemistry to 
identify the spatial location of the few T cells co-expressing inhibitory receptors (Figure 19). 
Granulomas from early in infection (6 weeks of Mtb infection) had an infiltration of T cells 
throughout the granuloma, with concentrated clusters of T cells in the outer periphery of the 
granuloma, and limited but present caseous necrosis. Cell populations in immunohistochemistry 
images were quantified using CellProfiler. LAG-3+ CD3+ cells (4.348% of CD3+ cells) were 
identified close to the periphery of the granuloma, but the majority of LAG-3+ cells were not 
CD3+. Similarly, there were few PD-1+CD3+ T cells identified in this particular section of 
granuloma (approximately 1.0%) (Figure 19A-J). In contrast, granulomas from later in infection 
(>12 weeks of Mtb infection) were more organized structures, with a region of necrosis in the 
middle (caseum), and fewer T cells spread throughout the granuloma, mostly concentrated in the 
lymphocyte cuff away from the region of caseum. Despite differences in organization compared 
to early granulomas, later granulomas also had very few LAG-3+ CD3+ cells (1.191% of CD3+ 
cells), but a higher frequency of PD-1+ CD3+ cells than at 6 weeks (4.94% of CD3+ cells). The 
few PD-1+ CD3+ or LAG-3+ CD3+ cells were localized in the periphery of the granuloma 
(Figure 19K-T).  
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In granulomas from both early and late stages in infection, most of the T cells in the 
granuloma had very little co-expression of CD3 with PD-1 or LAG-3, supporting our results 
observed by flow cytometry. Instead, most of the expression of these inhibitory receptors tended 
to be on other immune cells in the granuloma. While PD-1 co-localized with some of the CD3+ 
cells in the granuloma, LAG-3 was more often expressed on other cells in the granuloma than on 
T cells. For example, in the samples at 6 and 20 weeks post-infection, 82.9% and 78.2% of the 
LAG-3+ cells were CD3-, respectively. While we were unable to confirm the identity of the 
LAG-3+ cells, other immune cell types can express LAG-3, including NK cells, B cells, 
macrophages, and plasmacytoid dendritic cells [297-300]. Of the CD3+ cells expressing an 
inhibitory receptor, these cells tended to be in the periphery of the granuloma, further away from 
the necrotic center of the granuloma, where the Mtb bacilli are located.  
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Figure 19. Example spatial organization of inhibitory receptors on T cells within TB 
granulomas.  
 89 
Few T cells in lung granulomas express PD-1 or LAG-3 inhibitory receptors, most of the 
expression of these inhibitory receptors are on other CD3-negative cells. The rare CD3+ and PD-
1+ or LAG-3+ co-expressing cells are localized in the periphery of the granuloma, away from 
the necrotic caseous center. Granulomas isolated at 6 weeks (A-J) and 20 weeks (K-T) were 
stained using antibodies against CD3, PD-1, and LAG-3 (see methods for details). (A,K) DAPI 
staining of nuclei (B,L) Hematoxylin and eosin (H&E) staining (C,M) Merged image of CD3 
(green) and PD-1 (red). (D,N) Magnified region of interest (ROI) as indicated by white box in C 
or M, where arrowheads indicate PD-1+CD3+ cells. (E,O) Magnified ROI showing green 
channel only (CD3). (F,P) Magnified ROI showing red channel only (PD-1). (G, Q) Merged 
image of CD3 (green) and LAG-3 (red). (H,R) Magnified ROI as indicated by white box in G or 
Q, where arrowheads indicate LAG-3+CD3+ cells. (I,S) Magnified ROI showing green channel 
only (CD3). (J,T) Magnified ROI of red channel only (LAG-3). Figure courtesy of Nicole L. 
Grant, University of Pittsburgh. 
 
3.3.3 T cells expressing inhibitory receptors are not functionally exhausted 
Although few T cells in TB granulomas expressed inhibitory receptors, we investigated 
whether these rare cells were functionally exhausted. Exhausted T cells are characterized by 
hierarchical defects in function, beginning with decreased proliferation and IL-2 production, 
followed by decreased TNF production, and finally decreased IFN- production [301]. We 
examined the cytokine production by T cells expressing inhibitory receptors, and found that 
some of these cells continued to express Ki67 (proliferation marker), and produce IL-2, TNF, 
and IFN-Figure 20). Overall, the functionality of T cells expressing inhibitory receptors were 
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mostly not significantly different from the corresponding T cells not expressing inhibitory 
receptors. 
While only about 3% of CD3+T cells expressing PD-1 produced at least one of the 
cytokines usually lost in exhausted T cells, namely IL-2, TNF, and IFN- (Figure 20A), 
production was comparable to the cytokine response of CD3+T cells not expressing PD-1 
(median = 2.12%). Significantly more CD3+PD-1+ cells were expressing Ki67 (median = 
2.54%) and IFN- (median = 1.43%) than CD3+PD-1- cells (Ki-67 median = 0.04%, IFN- 
median = 1.03%), indicating ongoing, and perhaps increased proliferation in cells expressing 
PD-1 (Figure 20A). CD3+CTLA-4+ cells and CD3+LAG-3+ cells had a wide range of cytokine 
responses, but still expressed Ki67 or cytokines at comparable frequencies to CD3+ cells 
negative for inhibitory receptors (Figure 20B and 20C). The median Ki67 expression and 
cytokine response was low for CD3+CTLA-4+ cells, especially the significantly lower IFN- 
response compared to CD3+CTLA-4- cells (median = 0.13% vs. median = 1.32%) (Figure 20B). 
Some CD3+CTLA-4+ cells produced cytokines at high frequencies, causing more spread in the 
interquartile ranges (IFN-: 0 – 10.02%, TNF = 0 – 7.678%, and Any cytokine = 0 – 17.1%). 
About one-tenth of LAG-3-expressing CD3+ T cells still produced at least one of the cytokines, 
particularly IFN-, but cells seemed to be split between cells not producing any cytokines or 
proliferation marker and those that continue to function (Figure 20C). Although there were large 
ranges in cytokine production in CD3+LAG-3+ cells, there was significantly more frequencies of 
cells producing IFN- (median = 4.35, interquartile range = 0 – 14.30%) and Any cytokine 
(median = 10%, interquartile range = 0 – 17.74%) compared to CD3+LAG-3- cells (IFN-: 
median = 1.31%, interquartile range = 0.42 – 3.81%; Any: median = 2.76%, interquartile range = 
0.87 – 6.15%). The T cells expressing inhibitory receptors in the most severe form of TB disease 
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pathology, TB pneumonia, still show signs of proliferation and cytokine production (diamond, 
Figure 20A-C). With the exception of frequency of CD3+CTLA-4+ cells producing IFN-, 
CD3+ T cells that also expressed an inhibitory receptor had similar or even higher frequencies of 







Figure 20. T cells from 2 species of NHP expressing inhibitory receptors in lung 
granulomas, granuloma clusters, and TB pneumonia remain functional.  
Cytokine and Ki67 (proliferation) expression from 2 NHP species were compared between (A) 
CD3+PD-1+ cells and CD3+PD-1- cells, (B) CD3+CTLA-4+ cells and CD3+CTLA-4- cells, (C) 
CD3+LAG3+ cells and CD3+LAG3- cells. Each point indicates a lung sample (granuloma, 
granuloma cluster, or pneumonia) (N = 29), each color corresponds to a NHP (12 NHPs), circles 
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indicate cynomolgus macaques, squares indicate rhesus macaques, diamond indicates TB 
pneumonia. P-values from Wilcoxon matched-pairs signed rank test. (D) Frequency of CD69 
expression on T cells in the granuloma, and co-expression with PD-1 on T cells in the 
granuloma. Each point indicates a lung sample (granuloma or granuloma cluster) (N = 25), each 
color corresponds to a NHP (6 NHPs), diamond indicates TB pneumonia. Lines at the medians. 
(E) Median Fluorescence Intensity (MFI) of expression of PD-1 (Spearman  = -0.43, p = 0.01) 
on CD3 T cells negatively correlates with cytokine production. In contrast, MFI of (F) CTLA-4 
(Spearman  = 0.16, p = 0.37), and (G) LAG-3 (Spearman  = 0.13, p = 0.47) on CD3 T cells 
does not correlate with cytokine production. Each point indicates a lung sample (granuloma, 
granuloma cluster, or pneumonia) (N = 33), each color corresponds to a NHP (12 NHPs), circles 
indicate cynomolgus macaques, squares indicate rhesus macaques, spearman  correlations. 
 
As many of the cells with inhibitory receptors are still proliferating or producing 
cytokines, they are unlikely to be exhausted. In fact, it may be that these markers, at least when 
expressed singly, are actually identifying activated T cells within granulomas. Co-expression of 
PD-1 and CD69 on 10% of the T cells in the granulomas suggests that at least a portion of the 
few cells expressing inhibitory receptors in the granulomas are activated, and not exhausted 
(Figure 20D). Likewise, low cytokine response and proliferation activity of CD3+ T cells in 
Mtb-infected lymph nodes expressing inhibitory receptors likely results from the abundance of 
naïve T cells, rather than T cell exhaustion present in the lymph nodes (Figure 21). The intensity 
of PD-1 expression, as measured by median fluorescence intensity, on the T cells of the 
granulomas did negatively correlate with production of cytokines, suggesting granulomas with 
stronger expression of PD-1 may be more exhausted, although the correlation was moderate 
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(Spearman  = -0.43, p = 0.01) (Figure 20E). There was no correlation between intensity of 
CTLA-4 or LAG-3 expression and cytokine production, indicating that higher expression of 





Figure 21. Frequency of cytokine expression in inhibitory receptor-positive T cells in Mtb-
infected thoracic LNs.  
Frequencies of cytokine or proliferation marker expression in CD3+ cells from Mtb-infected 
lymph nodes also expressing (B) PD-1, (C) CTLA-4, or (D) LAG-3. Each point indicates an 
Mtb-infected lymph node (N = 14), each color corresponds to a NHP (12 NHPs), circles indicate 
cynomolgus macaque, squares indicate rhesus macaques. Lines at medians. 
 
To test whether the T cell cytokine response could be enhanced by blocking PD-1 as had 
been done with clinical samples [159], we incubated Mtb-infected samples ex vivo with anti-PD-
1 and PD-L1 antibodies, compared to matched media controls of the same samples. While 
blocking PD-1 indeed significantly reduced PD-1 expression on T cells, samples with blocked 
did not lead to markedly increased cytokine response or proliferation (Figure 22), supporting that 
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PD-1 expression on T cells in Mtb does not necessarily indicate exhaustion or inhibited T cell 
responses. Together with the continued functionality of these cells (proliferation and cytokine 






Figure 22. Neutralization of PD-1 and PD-L1 do not always increase cytokine response in 
tissue or blood.  
PD-1 in lung samples and PBMCs from Mtb-infected macaques can be significantly blocked by 
anti-PD-1 and anti-PD-L1 antibodies, but cytokine and proliferation frequencies do not increase 
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in response to decreased PD-1 levels. Lines connect matched IgG isotype controls and anti-PD-
1/anti-PD-L1 treated samples (N = 6), each color corresponds to a NHP (2 NHPs), filled circles 
indicate lung sample, open circles indicate PBMC sample. 
 
3.3.4 Expression of inhibitory receptors on T cells in TB granulomas is not correlated 
with bacterial burden 
To determine whether the presence of potentially exhausted T cells in the TB granulomas was 
related to higher bacterial burden or an inability to control infection, we tested the correlation of 
inhibitory receptor expression to the colony forming units (CFU) of each individual granuloma. 
There was no correlation between frequency of CD3+PD-1+, CD3+CTLA-4+, or CD3+LAG-3+ 
cells with the bacterial burden of each granuloma (Figure 23A-C). Frequencies of T cells co-
expressing PD-1 and CTLA-4 or PD-1 and LAG-3 also did not correlate with bacterial burden of 




Figure 23. Expression of inhibitory receptors on T cells in TB granulomas and clusters is 
not correlated with bacterial burden.  
Frequency of (A) CD3+PD-1+ cells (Spearman  = -0.093, p = 0.55), (B) CD3+CTLA-4+ cells 
(Spearman  = -0.19, p = 0.21), (C) CD3+LAG3+ cells (Spearman  = -0.21, p = 0.16), (D) 
CD3+PD-1+CTLA4+ cells (Spearman  = -0.040, p = 0.79), or (E) CD3+PD-1+LAG3+ cells 
(Spearman  = 0.077, p = 0.62)  from TB granulomas and clusters do not correlate with their 
bacterial burdens, measured by colony forming units (CFU). Each point indicates a lung sample 
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(granuloma, granuloma cluster, or pneumonia) (N = 42), each color corresponds to a NHP (8 
NHPs), circles indicate cynomolgus macaques, squares indicate rhesus macaques, nonparametric 
Spearman correlation.  
 
3.3.5 Granuloma structure may prevent T cell exhaustion 
Our in vivo data did not support wide-spread T cell exhaustion within granulomas. Further, in 
vivo data could not answer the following questions about T cell exhaustion: 1) What are the 
temporal dynamics of exhaustion in the granuloma? 2) Within the granuloma, are there areas 
where a T cell has greater likelihood of becoming exhausted? 3) Can we generally explain the 
presence of only low quantities of exhausted T cells? These questions required a technique that 
could address the spatial and temporal dynamics intrinsic to development of a T cell exhaustion 
phenotype. To further explore the relationship between T cell exhaustion and granuloma 
function, our computational biologist collaborators at University of Michigan (Louis Joslyn and 
Denise E. Kirschner) used their existing computational model, GranSim [275, 285, 302-305]. 
Using the uncertainty analysis technique of Latin Hypercube Sampling, we explored the 
parameter space of granuloma formation and simulated a wide range of granuloma outcomes 
[306]. We also incorporated varying levels of exhausted T cell phenotypes to ascertain the 
effects on granuloma outcomes. Finally, we evaluated T cell dynamics in both a temporal and 
spatial manner, with the aim of developing a hypothesis to explain the low levels of exhaustion 
observed in the NHP studies herein.  
  After creating an in silico biorepository of 4,500 granulomas (see Methods), we found 
that every macaque granuloma sample has at least one corresponding simulation match. We 
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selected three individual granuloma simulations that best matched bacterial burden and CD3+ T 
cell counts of the three NHP granuloma samples 2016_LLL GR B, 9515_RLL GR 20, 
4017_LLL TB pneumonia to investigate the potential roles of exhaustion in granulomas. These 
were chosen to represent a spectrum of granuloma outcomes: sterile, median bacterial load, and 
high bacterial load samples, respectively. We directly compared these three NHP samples and 
their corresponding simulations from GranSim (Figure 24). The leftmost column represents a 
sample that was sterile at the time of necropsy (112 days post-infection with 0 CFU), the middle 
column shows a sample with median bacterial burden during the time of necropsy (84 days post-
infection with 600 CFU), and the far-right column displays a high burden sample (70 days post-
infection, with 138000 CFU). The first row displays the H&E of sections, while the second row 
displays the PD-1 and CD3 expression in the matched granulomas. The third row displays an in 
silico snapshot taken at day 100 for each corresponding granuloma simulation (near time of 
necropsy of the NHPs). The fourth row represents a prediction: each figure is an in silico 
snapshot of the granuloma simulation at day 200. These comparisons support that the simulated 




Figure 24. Comparison of macaque and simulated granulomas with varying levels of 
bacterial burden.  
Row 1: H&E sections from granulomas excised from NHPs. Row 2: IHC staining showing 
spatial organization of PD-1 and CD3 expressing cells in lung granulomas excised from NHPs, 
green = CD3, red = PD1. Inset is a magnification of the region of interest (indicated by white 
box), where arrowheads indicate PD-1+CD3+ cells. Row 3: Simulated granuloma snapshots at 
day 100 (near the matching time of necropsy). Row 4: A snapshot prediction of the granuloma 
outcome if each simulation is continued until day 200.  In both Rows 3 and 4, green - resting 
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macrophages, blue - activated macrophages, orange - infected macrophages, red - chronically 
infected macrophages, brown - extracellular bacteria, pink - gamma-producing T cells, purple - 
cytotoxic T cells, aqua - regulatory T cells, and white crosshatched – caseated. Figure courtesy of 
Edwin Klein (University of Pittsburgh), Nicole L. Grant (University of Pittsburgh), and Louis 
Joslyn (University of Michigan). 
 
Under the assumption that T cell exhaustion occurs upon repeated exposure to antigen, 
we defined an Exposure Event (EE) as the interaction between a T cell and an antigen exposed 
macrophage in the granuloma. The range of EE across the 2945 simulations that matched the 44 
macaque granuloma samples was 205 to 9199, with a median of 5236. Therefore, a threshold of 
5236 EE was set as a conservative estimate of our exhaustion threshold, as 5000 interactions 
across the average life of a T cell (~ 3 days) equates to approximately 1 APC-T cell interaction 
per minute. We created a new biorepository of 4500 granulomas, using this EE threshold for 
exhaustion. Using the same three granulomas as in Figure 24, we performed a spatial and 
temporal analysis (out to 200 days) to investigate the location of exhausted T cells within 
granulomas (Figure 25). Row 1 displays the spatial location and magnitude of EE throughout the 
sterile (Figure 25A), median CFU (Figure 25B), and TB pneumonia (Figure 25C) simulations, 
where dark blue represents high density EE areas and white represents areas within the 
simulation that lack EE. Row 2 reveals the spatial location of T cells as they exceed the EE 
threshold and become labeled with an exhaustion phenotype. Each simulation (sterile – Figure 
25D, median CFU – Figure 25E, TB pneumonia – Figure 25F) has its own scale ranging from 
white to dark blue, thus comparison from one EE map to another simulation’s EE map should 
not be performed. Row 3 (Figure 25G-I) displays a plot of the level of overall exhaustion, across 
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time, as a cumulative percentage of all T cells that were activated in the granuloma simulation. 
As these simulations show, many granulomas show little cumulative exhaustion throughout the 
simulation. T cells only become exhausted when they enter the center of the granuloma, where 
they can accrue sufficient EE. Further the cumulative exhaustion plots reveal that, across time, 
exhaustion accumulates faster in early time points (between days 25 and 50) than later time 
points (between days 100 and 200). As the granuloma matures and organizes, T cell exposure 




Figure 25. T cell location within granulomas prevents T cell exhaustion by reducing 
exposure events.  
Row 1 (A, B, C):  Cloud Maps showing the location of every EE in sterile, medium CFU, and 
TB pneumonia simulations. Dark blue represents areas of high numbers of EE and white 
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represents a lack of EE. Row 2 (D, E, F): Heatmap location where T-cells (cytotoxic or IFN-
producers) became exhausted.  White represents the location of T cell at time of exhaustion. 
Row 3 (G, H, I): Time series graphs that display cumulative levels of exhaustion (as a percentage 
of total cytotoxic and IFN- producers) within corresponding simulations to Rows 1 and 2. 
Figure courtesy of Louis Joslyn, University of Michigan. 
 
Based on the location of exhausted T cells in the simulations, it appears that cells are 
more likely to become exhausted as they penetrate deeper into the granuloma. As previously 
shown, Mtb bacilli are primarily located in the inner core of macrophages and within the necrotic 
center [268]. As the structure becomes more organized, fewer T cells appear in this region. Thus, 
GranSim predicts that identifying large quantities of a T-cell exhaustion phenotype is unlikely 
after granuloma formation.  
Using our biorepository of nearly 3000 simulated granulomas that matched to all 45 NHP 
granulomas, we compared observed levels of exhaustion (NHP granulomas) versus those 
obtained from simulations (Figure 26A).  Note that we did not calibrate to the exhaustion levels 
found in NHP data, but instead calibrated the model to the NHP CFU and CD3+ T cell counts, 
and then compared exhaustion levels within these simulations to those obtained from NHP 
studies. The average difference between pairs in these two populations was not significant.  That 
is, overall, our model was able to recapitulate the observed levels of exhaustion.  
Computational modeling allows us to artificially inflate the levels of T cell exhaustion in 
granulomas, to test the impact of widespread T-cell exhaustion on granuloma outcome. We 
selected the median bacterial burden simulation (Panel B from Fig 25) and re-simulated that 
same granuloma under hypothetical condition of decreasing EE threshold. We reasoned that a 
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lower EE threshold would result in a larger number of T cells becoming exhausted, and a 
decreased ability of the granuloma to contain bacterial growth. We observe that inflated levels of 
exhaustion in the simulation lead to unfeasible granuloma outcomes, particularly in those 
granulomas whose EE threshold was less than 200 (Figure 26B). The previous simulation with 
an EE threshold of 5236 has a bacterial burden of about 288 CFU by day 200 (Figure 26C) and 
the simulation with an EE of 1 has 115,192,400 CFU (Figure 26D). To our knowledge and in our 
experience with macaque granulomas [307], these bacterial burdens are biologically 
unreasonable and can only be attained computationally when exhaustion levels are extremely 
high, well beyond the NHP findings. We conclude that T-cell exhaustion alone cannot explain 
the low-frequency of Mtb-responsive T cells in the granuloma, as the vast majority of T cells do 





Figure 26. Artificially increasing T cell exhaustion levels result in bacterial burdens that 
are not observed experimentally.  
(A) A box and whisker plot demonstrating the distribution of exhaustion levels from NHP 
studies versus those obtained via simulation in the 45 macaque granulomas (blue) and the 
simulations that matched (red).  (B) Graph of CFU vs time at varying EE thresholds. (C) 
Snapshot of granuloma with an EE threshold of 5236 taken at day 200. This granuloma epresents 
a biologically feasible outcome, and had a bacterial burden of  288 CFU. (D) Snapshot of 
granuloma with an EE threshold of 1 taken at day 200. This granuloma had a bacterial burden of 
115192400 CFU. Figure courtesy of Louis Joslyn, University of Michigan. 
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3.4 DISCUSSION 
The presence and effect of T cell exhaustion has been studied in many chronic diseases. The 
chronic nature of Mtb infection and continued presence of bacterial antigens in granulomas 
seemed to be an obvious scenario for development of exhausted T cells, which could explain the 
inability of some granulomas to completely eliminate the organisms. However, in NHP models 
of TB, both rhesus and cynomolgus macaques, we detected only limited apparent exhaustion of 
T cells within granulomas, based on the expression of inhibitory receptors. In fact, the small 
number of granuloma T cells expressing inhibitory receptors were apparently still functional and 
producing cytokines or proliferating at similar or higher frequencies as T cells not expressing 
inhibitory receptors. We observed a moderate negative correlation between the intensity of PD-1 
expression (MFI) compared to T cell cytokine expression, suggesting that T cells that express 
more PD-1 may be more likely to be exhausted, but there may be few T cells strongly expressing 
PD-1 in TB granulomas. To further investigate the lack of apparent exhaustion in granulomas, 
we turned to our computational (agent-based) model of a granuloma, GranSim. We demonstrated 
that GranSim can match macaque granuloma data, and then explored the extent of exhaustion in 
the simulated granulomas. Again, we found low levels of exhausted T cells in most granulomas. 
GranSim revealed that T cells could not readily penetrate into the macrophage or caseous layers 
of the granulomas, where most bacilli exist. Thus, the organized structure of the granuloma 
precludes widespread T cell exhaustion, in that macrophages and Mtb bacilli tend to be in the 
center of the granuloma, while T cells are concentrated in the lymphocyte cuff on the periphery 
of the granuloma. In fact, in cases of less organized pathology (TB pneumonia), we did observe, 
experimentally and computationally, somewhat higher levels of exhaustion, although still 
relatively low. Finally, we used our computational model to artificially inflate the level of T cell 
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exhaustion in granulomas (by decreasing the threshold of T cell-APC interactions), and found 
that this would lead to exceptionally high bacterial burdens in granulomas. Such high bacterial 
burdens in individual granulomas are rarely seen in macaque models, even including those with 
substantial amounts of disease. Thus, we conclude that limited T cell exhaustion in granulomas is 
due to the relative infrequency of T cells contacting Mtb infected macrophages (or APCs 
carrying Mtb antigens), which is a key feature of the organized structure of granulomas. 
The most frequent inhibitory receptor expressed in granulomas was PD-1, but like the 
other inhibitory receptors, PD-1 is both an activation and exhaustion marker. There was very 
little co-expression of multiple inhibitory receptors, with more co-expression of PD-1 with 
CD69, further suggesting that PD-1 expressing T cells in the granulomas are activated, not 
exhausted. Thus, we conjecture that the low levels of “inhibitory” receptor expression on 
granuloma derived T cells actually represent activation markers. This alternative role of 
inhibitory receptors as markers for proliferating activated cells has been previously explored in 
Mtb infection and SIV infection. A study of PD-1+ T cells in mice during Mtb infection showed 
that these cells proliferated, and actually were necessary for maintaining effector cells [169]. 
Hong et al. also found a similar role for PD-1+ T cells during chronic SIV infections [176]. The 
necessity of PD-1+ T cells for protection during Mtb infection was further highlighted by studies 
in PD-1 knockout mice that had higher bacterial burden and extreme inflammation [171, 172] 
compared to wildtype infected mice.  
Although some of our data contradict other studies of T cell exhaustion in TB, we also 
observed some similar findings. Like the mouse model of TB, PD-1 was one of the most 
frequently expressed inhibitory markers on T cells [180]. Unfortunately, we were unable to 
confirm the presence of TIM-3 on granuloma T cells because of lack of a reliable antibody for 
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NHPs. Although Phillips et al. showed higher LAG-3 expression on T cells from the lungs of 
Mtb-infected rhesus macaques, we saw much lower levels in individual granulomas from Mtb-
infected cynomolgus and rhesus macaques, closer to the levels they observed in clinically latent 
animals [168]. However, similar to Phillips et al., we observed high frequencies of LAG-3+ cells 
that were also not CD3+. Some of these discrepancies could be due to differences in the animal 
models used to investigate exhaustion in Mtb granulomas. Mtb infections in mice do not create 
the same structured organization in granulomas as observed in humans and NHPs, and therefore 
T cells may have more interactions with the Mtb bacilli, creating more opportunities for 
exhausted T cells. We primarily, although not exclusively, used samples from cynomolgus 
macaques in this study, which tend to have less severe disease than rhesus macaques, thus we 
may have observed slightly lower expression of LAG-3 in lung granulomas than published 
studies on lung tissue from Mtb-infected rhesus macaques. There were also differences in timing. 
In the current study, we examined longer, more chronic infections than was done in previous 
mouse or rhesus studies, although our samples from early infections also had few T cells 
expressing inhibitory receptors. Most of the data in Mtb-infected patients is from peripheral 
blood, so we were unable to confirm our T-cell exhaustion observations at the lung granuloma 
level to peripheral human data; however, we have previously shown that peripheral immune 
responses do not reflect local (granuloma) immune responses [102].  
Our data support that the lack of T cell exhaustion in a chronic disease like TB is likely a 
result of the unique characteristic of the disease – containment of the Mtb bacilli within a well-
structured granuloma. While the close proximity of bacterial antigens to the host immune cells 
seemed to be an obvious environment for T cell exhaustion, the structure and spatial arrangement 
of the immune cells in the granuloma may be responsible for the low levels of T cell exhaustion. 
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T cells infiltrate the granulomas early in infection, but during chronic infection (>3 months), the 
vast majority of T cells are on the outer periphery of the granuloma, away from bacteria and 
exposed macrophages in the center of the granuloma, thus preventing low levels of Mtb-T cell 
interactions, as also previously suggested by Kauffman et al. [179]. Likewise, we and Phillips et 
al. observed T cells that express the inhibitory receptors tend to be on the outer edges of the 
granuloma (Figure 19)[168].  
An alternative hypothesis to T cell exhaustion that could explain the low levels of 
cytokine production by T cells in the granuloma is that many granuloma T cells that are not 
specific for Mtb antigens. Unfortunately, tetramers for cynomolgus macaques currently do not 
exist, and we did not use tetramers for the rhesus samples included in this study. Thus, we were 
unable to quantify the number of Mtb-specific T cells in the granuloma and determine the 
frequency of T cell exhaustion within Mtb-specific T cells in this current study. In addition, 
production of immunomodulatory cytokines, such as IL-10 or TGF-, or inflammation or oxygen 
or nitric oxide species in granulomas, may regulate T cell function. The low frequency of 
cytokine producing T cells may be a beneficial characteristic of lung granulomas. Sakai et al. 
suggested that in a mouse model of Mtb infection, increasing the IFN- production by CD4 T 
cells in lung tissue by reducing PD-1 inhibition exacerbated the bacterial burden within the 
lungs, worsening TB disease and shortening host lifespan [170]. Our data from macaque 
granulomas and our computational modeling indicate that a balance of anti-inflammatory (e.g. 
IL-10) and pro-inflammatory cytokines (TNF, IL-2) within a granuloma is correlated with lower 
bacterial burdens or sterilization [102, 275, 285]. Studies to examine the T cell cytokine response 
relative to antigen specificity are underway. 
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Together, these data support and extend the notion that a balance of cytokine responses 
and T cell functionality are necessary for control of Mtb within granulomas, and that due to the 
spatial organization of the granuloma, T cell exhaustion is likely not a major contributor to this 
balance at the local granuloma level.   
3.5 METHODS 
3.5.1 Experimental animals 
Samples from eleven cynomolgus macaques (Macaca fascicularis) between 6.4 and 9.2 years of 
age, with starting weights of 5-7.8kg (Valley Biosystems, Sacramento, CA), and four rhesus 
macaques (Macaca mulatta) between 5.1 and 14.8 years of age, with starting weights of 5.4-
7.9kg (Vaccine Research Center, NIH) were assessed in this study. Animal care was in 
accordance with institutional guidelines, and all experimental manipulations, protocols, and care 
of the animals were approved by the University of Pittsburgh School of Medicine Institutional 
Animal Care and Use Committee (IACUC). Animals were examined while in quarantine as 
previously described to ensure animals were in good physical health with no previous M. 
tuberculosis infection [57, 291]. Samples were obtained for this study from NHPs from other 
studies, and infected with 3-31 colony forming units (CFUs) of the virulent Erdman strain of Mtb 
by bronchoscopic instillation to the lower lung lobe, as previously described [267]. 
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3.5.2 Necropsy procedures, bacterial burden, and staining for flow cytometry 
Necropsy was performed as previously described [57, 291]. In summary, NHPs were humanely 
sacrificed by terminal bleed, and granulomas in lungs identified by PET-CT or at necropsy were 
individually excised, with half of the granuloma homogenized into single cell suspension for 
bacterial burden and immunological assays, and the other half for histological analysis, size 
permitting. To determine the bacterial burden, each granuloma homogenate was plated in serial 
dilutions on 7H11 medium and incubated at 37°C/5% CO2 for 21 days before CFU enumeration.  
Excised and homogenized granulomas were analyzed for immunological response by 
surface and intracellular staining and flow cytometry. For each granuloma, cells were 
resuspended in 1ml of RPMI-1640 containing 1% HEPES, 1% L-glutamine, 10% human AB 
serum, and 0.1% Brefeldin A (Golgiplug: BD Biosciences), and incubated for 2-3 hours at 
37°C/5% CO2 after homogenization to capture cytokine response. Our previous data indicate that 
additional ex vivo stimulation with Mtb antigens does not increase cytokine production, and can 
lead to decreased cell recovery. In excised granulomas, Mtb and Mtb antigens are present and 
likely are restimulating T cells in the homogenized samples. After incubation, granuloma cells 
were washed with 1xPBS and stained for viability (Invitrogen). Granuloma cells were stained for 
surface markers, inhibitory receptors, and cytokines in the presence of 1%FBS in PBS. 
Antibodies for cell surface markers included: CD3 (clone SP34-2, BD Biosciences), CD4 (clone 
L200, BD Biosciences), CD8 (clone RPA-T8, BD Biosciences), and PD-1 (clone EH12.1, BD 
Biosciences). Cells were fixed and permeabilized (BD Biosciences). Intracellular staining of 
inhibitory receptors, activation and proliferation markers, and cytokines included: LAG-3 (clone 
FAB23193P, R&D Biosystems), CTLA-4 (clone BNI3, BD Biosciences), CD69 (clone 
TP1.55.3, Beckman Coulter), Ki67 (clone B56, BD Biosciences), IFN- (clone B27, BD 
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Biosciences), IL-2 (clone MQ1-17H12, BD Biosciences), and TNF (clone MAB11, BD 
Biosciences). Cells were fixed in 1% paraformaldehyde. Data acquisition was performed using a 
LSR II flow cytometer (BD Biosciences) and analyzed using FlowJo Software v.9.7 (Treestar 
Inc.).  
For the PD-1 and PD-L1 neutralization assay, a subset of lung granulomas and TB 
pneumonia from two cynomolgus macaques were excised and homogenized as described above. 
PBMCs were also isolated at the time of necropsy as previously described [291]. Single cell 
suspensions were divided and each half of the sample incubated ex vivo: (1) with 10ug/ml goat 
polyclonal anti-human-PD-1 antibody (R&D Biosystems) and 10ug/ml goat polyclonal anti-
human-PD-L1 antibody (R&D Biosystems), or (2) with polyclonal goat IgG isotype (R&D 
Biosystems) in 150l of RPMI-1640 containing 1% HEPES, 1% L-glutamine, 10% human AB 
serum for 1.5-2.5 hours at 37°C/5% CO2. After the initial incubation, additional Mtb peptide 
pools (ESAT-6 and CFP-10, 2ug/ml) were added to the samples to stimulate Mtb-specific 
cytokine response in the presence of Brefeldin A (Golgiplug: BD Biosystems) and incubated at 
37°C/5% CO2 for an additional 2.5 hours. Samples were then stained for viability, surface 
markers, inhibitory receptors, and cytokines, then collected and analyzed as described above. 
3.5.3 Immunofluorescence of paraffin-embedded samples 
Immunofluorescence of paraffin-embedded samples was performed by Nicole L. Grant, 
University of Pittsburgh. Portions of granulomas excised during necropsy were formalin-fixed, 
paraffin-embedded, and consecutively cut in 5um sections for histological analysis. For 
immunofluorescent assays, slides with two consecutive tissue sections were de-paraffinized by 
xylene, followed by washes in 95% and 70% ethanol before antigen retrieval in Tris-EDTA (pH 
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9) under heat and pressure. Slides were cooled, washed with PBS, and blocked using 1% BSA in 
PBS, before incubation overnight at 4°C or 1 hour at room temperature with primary antibodies 
against CD3 (clone CD3-12, Abcam; DAKO), PD-1 (clone NAT105, Abcam) and LAG-3 (clone 
EPR4392, Abcam). Antibodies were tested in lymph node samples (S2 Fig). After washing with 
PBS, slides were stained with secondary anti-mouse, anti-rat, and anti-rabbit antibodies (Jackson 
Laboratories and Invitrogen) for 1 hour at room temperature and coverslips mounted with 
ProLong Gold with DAPI (Invitrogen). Confocal microscopy was performed using an Olympus 
microscope equipped with three lasers. Images were collected using a 20x objective at 
1024x1024 size, then compiled using Adobe Photoshop before quantification. Individual cell 
numbers were identified using the open source image analysis software CellProfiler. To 
analyze larger granulomas, small regions of interest were selected and CellProfiler settings were 
modulated based on image quality so that relevant cell types were accurately quantified. Once 
pipelines were determined per image, both isotype (secondary only staining) and stained image 
were analyzed using the same parameters. Isotype image numbers were subtracted from stained 
images, resulting in an adjusted number representing the cells identified per tissue section.   
3.5.4 Computational modeling with GranSim 
All computational modeling was conducted by Louis Joslyn, University of Michigan. All 
simulations utilize a 2D hybrid, agent-based model (ABM) called GranSim that captures 
environmental, cellular, and bacterial dynamics across molecular, cellular, and tissue scale 
events [302, 304, 308, 309]. As an established model, GranSim has been calibrated extensively 
to data from a non-human primate model of TB [302-304, 308-313]. At the molecular scale, 
GranSim incorporates cytokine and chemokine diffusion, secretion and degradation.  GranSim 
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also tracks individual immune cells on a 2D simulation grid of micro-compartments, including 
four macrophage states (resting, activated, infected, and chronically infected) and T-cell types 
(cytotoxic, IFN-producing, and regulatory). Granuloma formation at the tissue level is an 
emergent behavior of GranSim. See http://malthus.micro.med.umich.edu/GranSim for full model 
details and an executable file. The following methods provide detail on added mechanisms to 
GranSim so that we can use GranSim as a tool to study exhaustion in granulomas. 
3.5.4.1 Model definitions, assumptions, and justifications.  
A great advantage of our in silico representation is that we can track cellular movement, 
behavior, and interaction across time. In GranSim, we define an interaction between a T cell and 
macrophage by the occurrence of a macrophage entering the double Moore neighborhood of a T 
cell [314-316] (i.e. Moore neighborhood is defined as all micro-compartments on the grid 
immediately adjacent to the one the cell is in; double Moore includes the next outer ring of 
micro-compartments). In particular, as we evaluate the possibility of T-cell exhaustion 
influencing the pathology of granuloma formation, we become solely interested in Exposure 
Events (EE), defined as the interactions between a T cell and an antigen “exposed” macrophage.   
In previous model versions, we defined an exposed macrophage according to three 
criteria: 1) If the cell contained any intracellular Mtb, 2) If, within the single Moore 
neighborhood of the macrophage, there exists any live or dead extracellular Mtb, and 3) If, 
within the single Moore neighborhood of the macrophage, there is another macrophage that was 
determined to be exposed during a previous timestep.  Additionally, once a macrophage becomes 
exposed, it remains exposed for the entirety of its lifespan [275].    
As noted in the Introduction, chronic antigenic stimulation is sufficient to develop 
exhaustion within a T-cell population. Based on current literature, we model antigenic 
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stimulation via EE [317-319]. We use EE as a standard of stimulation across a T-cell’s lifetime 
to evaluate various analytical measures about T-cell exhaustion, including:  individual T-cell 
exposure to antigens, average EE across T-cell populations, and determination of whether only a 
few T cells out of the entire population accrue the majority burden of EE.   
Finally, we created a new parameter within GranSim to introduce an exhausted T-cell 
phenotype (this parameter was aptly named ‘ExhaustionThreshold’). If the EE of an IFN- 
producing T cell or a cytotoxic T cell exceeds this preset threshold, then a T cell is marked as 
‘exhausted’. Once labeled, it loses all effector function, but continues to move around the grid 
until it dies from its natural lifespan (we do not assume there is an enhanced death rate for 
exhausted cells). Because we explore the possible role of exhaustion within granuloma 
formation, we crafted this parameter to represent the worst-case scenario:  if a T cell exceeds the 
threshold, it immediately ceases effector function rather than for example, exhibiting a 
progressive loss of function.  Other formulations are possible, but we have considered this case 
as an upper bound for quantifying exhaustion levels (yielding the worst case scenario). 
Computational Platform and Post-Run Analysis 
GranSim is constructed through use of the C++ programming language, Boost libraries 
(distributed under the Boost Software License – www.boost.org), and the Qt framework for 
visualization (distributed under GPL – www.qt.digia.com). The ABM is cross-platform 
(Macintosh, Windows, Unix) and runs with or without visualization software. GranSim model 
simulations were performed locally and also on the XSEDE’s OSG Condor pool resources.   
We relied on uncertainty analysis (UA) techniques to explore model parameter space.  In 
particular, we used Latin Hypercube Sampling (LHS, reviewed in [306]) for UA. The LHS 
algorithm is a stratified Monte Carlo sampling method without replacement [306] and was used 
 117 
to generate 1,500 unique parameter sets, which were simulated in replication 3 times (a total of 
4,500 in silico simulations) for 200 days. When we matched our simulations to NHP granulomas, 
often the size of the high and median bacterial burden samples necessitated the use of a 200 by 
200 micro-compartment simulation space, whereas the simulation space for sterile samples could 
be performed within 100 by 100 micro-compartments.  
Analysis of statistical data derived on EE from simulations was performed using 
smoothScatter, ggplot2 and base packages in R [320] and Matlab [321].  Additional analysis was 
conducted on more general data concerning granuloma-scale infection outcomes, granuloma 
formation, and concentration values of various effector molecules and CFU within the 
simulations.   
3.5.4.2 Model calibration and defining exhaustion.  
Once the model was updated, we re-calibrated GranSim with respect to i) CFU totals, ii) CD3 
totals, and iii) time based on 45 separate NHP granuloma sample data. Table 1 outlines a portion 
of the comprehensive analysis we performed to compare T-cell exhaustion in silico versus the 
data derived on T-cell exhaustion in vivo. Table 2 shows the parameter ranges we used to 









Table 1. Example analysis of in silico versus in vivo T cell exhaustion data.  
Table 1.3 displays the direct comparison between exhaustion in our matching simulations and the 
level of observed exhaustion in NHP samples.  Tables 1.1 and 1.2 explain our method of 
matching and aggregating data.   Table 1.1 displays 1 of the 44 granuloma NHP samples that we 
used for calibration.  The right-most column shows the number of simulations that matched to 
the NHP sample CFU values and CD3 Count.  Each simulation could match the criteria across 
several time points. Table 1.2 shows each of the 5 simulations that calibrated to NHP sample 
13516_RLL 17_20 cluster and the average percentage of exhausted T cells across the simulation 
timepoints that matched NHP sample criteria.  Finally, we aggregated the data to display an 
overall sense of model fit by selecting the “median of the means” for each matching simulation. 
Thus, for NHP sample 13516_RLL 17_20 cluster, the median percent of exhaustion across all 
samples that matched was 0.0%.  Flow cytometry data shows that this sample had 0.66% of T 




Since the exact roles of individual inhibitory receptors as markers in the progression of T-
cell exhaustion is unclear [175], we assume that a T cell is only truly exhausted if it co-expresses 
any two or more inhibitory receptors. Thus, when we compared T-cell exhaustion levels and 
markers in vivo against T-cell exhaustion in silico, the in vivo percentage of T-cells that are 
“exhausted” are actually the percent of T-cells that expressed 2 or more inhibitory receptors. 
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Out of the 4,500 granulomas in our in silico bio-repository, we matched simulations to 
samples according to our criteria, as shown in Table 1.1 of Table 1. As an example, if we 
examine NHP Sample 13516_RLL 17_20, we were able to select 5 unique simulations that 
matched CFU and CD3 values across various simulation time points. For each of the 5 
simulations, across every time point that matched the NHP sample’s CFU and CD3+ T cell 
levels, we found the average percent of exhausted T cells (Table 1.2). For example, the first 
replication of simulation no. 33 matched CFU and CD3 counts across 5 different time points 
over the 200-day simulation. We averaged the exhausted T cells across each of the 5 days and 
found that the mean percentage of exhausted T cells when this simulation matched our criteria, 
was 0.0%.   
Finally, we aggregated the data to provide a sense of overall model fit for each of the 45 
NHP samples.  Table 1.3 displays the median value across all the mean percentages of exhausted 
T cells for each sample’s matching simulations. Thus, for Sample 13516_RLL 17_20, the 
median percent of exhaustion across all the samples that matched was 0.0%.  Flow cytometry 










Table 2. Table of parameter ranges used to create both biorepositories of 4500 unique 
granulomas.  
All ranges, with the exception of exhaustionThreshold, were performed within the ranges 
outlined by previous versions of GranSim. See methods text for details on how the ranges were 
assigned for exhaustionThreshold. 
 
Parameter Name Description Range Units Reference 
growthExtMtbBound Upper bound of 
number of external 
Mtb used in growth 
function  




growthRateIntMtb Fractional growth 
rate of intracellular 
bacteria 
[0.001,0.005] Unitless [275, 285, 
302-305] 
growthRateExtMtb Fractional growth 
rate of extracellular 
bacteria 
[0.001,0.003] Unitless [275, 285, 
302-305] 
deathRateExtMtbCaseated Upper bound on the 
number of external 
Mtb used in growth 
function 




Core     




[0.4,0.5] Unitless [275, 285, 
302-305] 




[0.4,0.6] Unitless [275, 285, 
302-305] 
estConsRateTNF Scaling Factor for 
coarse grained TNF 
dynamics 
[5e-4,9e-4] Unitless [275, 285, 
302-305] 
estConsRateIL10 Scaling Factor for 
coarse grained IL10 
dynamics 
[2e-4,6e-4] Unitless [275, 285, 
302-305] 
estIntPartitionTNF Scaling Factor for 
coarse grained 
internalization of 
bound TNFR1  
[9,13] Unitless [275, 285, 
302-305] 
nrKillingCaseation Number of killings 
for a compartment to 
become caseated 
[7,13] Number [275, 285, 
302-305] 
caseationHealingTime Time it takes for a 
caseated 
compartment to heal 
 
[1700,2600] Timesteps [275, 285, 
302-305] 
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Table 2 (continued) 
sourceDensity Density of vascular 
sources on the 
gridspace 
[0.002,0.05] Unitless [275, 285, 
302-305] 




[4e-08,6e-08] Cm^2/second [275, 285, 
302-305] 





[0.0005,0.005] 1/second [275, 285, 
302-305] 
kDeg TNF degradation 
rate constant 
[0.0005,0.005] 1/second [275, 285, 
302-305] 
Ikdeg Degradation rate 
constant for IL10 
[0.0003,0.003] 1/second [275, 285, 
302-305] 
IC50ChemokineIL10 IC50 of IL10 
inhibition of 
chemokine secretion 
[1,10] Molecules/mL [275, 285, 
302-305] 
thresholdApoptosisTNF TNF threshold for 
TNF-induced 
apoptosis 
[1000, 5000] Unitless [275, 285, 
302-305] 
kApoptosis Rate of apoptosis 
happening 
[1e-07, 2e-6] 1/second [275, 285, 
302-305] 
saturationApoptosisTNF Signal saturation of 
number of internal 
bound TNFR1 
Molecules 
[5000, 9000] Molecules [275, 285, 
302-305] 
minChemotaxis Minimum of 
Chemotaxis 
sensitivity range 
[1, 50] Molecules [275, 285, 
302-305] 
maxChemotaxis Maximum of 
Chemotaxis 
sensitivity range 
[100,1000] Molecules [275, 285, 
302-305] 




[0.05, 0.3] Log10(ng/mL) [275, 285, 
302-305] 
Mac      
initDensity Initial density of 
macrophages on the 
gridspace 
[0.005,0.03] Unitless [275, 285, 
302-305] 
movementRest Time required for a 
resting macrophage 
to move one micro-
compartment 
[1,10] Timesteps [275, 285, 
302-305] 
movementAct Time required for an 
activated 
macrophage to move 
one micro-
compartment 
[10,50] Timesteps [275, 285, 
302-305] 
 122 
Table 2 (continued) 
movementInf Time required for an 
infected macrophage 
to move one micro-
compartment 
[100,200] Timesteps [275, 285, 
302-305] 
dTNF Secretion rate of 
TNF by a 
macrophage 
[1.3,1.7] Molecules/second [275, 285, 
302-305] 
dCCL2 Secretion rate of 
CCL2 by a 
macrophage 
[4,8] Molecules/second [275, 285, 
302-305] 
dCCL5 Secretion rate of 
CCL5 by a 
macrophage 
[4,8] Molecules/second [275, 285, 
302-305] 
dIL10Act Secretion rate of 
IL10 by an activated 
macrophage 
[0.2, 0.4] Molecules/second [275, 285, 
302-305] 
halfSatIL10 Half saturation for 
TNF induction of 
IL10 in an activated 
macrophage 
[170,210] Number/cell [275, 285, 
302-305] 
thresholdNFkBTNF TNF threshold for 
NFkB activation 
[75,115] Molecules [275, 285, 
302-305] 
kNFkB Rate of NFkB 
activation 
[0.7e-5, 1e-5] Fraction [275, 285, 
302-305] 
probKillExtMtbRest Probability of a 
resting macrophage 
to kill extracellular 
bacteria  
[0.05, 0.3] Unitless [275, 285, 
302-305] 
fKillExtMtbRest Fractional increase 
of a resting 
macrophage to kill 
extracellular bacteria 
when STAT1 or 
NFkB pathways are 
on 
[0.3,0.5] Unitless [275, 285, 
302-305] 
nrExtMtbNFkB Number of 
extracellular bacteria 
for NFkB activation 
in an infected 
macrophage 
[150, 250] Bacteria [275, 285, 
302-305] 
nrIntMtbCInf Number of 
intracellular bacteria 




[8,12] Bacteria [275, 285, 
302-305] 
nrIntMtbBurstCInf Number of 
intracellular bacteria 
necessary for a 
chronically infected 
macrophage to burst 
 
 
[13,20] Bacteria [275, 285, 
302-305] 
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Table 2 (continued) 




uptake and kill 
[3,7] Bacteria [275, 285, 
302-305] 
Stat1ActivationTime Time a macrophage 
is Stat1 activated 
[400,460] Timesteps [275, 285, 
302-305] 
nfkbActivationTime Time a macrophage 
is NFkB activated 
[13,17] Timesteps [275, 285, 
302-305] 
Stat3ActivationTime Time a macrophage 
is Stat3 activated 
[75,125] Timesteps [275, 285, 
302-305] 
thresholdSTAT3IL10 Threshold of IL10 to 
IL10R1 for STAT3 
signaling 
[5,15] Unitless [275, 285, 
302-305] 
kSTAT3IL10 Rate constant of 
bound IL10 to 
IL10R1 for STAT3 
signaling 
[5e-4, 1.5e-3] Unitless [275, 285, 
302-305] 
probHealCaseation Rate constant for 
wound healing 
[0.005, 0.05] Unitless [275, 285, 
302-305] 
T cell     
maxAge Maximum age of a T 
cell 
[400,460] Timesteps [275, 285, 
302-305] 
exhaustionThreshold Threshold of 
Exposure Events for 
an individual T cell 




generation of 2nd 
biorepository) 
Count Estimated 
probMoveToMac Probability of a T 




[0.01, 0.2] Unitless [275, 285, 
302-305] 
probMoveToTcell Probability of a T 
cell moving into a 
compartment already 
containing another T 
cell 
[0.01, 0.2] Unitless [275, 285, 
302-305] 
maxDivisions Maximum number 
of times a T cell can 
create a daughter cell  
[3,5] Timesteps [275, 285, 
302-305] 
γ-producing T cells     
dTNF Secretion rate of 
TNF by γ-producing 
T cell 
[0.1, 0.2] Molecules/second [275, 285, 
302-305] 
maxTimeReg Time span during 
which a γ producing 




[30,40] Timesteps [275, 285, 
302-305] 
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Table 2 (continued) 
probApoptosisFasFasL Probability of 
Fas/FasL induced 
apoptosis by a γ-
producing T cell 
[0.01,0.03] Unitless [275, 285, 
302-305] 
probTNFProducer Probability that a γ-
producing T cell can 
produce TNF 
[0.04, 0.1] Unitless [275, 285, 
302-305] 
probIFNProducer Probability that a γ-
producing T cell can 
produce IFNγ 
[0.3, 0.4] Unitless [275, 285, 
302-305] 
probIFNMooreExtend Probability a 
macrophage will be 
IFNγ/STAT1 
activated in the 
extended Moore 
Neighborhood.  
[0.2, 0.3] Unitless [275, 285, 
302-305] 
Cytotoxic T cells     
dTNF Secretion rate of 
TNF by a cytotoxic 
T cell 
[0.01, 0.02] Molecules/second [275, 285, 
302-305] 
maxTimeReg Time span during 
which a cytotoxic T 
cell remains down-
regulated 
[30,40] Timesteps [275, 285, 
302-305] 
probKillMac Probability of a 
cytotoxic T cell 
killing a chronically 
infected mac 
[0.005, 0.015] Unitless [275, 285, 
302-305] 
probKillMacCleanly Probability of a 
cytotoxic T cell 
killing a chronically 
infected mac cleanly 
[0.6, 0.9] Unitless [275, 285, 
302-305] 
probTNFProducer Probability that a 
cytotoxic T cell is 
producing TNF 
[0.05, 0.09] Unitless [275, 285, 
302-305] 
Regulatory T cells     
dIL10 Secretion of IL10 by 
a regulatory T cell 
[0.7, 0.8] Molecules/second [275, 285, 
302-305] 
probTregDeactivate Probability of 
successful 
downregulation by a 
regulatory T cell 
[0.01, 0.02] Unitless [275, 285, 
302-305] 
factorDeactIL10 Factor when a 
regulatory T cell is 
making IL10 to scale 
probTregDeactivate 




3.5.4.3 EE threshold selection.  
Initially, we created a biorepository of 4500 granulomas using the LHS technique. Within this 
biorepository, the EE threshold for T cell exhaustion ranged from 200 to 10000. We calculated 
the upper bound of 10000 interactions of the EE threshold as a T cell that has every location in a 
T cell double Moore Neighborhood occupied by an exposed macrophage throughout the entirety 
of its life (average of 3 days in our simulation), will accrue 10500 interactions. We selected 200 
interactions as the lower level of EE because a T cell with 200 interactions has encountered 
exposed macrophages less than 2% of the time it has been alive – certainly, a sufficient EE 
threshold for a phenotype that is caused by chronic stimulation.  
Figures 25 and 26 were produced from a second biorepository of 4500 granulomas.  This 
biorepository was created with the exact same parameter ranges as in Table 2, but the EE 
threshold was set to 5236, the median of all simulations that matched the macaque granulomas.  
A threshold of 5236 EE seems reasonable, as 4320 interactions equals 1 interaction per minute 
through the average lifespan of a T cell.  
3.5.5 Statistical Analyses 
Statistical analyses were conducted in GraphPad Prism 7 (GraphPad Software, San Diego, CA). 
Data were tested for normality by D’Agostino & Pearson Omnibus Normality Test. Since data 
analyzed in this study were not normally distributed but were paired, Wilcoxon matched-pair 
signed rank tests were used to compare two groups for multiple comparisons, with no multiple 
comparison adjustments to p-values. Correlations were calculated by nonparametric Spearman 
rho tests. P-values ≤ 0.05 were considered significant and noted in individual graphs. 
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4.0  VACCINATION CAN MODULATE IMMUNE RESPONSES IN TB GRANULOMAS 
4.1 ABSTRACT 
Despite the availability of the Bacille Calmette-Guérin (BCG) vaccine against TB for the past 
century, tuberculosis (TB) remains a major threat to global health. Although BCG can protect 
infants from disseminated disease, its efficacy against adult pulmonary TB is much more 
variable. Several TB vaccines are currently in various stages of development and clinical trials to 
replace, boost, or improve the only currently licensed vaccine BCG. We tested combinations of 
novel TB subunit vaccines and adjuvants via different strategies for their ability to induce 
immune response and protection against TB using a non-human primate (NHP) model in a two-
part study. In the initial study, we vaccinated cynomolgus macaques with a recombinant protein 
vaccine (H56) admixed with a novel adjuvant (CAF09) by three routes—intranasal, 
subcutaneous, and aerosol to assess the immunological and protective effects of different 
vaccination routes. Frequencies of T cells producing pro-inflammatory cytokines increased in the 
blood and BAL following vaccinations in all groups, but NHPs vaccinated by aerosol had a rapid 
and transient recall of T cells to the airways after the third vaccination. After M. tuberculosis 
(Mtb) challenge, aerosol vaccinated NHPs had less inflammation by PET-CT compared to other 
vaccinated groups and unvaccinated controls, although they had little to no improvement in 
disease pathology or total bacterial burden compared to controls at necropsy. Although 
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vaccination in this initial study did not lead to protection of NHPs, the aerosol vaccinated 
animals appeared to have slightly improved disease outcomes after Mtb challenge. Following the 
reduction of inflammation and improved T cell recruitment to the airways, we further examined 
aerosol vaccination in the second part of this study, with all vaccines used as a “boost” in the 
context of BCG vaccination. We examined a novel recombinant fusion protein vaccine, H74, but 
because of adverse reactions during the first part of the study, we switched from CAF09 to 
CAF01 in the secondary study. Based on previous studies that suggested BCG could act as an 
adjuvant, and particularly could have synergistic effects on the immune response and protection 
with a fusion protein vaccine, we also tested whether simultaneous injection of BCG and 
H56/H74-CAF01 could improve protection. While we induced peripheral immune responses to 
vaccination and altered the granuloma cytokine response after Mtb challenge, these vaccination 
strategies did not improve disease pathology or bacterial loads in NHPs compared to BCG 
vaccination alone. Among the vaccination groups, BCG followed by intramuscular H74 boost 
vaccinations had some improved disease parameters, while simultaneous BCG&H74 
vaccination, with intramuscular and H74 boosts seemed to worsen TB disease compared to BCG 
alone. This study did not support that these new vaccination strategies improved upon the 
currently used BCG vaccination, but demonstrates the difficulty in optimizing the immune 
response within granulomas to prevent TB. The results from this study may help inform future 
vaccine studies and research on vaccination strategies. 
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4.2 INTRODUCTION 
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), continues to be a 
top cause of death by infectious disease worldwide. According to the World Health 
Organization, 1.7 million people died from TB in 2016 [1].  A live attenuated vaccine against 
TB, Bacille Calmette-Guérin (BCG), has been widely used over the past century, but has little 
efficacy in preventing the pulmonary TB commonly seen in adolescents and adults [322]. 
Although BCG can protect infants from more severe forms of disseminated TB disease, a more 
effective vaccine or vaccination method to prevent development of active TB disease or 
reactivation of latent infection is needed [323, 324]. BCG is traditionally administered 
intradermally, while most other vaccines are administered intramuscularly, orally, or 
subcutaneously [325]. Recently, vaccines that target the site of infection for mucosal pathogens 
have garnered increased interest [262]. In particular, a vaccination route that targets the airways 
has been suggested to increase the efficacy of TB vaccine protection from pulmonary disease 
[258-261]. Additionally, studies have shown that booster vaccines given simultaneously with 
BCG target the same draining lymph node and can boost immune responses [264].  
Several vaccine candidates employing different vaccination strategies for TB are in 
various stages of development, including multiple fusion protein vaccines, which combine a 
variety of Mtb immunogenic proteins to induce an immune response. Our collaborators led by 
Dr. Peter Andersen at Statens Serum Institut (SSI) recently developed two fusion protein vaccine 
candidates, H56 and H74. H56 is a fusion of the Mtb immunogenic antigens, Ag85B and ESAT-
6, as well as the latency-associated protein Rv2660c [326]. Administered with different 
adjuvants, H56 has been shown to induce vaccine-specific immune responses in mice, non-
human primates (NHPs), and humans [229, 326, 327]. H56 reduces bacterial burden after Mtb 
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challenge in mice and reduces disease and prevents reactivation in NHPs [326, 327]. H74 is 
composed of the Mtb antigens ESAT-6, Rv3881c (EspB), Rv3614c (EspD), Rv3615c (EspC), 
Rv3616c (EspA), and Rv3849 (EspR). These antigens are strongly immunogenic and co-
regulated and secreted through the ESX-1 secretion system of Mtb. Unlike classical vaccines that 
primarily emphasize the immune response to mycobacterial antigens only produced early in 
infection, such as Ag85B, these novel vaccines from SSI include immunogenic proteins that 
continue to be produced throughout the course of Mtb infection [231-241]. H74 has been 
demonstrated to cause strong immunogenic response and reduce bacterial burden in the mouse 
model of Mtb infection (data from Dr. Peter Andersen, not published). 
Protein vaccines require adjuvants for proper vaccine delivery and induction of immune 
responses. A series of novel liposome-based cationic adjuvant formulations (CAF) were 
developed by our collaborators at SSI to enhance the T cell responses during vaccination [242]. 
CD4 T cell (Th1 and Th17) responses are important for controlling Mtb replication and disease 
pathology, as shown in knock-out mouse models and patients with genetic defects in Th1IFN-
/IL-12 signaling pathways [71-73, 86, 328]. CD8 T cells in Mtb infections have been shown to 
be crucial for protection from TB, as mutations in the MHC I pathway in mice and CD8 
depletion in NHPs resulted in increased lung pathology and decreased control of Mtb [94-96]. 
Two of these liposomal delivery systems are CAF09 and CAF01. CAF09 was designed to 
enhance the CD4 and CD8 T cell response against vaccine antigens. CAF09 is composed of 
dimethyldioctadecyltammonium (DDA)-liposomes and monomycoloyl glycerol (MMG)-1, a 
synthetic analogue of a mycobacterial cell wall lipid, and Poly(I:C), a synthetic dsRNA and 
TLR3 agonist. Targeting TLR3 can enhance cross-priming and improve antigen presentation to 
CD8 T cells, while MMG induces Th1/Th17 immune responses and stimulates DCs. In mice, 
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CAF09 delivered with various antigens from HIV, Mtb, and HPV increased antigen-specific 
CD8 T cell responses [244]. CAF09 used as an adjuvant for another TB protein vaccine in mouse 
and guinea pig models induced a strong pro-inflammatory (IFN-, TNF, IL-2) CD4 T cell 
response, and reduced bacterial burdens in vaccinated animals compared to unvaccinated 
controls [243]. Similar to CAF09, CAF01 is also composed of DDA liposomes, but with 
trehalose 6,6-dibehenate (TDB) glycolipids, a synthetic variant of a mycobacterial cell wall cord 
factor, as a stabilizer and immunomodulator. In different animal models and humans, CAF01 
with TB protein vaccines has been demonstrated to promote long-lasting Th1 and Th17 immune 
responses [242, 245-248]. Targeting particular T cell responses by vaccination may help with 
protection against Mtb challenge.  
While fusion protein vaccines H56 and H74, along with liposomal adjuvants CAF01 and 
CAF09, have shown encouraging vaccine-specific immune response in the mouse model and, in 
the case of H56, in NHP models [221, 222, 229, 230, 242-245], different vaccination strategies 
using these promising TB vaccine candidates in NHPs has not yet been thoroughly investigated. 
Using a low-dose Mtb infection of cynomolgus macaques (M. fasicularis), we can recapitulate 
the spectrum of human Mtb infection in both disease progression and pathology [77, 267]. 
Initially, we investigated whether targeting the mucosal airways by intranasal or aerosol 
administration, or targeting the lymphatic system by subcutaneous administration would increase 
the efficacy of vaccination. Thus, we conducted an in vivo immunogenicity study using H56 
admixed with CAF09 and administered by different routes – intranasal, subcutaneous, aerosol – 
and then assessed the protection conferred by vaccination after Mtb challenge in a NHP model. 
Following the somewhat encouraging aerosol results of our initial study but noting adverse 
reactions in NHPs to CAF09, we further investigated the protection conferred by H56 or H74 
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admixed with CAF01 boosts followed by aerosolized vaccination of H56 or H74. Additionally, 
based on previously published results of the synergistic immunogenic response of simultaneous 
vaccination of protein vaccines and BCG [264], we tested whether simultaneous vaccination of 
H74-CAF01 and BCG would improve protection from Mtb challenge. Although the entire study 
is not yet complete, from the first two cohorts of NHPs we can infer that boosting BCG 
vaccination with H74-CAF01 or H56-CAF01 by aerosol vaccination, intramuscular injection, or 
simultaneous administration did not increase protection against Mtb infection or disease over 
BCG vaccination alone.  
 
4.3 RESULTS  
4.3.1 Vaccination with H56 and CAF09 can induce adverse inflammatory responses 
To first determine whether vaccination route influenced immune responses or protection, 
cynomolgus macaques were randomly assigned to three vaccination cohorts, and vaccinated with 
H56 admixed with CAF09 adjuvant three times each as indicated in Table 3. Each cohort 
received their vaccinations by different administrations routes – intranasal, subcutaneous, 
aerosol. The subcutaneous cohort received a pegylated form of CAF09 injected directly above an 





Table 3. Vaccination cohorts for H56-CAF09 vaccination routes.  
Nine NHPs were randomized to receive vaccination by different routes. Each group received 3 
vaccinations of the same dose of H56 vaccine (50ug) in CAF09 adjuvant, with 4-5 weeks 
between each vaccination, except for the aerosol group, which received H56 alone for the third 
vaccination. 
 







Intranasal 3 H56-CAF09 H56-CAF09 H56-CAF09 
Subcutaneous (over LN) 3 H56-CAF09 H56-CAF09 H56-CAF09 
Aerosol 3 H56-CAF09 H56-CAF09 H56 
 
 
The intranasal group received their vaccinations with no notable side effects or 
inflammation, but the subcutaneous and aerosol groups had some adverse reactions to 
vaccination. Four weeks after their initial vaccination, animals in the subcutaneous group had 
small minor lesions in the injection region. Two days after the second injection, the right axillary 
lymph node became swollen in all three macaques, ranging from 5-15 mm by 10-13 mm. The 
lymph nodes remained enlarged through the course of vaccinations, and small ulcerations at the 
sites of injections appeared after the third vaccination. The aerosol group was resistant to the 
aerosolization mask despite sedation during the first vaccination. Thirty seconds into their 
second vaccination, animals in the aerosol group began to hyperventilate and their mucus 
membranes turned bright red. To prevent repeat adverse effects during the third vaccination, the 
aerosol group received the last vaccination without CAF09 (H56 protein only), and received a 
small dose of Benadryl and Tylenol prior to third vaccination. 
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4.3.2 T cells are pulled into the airways after H56-CAF09 vaccination 
After the third and last vaccination, there was an increase in CD3+ T cells in the airways, as 
measured in bronchoalveolar lavage (BAL), in all of the cohorts (Figure 27). The aerosol cohort 
that received a third, protein-only “pull” vaccination had an immediate but transient increase in 
CD3+ T cells in airways, with numbers of T cells peaking one day after the third vaccination, 
and decreasing by one week after the third vaccination. In both intranasal and subcutaneous 
groups, T cell numbers in the BAL increased 1 week after the third vaccination, although the 













































































Figure 27. T cell are drawn to the airways (BAL).  
Numbers of CD3+ T cells per ml in BAL in each vaccination cohort. T cells are pulled to the 
lungs 1 day after third H56 only vaccination in aerosol cohort, while intranasal and subcutaneous 
cohorts have increase in T cells 1 week after third vaccination. Blue arrowheads indicate 




4.3.3 Immune response to H56-CAF09 vaccinations in the airways and blood 
We investigated the immune response in the BAL to vaccination by intracellular staining and 
flow cytometry. NHPs in all cohorts had a detectable T cell cytokine response in the BAL 
following the third vaccination. The increase in concentrations of CD4+ and CD8+ T cells 
producing IFN-, TNF, IL-17, or IL-2 corresponded to the peak in numbers of T cells in the BAL 
(i.e., 1 week after third vaccination for intranasal and subcutaneous, 1 day after third vaccination 
for aerosol) (Figure 28A). The transient increase and decrease in T cells after the last vaccination 
in the aerosol group (Figure 27) also corresponded to the cytokine response in CD4+ and CD8+T 
cells in the BAL. 
Some patterns of CD4 T cell functionality were observed in the BAL. The CD4 T cells in 
the BAL of NHPs vaccinated by the intranasal and subcutaneous routes at the time points with 
highest T cell response (1 week after third vaccination) had similar T cell cytokine patterns, with 
more polyfunctional CD4 T cells producing different cytokines (intranasal median = 1.47% CD4 
T cells, and subcutaneous median = 1.13% of CD4 T cells making three or more cytokines). In 
contrast, the cytokine profile of CD4 T cells of aerosol vaccinated NHPs was dominated by 
single cytokine producers, particularly TNF-only T cells 1 day and 1 week after third vaccination 
(Figure 28B). Aerosol vaccinated animals had median polyfunctional CD4 T cell (three or more 
cytokines) response of 0.24% and 0.36% 1 day and 1 week after third vaccination, respectively. 
This suggests that the third boosting vaccination with the protein alone directly to the lung by 
aerosol may rapidly increase CD3+ T cells in the airways and induce a strong TNF-producing 
response with fewer polyfunctional T cells, compared to administering the vaccine with the 




Figure 28. T cell cytokine responses in the airways to H56-CAF09 vaccination. 
(A) Numbers of BAL CD4 or CD8 T cells producing IFN-, IL-2, TNF, or IL-17 cytokines per 
mL of BAL fluid after vaccinations (marked by blue arrowheads). Slight increase in intranasal 
group after first two vaccinations (Week 6), with majority of response from all groups after the 
third vaccination (Week 9/10). BAL cells were unstimulated with Brefeldin A for 12 hours. 
Lines at medians. IN = Intranasal, SQ = Subcutaneous, AE = Aerosol (B) Polyfunctional CD4 T 
cell cytokine response in BAL at times of peak T cell response. Intranasal and subcutaneous 
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groups have more polyfunctional T cells at Week 10 compared to aerosol group at either Week 9 
or Week 10 (i.e., more overlapping lines for intranasal and subcutaneous groups compared to 
aerosol group). Pie charts are of unstimulated CD4 T cells from BAL. 
 
The BAL fluid was used to assess antibody responses using ELISAs. Only aerosol and 
subcutaneous vaccinated animals had H56-specific antibody responses in their BAL (Figure 
29A). Levels of H56-specific IgG peaked 1 week after the third vaccination in the BAL of 
aerosol animals (black lines), decreasing to minimal levels again 5 weeks later. H56-specific IgG 
also increased 1 week after the third vaccination in subcutaneous animals, but this group showed 
increased or maintained levels of IgG after another 5 weeks. Only one animal from the aerosol 
group had measurable levels of H56-specific IgA in its BAL (Figure 29B). 
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Figure 29. Antibody response in the airways to H56-CAF09 vaccination.  
 H56-specific (A) IgG and (B) IgA antibody responses in the BAL fluid of vaccinated animals 
during the course of vaccination. Intranasal = purple, subcutaneous = red, aerosol = black. 
Vaccinations in all graphs marked by blue arrowheads.  
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The immune response to vaccination in PBMCs was more variable than in the BAL. The 
frequency of CD4+ and CD8+ T cells producing pro-inflammatory cytokines in the PBMCs 
increased following the vaccinations, but the response was variable within groups, and typically 
transient (Figure 30A). However, the subcutaneous group had higher levels of H56-specific IgG 
in their plasma than the other two vaccination groups, particularly after their second and third 




Figure 30. Peripheral blood response to vaccinations with H56-CAF09. 
(A) PBMC T cell cytokine response after vaccinations (marked by blue arrowheads). Variable 
PBMC response between cohorts, with some increase after vaccinations. PBMC cells were 
stimulated with peptide pools of Ag85B for 6 hours (5 hours with Brefeldin A), and cytokine 
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frequencies were media-subtracted. Lines at medians. IN = Intranasal, SQ = Subcutaneous, AE = 
Aerosol (B) H56-specific IgG in plasma of vaccinated animals during the course of vaccination. 
Intranasal = purple, subcutaneous = red, aerosol = black. Vaccinations in all graphs marked by 
blue arrowheads.  
 
4.3.4 Aerosol vaccinated NHPs have less inflammation and dissemination after Mtb 
challenge 
We then investigated whether the differences in immune response after vaccination would 
translate to different levels of protection of NHPs following Mtb challenge. NHPs were 
intrabronchially challenged with a low dose of Mtb Erdman (12-21 CFU). Inflammation in NHP 
lungs was quantified by total 18F-FDG activity in lung on PET-CT scans over the course of 
infection as described [329]. Total FDG activity has been previously shown by our group to 
correlate with bacterial burden in lungs [61]. Aerosol vaccinated NHPs had lower total FDG 
activity than other vaccinated cohorts and unvaccinated controls (black lines, Figure 31A). 
Intranasal and subcutaneous vaccinated NHPs rapidly increased in inflammation 3 weeks after 
challenge, with inflammation levels similar to or above those seen in unvaccinated control NHPs 
(green lines). Although two of the aerosol vaccinated NHPs had increased inflammation early in 
infection, this decreased over the course of infection. In contrast, the other vaccination cohorts 
tended to stabilize at high levels of inflammation. By necropsy, two of the three aerosol 
vaccinated NHPs had less inflammation than the unvaccinated controls. Although not significant 
due to low numbers of animals in this pilot study, the results were intriguing. 
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We also tracked granuloma numbers in the lungs during the course of infection by PET-
CT scans. The aerosol vaccinated NHPs tended to have less change in granuloma numbers 
between 3 and 6 weeks after infection compared to the other vaccinated groups, but similar to the 





Figure 31. Inflammation and granuloma dissemination in lungs of H56-CAF09 vaccinated 
after Mtb challenge.  
(A) Inflammation in lungs, as measured by the summation of 18F-FDG uptake in the lungs by 
PET-CT scans. Intranasal (purple) and subcutaneous (red) cohorts have similarly high levels of 
inflammation as unvaccinated control monkeys (green) after Mtb challenge. In contrast, aerosol 
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vaccinated monkeys (black) have less inflammation compared to other vaccinated cohorts and 
unvaccinated controls. Dotted line represents PET Hot of 947.2, which we have found to be the 
cutoff for high risk of reactivation in latent TB macaques (i.e., PET Hot below 947.2 has low risk 
of reactivation) [330]. (B) Change in numbers of granulomas in the lungs during infection, from 
first scan at 3 weeks post-infection to 6 weeks, quantified by PET-CT scans. Aerosol vaccinated 
monkeys have the least change in granulomas numbers in the lungs, indicating more stable 
granulomas. 
4.3.5 Vaccination with H56-CAF09 did not substantially improve disease pathology and 
bacterial burden  
Although vaccinated NHPs, particularly the aerosol vaccinated cohort, had indicators of less 
disease by PET-CT during the course of infection, the overall disease pathology and bacterial 
burden at necropsy was not significantly different from unvaccinated controls; again, there were 
a small number of animals in this pilot study. The total disease pathology (lung, lymph node, 
extrapulmonary) quantified at necropsy in vaccinated NHPs was similar to unvaccinated controls 
(Figure 32A). The aerosol cohort, which had the least inflammation after Mtb challenge, had 
slightly less disease pathology, but was still within the range of the unvaccinated controls. The 
aerosol vaccinated macaques had less extrapulmonary disease than intranasal and subcutaneous 
groups, but it was not less than the unvaccinated controls (Figure 32B). Overall, the aerosol 
cohort had slightly less disease pathology than other groups, but still within the range of the 
unvaccinated controls. In this model, approximately half of unvaccinated controls will develop 
latent infection, while the other half develops active TB, thus the range of infection outcomes in 












































































Figure 32. Disease pathology of vaccinated animals and controls at the end of challenge.  
(A) At necropsy, aerosol vaccinated has slightly less disease pathology than other vaccinated 
cohorts, but within the range of unvaccinated control monkeys. (B) Less disease in 
extrapulmonary tissues of aerosol vaccinated monkeys, comparable to controls. Necropsy scores 
are tabulated based on spread and extent of disease at time of necropsy. Lines at medians. Each 
point is a NHP. 
 
An important outcome measure of vaccine protection is bacterial burden and 
dissemination of disease. The total bacterial burden (thoracic cavity) of the vaccinated NHPs at 
necropsy was similar to the unvaccinated controls. The aerosol cohort had slightly less total 
bacterial burden in lymph nodes than other groups, but similar bacterial burden within lungs 
(Figure 33A). Bacterial burden by individual granulomas shows that granulomas from all 
vaccinated animals have fewer bacteria than unvaccinated, which is reflected in a higher 
frequency of sterile granulomas in vaccinated compared to unvaccinated (Figure 33B). The 
aerosol group has slightly higher frequency of sterile granulomas than other vaccination groups, 
but with overlapping variability (Figure 33C). The bacterial burdens in individual thoracic lymph 
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nodes of vaccinated and unvaccinated macaques are similar, as well as the frequency of sterile 
lymph nodes between the cohorts (Figure 33D and 33E). Generally, all groups poorly controlled 
bacterial replication and had high lung and lymph node bacterial burdens, but the aerosol cohort 































































































































































































































































































Figure 33. Bacterial burden in total, lung, and lymph nodes after challenge.  
(A) Vaccinated monkeys have bacterial burdens within the range of unvaccinated controls, 
although aerosol vaccinated monkeys have slightly less CFU in the LN than the other groups. 
Each point is a NHP. (B) Bacterial burden in excised granulomas at necropsy. Vaccinated groups 
have significantly less bacterial burden in granulomas compared to unvaccinated controls. Each 
point is a granuloma. (C) Vaccinated animals also have slightly higher frequencies of sterile 
granulomas, particularly in the aerosol cohort. Each point is a NHP. (D) Bacterial burden in 
lymph nodes at necropsy. Vaccinated and unvaccinated animals have similar bacterial burden in 
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lymph nodes. Each point is a LN. (E) Vaccinated groups have similar frequencies of sterile 
lymph nodes as unvaccinated controls. Each point is a NHP. All tests for significance compared 
experimental groups to control groups by Dunn’s multiple comparisons tests. Lines at medians. 
4.3.6 Variable cytokine response in lymph nodes and granulomas after H56-CAF09 
vaccination 
To investigate the local immune response, individual lymph nodes and granulomas were excised 
from NHPs and stained for cell surface markers and intracellular cytokines for flow cytometry. 
The peripheral lymph node immune response, specifically the right axillary lymph nodes 
draining the subcutaneous vaccine site, were of interest because of their particularly large size 
after vaccination. At necropsy, the subcutaneous group had higher IFN- responses in their 
peripheral lymph nodes compared to other groups (Figure 34). However, there was no difference 
between the right axillary lymph node and the unrelated inguinal lymph node (stars vs. dots in 
Figure 34). It is likely that vaccination over the lymph node had a local effect on immune 
responses in the lymph node, but that over time, this effect spread to other peripheral lymph 






























































































































































Figure 34. Cytokine response in peripheral (axillary/inguinal) lymph nodes after Mtb 
challenge.  
Subcutaneous vaccination above right axillary LN (indicated by stars in figure) increases IFN- 
response in peripheral LNs compared to other vaccinated cohorts, but other cytokine responses 
similar to other vaccinated cohorts. Dunn’s multiple comparisons test for significance. Lines at 
medians. Each point is a LN, stars mark R axillary LN. 
 
The lung granulomas also had diverse cytokine responses as previously reported [102] 
(Figure 35). Aerosol vaccinated macaques had higher frequencies of IFN- producing granuloma 
T cells compared to the unvaccinated controls. The intranasal cohort had higher frequencies of 
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IFN- and TNF producing T cells, but lower frequencies of IL17 producing T cells compared to 
unvaccinated controls. Subcutaneously vaccinated NHPs had lower frequencies of IL17 
producing T cells compared to the unvaccinated. All groups had similar frequencies of T cells 
producing IL2. These differences in T cell cytokine responses within the granulomas may 









































































































































































Figure 35. Local T cell cytokine response in lung granulomas after Mtb challenge.  
Intranasal group has significantly higher IFN- and TNF, and lower IL-17 response compared to 
the unvaccinated monkeys, while other vaccinated cohorts had fewer differences in granuloma T 
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cell response relative to unvaccinated monkeys. Aerosol vaccinated monkeys had significantly 
higher IFN- response compared to the unvaccinated. Dunn’s multiple comparisons for 
significance. Lines at medians. Each point is a granuloma. 
4.3.7 Experimental boost of BCG responses by aerosolization of protein vaccines 
Based on the H56-CAF09 results, aerosolization of the vaccine seemed to draw T cells to the 
airways, decrease inflammation, and alter the T cell response within granulomas, although it did 
not decrease total bacterial burden. Since H56 was optimized as a booster vaccine to BCG, to 
further investigate the efficacy of aerosolizing TB vaccines, we designed another in vivo NHP 
study to determine whether there were benefits to aerosolizing the protein fusion vaccine in the 
context of a BCG vaccination. We also wanted to test whether simultaneous administration of a 
protein vaccine and BCG had synergistic immunogenic effects in the NHP model as it did in 
mouse studies [264]. At the same time, we decided to investigate a newer fusion protein vaccine, 
H74, which had shown protection in mouse studies. Finally, since CAF09 caused adverse effects 
in the initial study, we chose to continue our study using an adjuvant that we knew worked well 
in NHPs, CAF01. The different experimental groups to encompass these vaccines, adjuvants, and 








Table 4. Vaccination cohorts for H56/H74-CAF01 vaccination routes.  
Thirty-six NHPs were randomized to receive vaccination by different routes. Each group 
received BCG intradermally (ID), with or without simultaneous booster vaccine (H56-CAF01 or 
H74-CAF01) intramuscularly in the same region on the right quadriceps to ensure drainage to the 
same LN. Fourteen weeks after the initial priming vaccination, most groups except for BCG only 
group received H56/H74-CAF01. After 6 weeks, NHPs received a second boost of H74-CAF0 
intramuscularly or H56 or H74 without adjuvant. While the majority of the cohorts are 
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 For statistical analyses, we compared vaccine-boosted animals to BCG only animals 
(Table 4, Figure 36) using unpaired non-parametric ANOVA (Kruskal-Wallis) and post-hoc 
analysis Dunn’s multiple comparisons test. All NHPs were vaccinated at the same time with the 
initial priming intradermal BCG vaccination, with some receiving simultaneous intramuscular 
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vaccinations with H56-CAF01 or H74-CAF01. All groups, except the BCG only group, received 
additional 2 booster vaccinations, 6 weeks apart to compare aerosolization and intramuscular 
administration of booster vaccines. No adverse effects of vaccination were observed in any 
experimental animals. Eight to 10 weeks after final vaccination, NHPs were challenged with a 
low dose (4-25 CFU) to determine efficacy of vaccination. Throughout the course of vaccination 
and challenge, we assessed vaccine-specific peripheral and airway immune responses. After 
challenge, we monitored inflammation and disease progression by 18F-FDG PET-CT scans 












Figure 36. Experimental timeline of H56/H74-CAF01 vaccination route study.  
Day 0 = day of BCG prime vaccination, followed by two boost vaccinations at weeks 14 and 20. 
Eight to 10 weeks following final vaccination (28-30 weeks post-BCG), NHPs were challenged 
with a low dose (4-25 CFU) and the course of infection followed for 5 months. 
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4.3.8 T cells are not pulled to the airways during H56/H74-CAF01 aerosol vaccination 
Vaccinated animals had different T cell airway responses during vaccination and immediately 
after challenge (Figure 37). The BCG-only animals had fairly stable concentrations of T cells in 
the airway through vaccinations, increasing only after Mtb challenge. The two groups of animals 
that received their vaccinations by intramuscular administrations (BCG&H74-CAF01, IMx2 and 
BCG, H74-CAF01. IMx2) had some variable responses throughout infection, and a slight 
increase in numbers of T cells in the airway 1 week after the second boost (Week 21), compared 
to 1 day after the second boost (Week 20). With the exception of one or two animals, the two 
intramuscular vaccination groups did not have an influx of T cells in the airway 2 weeks after 
challenge. We were most interested to see if the aerosol vaccination increased the T cell response 
in the airways (BCG&H74-CAF01, IM AE and BCG&H56-CAF01, IM AE). Unlike with H56-
CAF09 vaccination animals, we did not observe much T cell pull to the airways after 
aerosolization of the boosting fusion protein vaccines, even in the group that received the same 
H56 protein aerosol vaccine as in the previous study (BCG&H56-CAF01, IM AE). We had 
expected to observe a similar increase in concentration in T cells in the BAL, especially 
immediately after the aerosol vaccination at the second boost, but we only saw modest changes 
in some of the animals between 1 day and 1 week after the second boost (Week 20 and Week 
21), instead of a peak 1 day after the second boost (Figures 27 and 37). Interestingly, there was a 
slight increase in T cell concentrations in the BAL of the BCG&H74-CAF01, IM AE group after 
the first boost, which was given by aerosol. Some of the animals in the two aerosol groups also 




Figure 37. T cells are not drawn to the airways after H56/H74-CAF01 vaccinations.  
Concentrations of CD3+ T cells/mL of BAL fluid recovered from the airways of vaccinated 
animals over the course of vaccination and initially after Mtb challenge. IM = intramuscular 
vaccination, AE = aerosol vaccination. Gray dotted lines mark vaccination time points, red 
dotted lines mark Mtb challenge. Each line is a NHP. BCG, N = 4 NHPs; BCG&H74-CAF01, 
IMx2, N = 8 NHPs; BCG&H74-CAF01, IM AE, N = 8 NHPs; BCG, H74-CAF01, IMx2, N = 8 




Although the numbers of T cells did not increase in the airways, the vaccine boosts may 
affect the functionality of the T cells in the airways. Some of the H56/H74-CAF01 animals had 
an increase in the concentrations of vaccine-specific CD4 T cells producing any of pro-
inflammatory cytokines (IFN-, IL-2, TNF, or IL-17) after the first or second boost (Figure 38). 
However, aerosolization of the H56 or H74 did not appear to further draw functional cells to the 
airways, as intramuscularly boosted animals also had an increase in their vaccine-specific CD4 T 
cells. The vaccine-specific CD8 T cell response appeared to be more variable, with the BAL 
cells from one BCG-vaccinated animal surprisingly stimulated by H74 throughout vaccination, 
and some early (2 week) high responses before the boost vaccinations (Figure 39). There were 
particularly low vaccine-specific CD8 T cell responses in H56-CAF01 vaccinated animals, 
especially responses after aerosol vaccination (week 20) compared to H56-CAF09 animals from 







Figure 38. CD4 T cell response in the airways to H56/H74-CAF01 vaccinations.  
BAL cells were stimulated with H74 or H56 peptide pools for 14 hours, and background media 
only responses were subtracted. H56/H74-CAF01 boosted NHPs have more cytokine response in 
their CD4 T cells after boosts. IM = intramuscular vaccination, AE = aerosol vaccination. Gray 
dotted lines mark vaccination time points, red dotted lines mark Mtb challenge. Each line is a 
NHP. BCG, N = 4 NHPs; BCG&H74-CAF01, IMx2, N = 8 NHPs; BCG&H74-CAF01, IM AE, 





Figure 39. CD8 T cell response in the airways to H56/H74-CAF01 vaccinations.  
BAL cells were stimulated with H74 or H56 peptide pools for 14 hours, and background media 
only responses were subtracted. IM = intramuscular vaccination, AE = aerosol vaccination. Gray 
dotted lines mark vaccination time points, red dotted lines mark Mtb challenge. Each line is a 
NHP. BCG, N = 4 NHPs; BCG&H74-CAF01, IMx2, N = 8 NHPs; BCG&H74-CAF01, IM AE, 
N = 8 NHPs; BCG, H74-CAF01, IMx2, N = 8 NHPs; BCG&H56-CAF01, IM AE, N = 8 NHPs. 
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4.3.9 Peripheral immune response in the blood during H56/H74-CAF01 vaccination 
To monitor the immune response throughout the study, we quantified the PBMC response to 
vaccine-specific peptide pools and general mycobacterial antigens in culture filtrate protein 
(CFP). The response to culture filtrate protein (CFP), a mixture of proteins secreted from Mtb, 
was strong and immediate, continuing through vaccination and Mtb challenge, which is expected 
since all of the animals were vaccinated with BCG, and proteins in BCG are also in CFP (Figure 
40). In contrast, there was little IFN- response to H74-specific peptides in BCG only animals 
(Figure 41). The greatest PBMC response to vaccination was in the H74-vaccinated animals, 
with slightly higher response in the intramuscularly vaccinated animals compared to the aerosol 
animals. There was a stronger response earlier in animals given BCG and H74 simultaneously 
(blue lines, Figure 41). H56-vaccinated animals had slight reaction to H74 peptides, probably 
because both vaccines contain Mtb-specific, immunogenic protein ESAT-6. 
All vaccination groups had some IFN- response to H56-specific peptide pools, including 
BCG only animals (Figure 42). Since H56 contains Ag85B, an immunogenic protein that is also 
in BCG, it is not surprising that all of the groups have some response to the peptide pools of 
H56. The majority of the response in H74-vaccinated animals was observed after vaccination 
boosts, when they may be responding to both Ag85B and ESAT-6 or other vaccine proteins. 
Interestingly, in each of the vaccination groups, including BCG only, only a subset of animals 
had stronger IFN- response to H56-specific peptide stimulation, and the responses were usually 
delayed until after the boosts. 
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BCG BCG & H74-CAF01, IMx2
BCG & H74-CAF01, IM AE BCG, H74-CAF01, IMx2
BCG & H56-CAF01, IM AE
 
Figure 40. PBMC IFN- response to Mtb culture filtrate protein (CFP) during vaccination 
and Mtb challenge. 
Strong responses in all vaccination groups to CFP throughout vaccination and challenge. All 
points are background response (media) subtracted. Gray dotted lines mark vaccination time 
points, red dotted lines mark Mtb challenge. Each line is a NHP. BCG, N = 4 NHPs; BCG&H74-
CAF01, IMx2, N = 8 NHPs; BCG&H74-CAF01, IM AE, N = 8 NHPs; BCG, H74-CAF01, 
IMx2, N = 8 NHPs; BCG&H56-CAF01, IM AE, N = 8 NHPs. 
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Figure 41. PBMC IFN- response to H74 vaccine peptides (ESAT-6, Rv3881c, Rv3614c, 
Rv3615c, Rv3616c, and Rv3849) during vaccination and Mtb challenge.  
All points are background response (media) subtracted. Gray dotted lines mark vaccination time 
points, red dotted lines mark Mtb challenge. Each line is a NHP. BCG, N = 4 NHPs; BCG&H74-
CAF01, IMx2, N = 8 NHPs; BCG&H74-CAF01, IM AE, N = 8 NHPs; BCG, H74-CAF01, 
IMx2, N = 8 NHPs; BCG&H56-CAF01, IM AE, N = 8 NHPs. 
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BCG BCG & H74-CAF01, IMx2
BCG & H74-CAF01, IM AE BCG, H74-CAF01, IMx2
BCG & H56-CAF01, IM AE






























































































































Figure 42. PBMC IFN- response to H56 vaccine peptides (ESAT-6, Ag85B, and Rv2660c) 
during vaccination and Mtb challenge.  
All points are background response (media) subtracted. Gray dotted lines mark vaccination time 
points, red dotted lines mark Mtb challenge. Each line is a NHP over course of infection. Each 
line is a NHP. BCG, N = 4 NHPs; BCG&H74-CAF01, IMx2, N = 8 NHPs; BCG&H74-CAF01, 
IM AE, N = 8 NHPs; BCG, H74-CAF01, IMx2, N = 8 NHPs; BCG&H56-CAF01, IM AE, N = 8 
NHPs. 
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4.3.10 Vaccination with H56/H74-CAF01 does not prevent granuloma formation 
Similar to our earlier study of H56-CAF09, we tracked disease progression by serial PET-CT 
scans after Mtb challenge, using 18F-FDG to quantify total inflammation in the lungs and as a 
proxy of bacterial burden [61]. However, none of H56/H74-CAF01 boost-vaccinated animals 
had less inflammation or disease progression in their lungs compared to animals that had 
received BCG only (Figure 43A). There was variability in the inflammation in all of the 
vaccination groups, with some animals controlling infection early and continually throughout the 
course of infection. NHPs with total lung 18F-FDG activity below 947.2 (gray dotted line, Figure 
43A) tend to do better and have less of a chance of reactivation if latent [330]. However, each 
vaccination group had at least one NHP with total lung 18F-FDG activity above that level during 
course of infection, indicating a poor outcome and high bacterial burden. Additionally, four 
animals reached their humane endpoint before their experimental endpoint and were from the 
two vaccination groups that received H74-CAF01 at the same time as BCG (BCG&H74-CAF01, 
IMx2 and BCG&H74-CAF01 IM AE, Figure 43A). Besides the BCG only animals, the only 
vaccination group with only one animal with a bad prognosis was the group that received H74-
CAF01 twice by intramuscular injections subsequent to their BCG vaccinations (BCG, H74-
CAF01, IMx2, Figure 43A). This suggests that concurrent vaccination of H74-CAF01 and BCG 
may cause increased inflammation and disease during Mtb challenge. 
We also enumerated granuloma numbers by PET-CT throughout infection. Our lab has 
previously shown that the change in the number of granulomas between early time points post-
infection can help predict disease outcome, with increase in number of granulomas associated 
with more disease and dissemination [270]. While the BCG and H56/H74-CAF01 concurrently 
vaccinated animals had new granulomas form between 4 and 8 weeks of infection, the 
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vaccination group that received H74-CAF01 subsequent to BCG had stable or decreased 
numbers of granulomas at the same time points (Figure 43B). Most of the BCG only animals had 
stable numbers of granulomas, with few new granulomas formed between 4 and 8 weeks of 
infection, although 2 animals formed more granulomas. Thus, by these disease parameters, 










Figure 43. Inflammation and granuloma dissemination in lungs after Mtb challenge.  
(A) Inflammation in lungs, quantified by summed 18F-FDG uptake from PET-CT scans for each 
of the vaccination groups. Gray dotted line represents PET Hot of 947.2, which we have found to 
be the cutoff for high risk of reactivation (i.e., PET Hot below 947.2 has low risk of reactivation) 
[330]. Each vaccination group has spectrum of NHPs with more or less lung inflammation, 
although BCG, H74-CAF01, IMx2 (green) has only one animal with higher total lung FDG 
activity. BCG&H74-CAF01, IMx2 (blue) and BCG&H74-CAF01, IM AE (purple) have a few 
more animals with higher total lung FDG activity during course of infection, and each group had 
two animals that reached humane endpoint early (marked by red circles). Each line is a NHP. (B) 
 163 
Change in numbers of granulomas in the lungs during infection between 4 and 8 weeks of 
infection, quantified by PET-CT scans. BCG, H74 IMx2 (green) has the least change or decrease 
in lung granulomas, indicating less dissemination. Each point is a NHP. BCG, N = 4 NHPs; 
BCG&H74-CAF01, IMx2, N = 8 NHPs; BCG&H74-CAF01, IM AE, N = 8 NHPs; BCG, H74-
CAF01, IMx2, N = 8 NHPs; BCG&H56-CAF01, IM AE, N = 8 NHPs. 
 
4.3.11 H56/H74-CAF01 vaccine boost does not greatly improve disease outcomes after Mtb 
challenge  
At necropsy, the extent of gross disease pathology in the lungs, LNs, and extrapulmonary sites 
was also quantified into a score (Figure 44A). There were no significant differences in disease 
pathology between the different vaccination groups, although BCG only and BCG, H74 IMx2 
animals seemed to have slightly lower median necropsy scores with less variability between 
animals. In order to assess the protection conferred from the addition of H56/H74-CAF01 boost 
vaccines, we quantified the bacterial load in each of the NHPs at necropsy 5 months after Mtb 
challenge (Figure 44B). Vaccination with H74-CAF01 intramuscularly after BCG vaccination 
(BCG, H74 IMx2) had a lower median of total and lung CFU compared to the other vaccination 
groups, including BCG only animals (Figure 44B). However, the variability within that 
experimental group was still within the range of BCG animals. Additionally, most animals in the 
boosted vaccine groups had at least some CFU+ LNs at the time of necropsy, but the BCG only 
animals had no involved LNs.  
Two of the H74-CAF01 vaccinated groups (BCG&H74 IMx2 and BCG, H74 IMx2) had 
significantly lower median CFU in their individual granulomas compared to BCG only animals 
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(Figure 44C), likely because of larger numbers of sterile granulomas. Indeed, BCG&H74-CAF01 
IMx2 animals had lower median CFU/granuloma and higher frequencies of sterile granulomas 
compared to other vaccinated groups, including BCG only animals (Figure 44C and 44D). BCG 
only animals tended to have lower frequencies of sterile granulomas compared to all vaccinated 
groups. Even though their lung CFU were similar to vaccinated groups, nearly all lung 
granulomas from BCG only animals had viable Mtb. In contrast, some of the H74-CAF01 boost 
vaccinated animals were able to clear the bacteria within their lung granulomas, even though 
their total CFU remained high. In summary, the BCG only vaccinated animals had the best 
overall disease outcomes, compared to boost-vaccinated animals, with lower bacterial loads, low 





Figure 44. Bacterial burden and disease pathology in vaccinated animals at necropsy 5 
months after Mtb challenge.  
(A) All vaccinated animals have similar disease pathology at the time of necropsy, quantified as 
necropsy scores. Necropsy scores are tabulated based on spread and extent of disease at time of 
necropsy. Each point is a NHP. BCG, N = 4 NHPs; BCG&H74-CAF01, IMx2, N = 8 NHPs; 
BCG&H74-CAF01, IM AE, N = 7 NHPs; BCG, H74-CAF01, IMx2, N = 8 NHPs; BCG&H56-
CAF01, IM AE, N = 7 NHPs. (B) Total, lung, and LN CFU of vaccinated animals are similar, 
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except BCG only animals do not have viable bacteria in their LNs. Each point is a NHP. (C) 
Bacterial burden of individual excised granulomas at necropsy. BCG&H74 IMx2 and BCG, H74 
IMx2 boost vaccinated animals have significantly less bacterial burden in granulomas compared 
to BCG only animals. Each point is a granuloma. Dunn’s Multiple Comparisons for significance. 
(D) Vaccinated animals, especially BCG&H74 IMx2, also have slightly higher frequencies of 
sterile granulomas. Each point is a NHP. Lines at medians. BCG, N = 3 NHPs; BCG&H74-
CAF01, IMx2, N = 8 NHPs; BCG&H74-CAF01, IM AE, N = 6 NHPs; BCG, H74-CAF01, 
IMx2, N = 6 NHPs; BCG&H56-CAF01, IM AE, N = 5 NHPs. 
4.3.12 Airway T cell response during vaccination does not correlate with bacterial burden 
There was substantial variability in both immune responses and protection in all the animals. We 
investigated whether the quality and quantity of immune responses in airways provided insight 
into protection in this vaccine study. Thus, we compared peak CD4 and CD8 T cell cytokine 
responses during vaccination after boost vaccinations with H56/H74-CAF01 with outcome of 
infection (total thoracic bacterial burden) to determine whether there were correlations (Figure 
45). As expected, Th1/Th17 responses in CD4 and CD8 T cells in the BAL after boosting 
vaccinations were higher than in BCG only animals, although some animals in BCG&H74 IMx2 
and BCG&H56 IM AE had low Th1/Th17 responses (Figure 45A and 45C). However, these 
BAL responses did not correlate with total bacterial load after Mtb challenge, even in the two 
aerosol vaccination groups (BCG&H74-CAF01 IM, AE and BCG&H56-CAF01 IM, AE) 
(Figure 45B and 45D). This suggests that these H56/H74-CAF01 vaccines to boost the airway 
responses, particularly the aerosolized vaccines, did not confer any additional protection or 
reduce bacterial burden in NHPs after Mtb challenge. 
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Figure 45. Maximum Th1/Th17 BAL responses after boost vaccinations do not correlate 
with bacterial burden.  
Maximum (A) CD4 and (C) CD8 Th1/Th17 (IFN-, IL-2, TNF, IL-17) responses after boost 
vaccinations for each vaccination group. Each point is a NHP, lines at medians. Post-boost 
vaccination and pre-challenge (B) CD4 and (D) CD8 Th1/Th17 BAL responses did not correlate 
with bacterial burden (CFU) at time of necropsy. Line represents linear regression, (B) r2 = 
0.05394, p-value = 0.2748 (D) r2 = 0.05445, p-value = 0.2725. Each point is a NHP. CFU 
correlations: BCG, N = 3 NHPs; BCG&H74-CAF01, IMx2, N = 6 NHPs; BCG&H74-CAF01, 
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IM AE, N = 5 NHPs; BCG, H74-CAF01, IMx2, N = 6 NHPs; BCG&H56-CAF01, IM AE, N = 5 
NHPs. 
4.3.13 Different vaccination strategies alter T cell cytokine response in lung granulomas 
Although H56/H74-CAF01 boost vaccinations did not appear to significantly enhance the 
protection conferred by BCG alone, we wanted to understand if the boost vaccinations could 
alter the local granuloma cytokine environment and to further investigate correlates of protection 
for Mtb infections. The H56/H74-CAF01 vaccinated animals overall were similar to BCG 
animals in terms of infection outcome, but BCG&H74 IM AE animals seemed to have the worst 
disease parameters and outcomes, with higher total lung inflammation, more granulomas formed, 
and slightly higher bacterial burden and necropsy scores compared to other vaccination groups, 
as well as 2 of the 8 animals reaching their endpoints early. In contrast, BCG, H74 IMx2 animals 
seemed to have the best disease parameters and outcomes of the vaccinated groups, with lower 
total lung inflammation, fewer granulomas formed, slightly lower bacterial burden, and lower 
necropsy scores compared to other H56/H74-CAF01 boost vaccinated animals.  
To first understand why BCG&H74 IM AE animals seemed to have worse outcomes than 
BCG animals and other boost vaccinated animals, we quantified the T cell responses in lung 
granulomas. Surprisingly, lung granulomas from BCG&H74 IM AE animals had significantly 
lower frequencies of T cells producing several cytokines compared to granulomas from BCG 
animals (Figure 46). Lung granulomas from BCG&H74 IM AE had particularly low frequencies 
of T cells producing total Th1 cytokines, IL-2, IFN-, or IFN-+IL-2+ co-expressing T cells. 
Additionally, there were significantly lower frequencies of T cells producing IL-17 or anti-
inflammatory cytokine IL-10 in the same lung granulomas compared to lung granulomas from 
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BCG animals. Interestingly, the other aerosol vaccinated group, BCG&H56 IM AE also had 
significantly lower frequencies of IFN-+IL-2+ co-expressing T cells in their lung granulomas 
compared to BCG animals. Otherwise, the other H74-CAF01 vaccinated groups had similar 



























































































































































































































































































































Figure 46. Lower cytokine response in lung granulomas of BCG&H74 IM AE vaccinated 
animals compared to BCG only animals.  
Frequency of cytokine response in CD3+ T cells for each vaccination group, as labeled. Each 
point is a granuloma, lines at medians. Dunn’s multiple comparisons test for significance. BCG, 
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N = 3 NHPs; BCG&H74-CAF01, IMx2, N = 6 NHPs; BCG&H74-CAF01, IM AE, N = 5 NHPs; 
BCG, H74-CAF01, IMx2, N = 6 NHPs; BCG&H56-CAF01, IM AE, N = 5 NHPs. 
 
At the other end of the spectrum, BCG, H74 IMx2 animals did relatively better than other 
vaccination groups, and similar or better than BCG animals in granuloma stabilization and 
sterilization. Within the lung granulomas of BCG, H74 IMx2 animals, there were higher 
frequencies of T cells producing TNF and IL-2+TNF+ together compared to BCG animals 
(Figure 47). Additionally, the T cells of BCG, H74 IMx2 animals had higher frequencies of 
Ki67, a proliferation marker, but lower frequencies of CD69, an early activation marker, 
compared to BCG only animals. Perhaps having one or more of these factors helped lung 


















































































































































































































Figure 47. Frequency of T cell proliferation and inflammatory cytokine response is higher 
in BCG, IMx2 animals compared to BCG only.  
Frequencies of CD3 T cell activation (CD69), proliferation (Ki67), and inflammatory cytokine 
response (IL-2+TNF+ and TNF). Each point is a granuloma, lines at medians. Dunn’s multiple 
comparisons test for significance. BCG, N = 3 NHPs; BCG&H74-CAF01, IMx2, N = 6 NHPs; 
BCG&H74-CAF01, IM AE, N = 5 NHPs; BCG, H74-CAF01, IMx2, N = 6 NHPs; BCG&H56-




We then investigated the differences in CD4 and CD8 T cell responses within lung 
granulomas of the vaccinated animals (Figure 48). CD4 and CD8 T cells had similar frequencies 
of Th1 cytokine responses between vaccinated and BCG animals, except BCG&H74 IM AE had 
lower Th1 response in CD4 T cells and BCG&H74 IMx2 had lower Th1 response in CD8 T cells 
compared to BCG animals. However, three of the vaccination groups had lower frequencies of 
IL-17 CD8 T cells in their lung granulomas compared to BCG animals. Since BCG, H74 IMx2 
animals did similar or better than BCG only animals, and also had similar levels of IL-17-
producing CD8 T cells, while the other vaccination groups had worse disease parameters and 
outcomes with fewer IL-17 CD8 T cells, this may suggest that CD8 T cell IL-17 response may 
be a factor worsening the protection from BCG. 
In summary, many of the T cell responses were similar between lung granulomas of 
vaccination groups and BCG animals. However, of the vaccination groups that had slightly 
worse and slightly better disease outcomes, particular cytokine responses in their lung 
granulomas could differentiate them from BCG animals. Additionally, decreased CD8 T cell IL-
17 response may decrease the protection conferred from BCG alone. 
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Figure 48. CD4 and CD8 T cells responses in granulomas of vaccinated animals.  
Frequencies of (A) CD3+CD4+ and (B) CD3+CD8+ T cells producing Th1 cytokines (IFN-, 
IL-2, or TNF) and IL-17. Each point is a granuloma, lines at medians. Dunn’s multiple 
comparisons test for significance, compared to BCG only animals. BCG, N = 3 NHPs; 
BCG&H74-CAF01, IMx2, N = 6 NHPs; BCG&H74-CAF01, IM AE, N = 5 NHPs; BCG, H74-
CAF01, IMx2, N = 6 NHPs; BCG&H56-CAF01, IM AE, N = 5 NHPs. 
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4.3.14 Similar LN responses to different vaccination strategies 
In addition to testing aerosolization of the boost vaccines, this study also investigated the 
benefits of simultaneous injection of the boost vaccine with BCG in the same area for increased 
LN response. Since we administered the vaccines in the right quadriceps of each NHP, we 
excised their right inguinal LN at necropsy, assuming that it was the primary vaccine draining 
LN. For comparison, we also excised the left axillary LN as a distant peripheral LN. We 
compared the cytokine response in the distant left axillary LN to the draining right inguinal LN 
for each NHP (Figure 49). In general, the immune response did not differ between the two LNs 
for all of the vaccination groups. There was more variable TNF response in T cells from the LNs, 
with some right inguinal LNs having higher frequencies of TNF compared to the left axillary LN 
T cell response. However, not all LNs had higher T cell TNF response in their right inguinal LNs 
compared to their left axillary LN. The simultaneous vaccination into the same draining LN did 




































































































































































Figure 49. Cytokine responses in draining lymph nodes of vaccinated animals.  
Simultaneous administration of BCG and H56/H74-CAF01 boosting vaccine does not enhance 
immune response in draining LN compared to distant LN. Distant, left axillary LN represented 
by dot on the left connected to corresponding vaccine draining right inguinal LN represented by 
star on the right for each NHP.  All samples were excised at necropsy and unstimulated. BCG, N 
= 3 NHPs; BCG&H74-CAF01, IMx2, N = 6 NHPs; BCG&H74-CAF01, IM AE, N = 5 NHPs; 
BCG, H74-CAF01, IMx2, N = 6 NHPs; BCG&H56-CAF01, IM AE, N = 5 NHPs. 
 
The BCG animals in this study did not have any LN involvement after Mtb challenge. 
We quantified the cytokine response in the thoracic LNs of the different vaccination groups to 
see if there were particular cytokines that may help prevent LN infection (Figure 50). Of the 
parameters we measured, there were few cytokines that differed between vaccination groups and 
BCG. Only LNs from BCG&H74 IM AE animals had significantly lower TNF compared to 
















































































































































































































Figure 50.  Frequencies of cytokine responses in thoracic LNs of vaccinated animals.  
Only BCG&H74 IM AE vaccinated animals had lower frequencies of T cells producing TNF in 
thoracic LNs compared to BCG only animals. Each point is a thoracic LN, lines at medians. 
Dunn’s multiple comparisons test for significance. BCG, N = 3 NHPs; BCG&H74-CAF01, 
IMx2, N = 6 NHPs; BCG&H74-CAF01, IM AE, N = 5 NHPs; BCG, H74-CAF01, IMx2, N = 6 
NHPs; BCG&H56-CAF01, IM AE, N = 5 NHPs. 
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4.4 DISCUSSION 
H56 fusion protein vaccine has been shown to be a promising TB vaccine candidate, boosting the 
protection against pulmonary TB when used in conjunction with BCG vaccination in mouse and 
NHP models [326, 327]. Previous NHP studies testing H56 admixed with the adjuvants IC31 and 
CAF01 intramuscularly, in macaques first vaccinated with BCG, showed that the boosting 
vaccination could help boost some aspects of BCG protection [327] (DiFazio et al, in 
preparation). H74 fusion protein vaccine has shown promising protective effects in mouse 
models (SSI, unpublished data). The adjuvant CAF09 was designed to boost both CD4 Th1/Th17 
and CD8 T cell responses, while CAF01 induces Th1/Th17 responses [242, 244-247]. In this 
study, we investigated multiple vaccination strategies, first testing vaccine delivery route 
(intranasal, subcutaneous, and aerosol) with fusion protein vaccine and the novel liposomal 
adjuvant CAF09 against Mtb challenge. Given the slightly decreased inflammation and improved 
disease outcomes of aerosol vaccinated animals compared to the other vaccination routes and 
unvaccinated controls, we further investigated the benefits of heterologous prime-boost aerosol 
vaccination using BCG, followed by H56 or H74 and liposomal adjuvant CAF01, demonstrating 
that aerosolized boost vaccinations led to similar or slightly worse disease outcomes and 
bacterial load compared to BCG only vaccinated animals. Additionally, we probed the benefits 
of simultaneous vaccination of H56/H74-CAF01 and BCG into the same draining LN, but found 
no increased protection or immune response from simultaneously vaccinated animals. Instead, 
BCG, H74 IMx2 had slightly improved outcomes compared to other experimental vaccination 
groups and in some respects compared to BCG only animals. However, overall animals that 
received H56/H74-CAF01 boosts had little increased protection from Mtb challenge compared to 
BCG alone, although vaccination altered the T cell immune responses within granulomas. 
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The initial adverse effects seen in giving H56 with CAF09 by aerosol suggest that CAF09 
is not an ideal adjuvant for delivering a vaccine against TB. The subcutaneously vaccinated 
NHPs also had substantial swelling at the site of injection with H56 and CAF09, implying a 
possibly robust and immediate local immune response to one of the components of the vaccine. 
When we did not use CAF09 adjuvant in the third vaccination of the aerosol cohort, only 
aerosolizing the H56 protein vaccine, we observed considerably less adverse response after 
vaccination, indicating the adjuvant CAF09 as the cause of the immediate response. 
Additionally, the intranasal and subcutaneous vaccination NHPs had strikingly high 
inflammation in their lungs soon after Mtb challenge, even compared to unvaccinated controls. 
The inclusion of Poly(I:C), a double-stranded RNA virus mimic, in the CAF09 liposomes may 
be the cause of this poor response in the case of TB, as Poly(I:C) has been shown to exacerbate 
TB disease [331]. In mouse studies, Poly(I:C) can induce a Type I IFN response, causing a rapid 
influx of neutrophils and monocytes to the lung tissue parenchyma of Poly(I:C) treated mice 
[331, 332]. For TB, induction of Type I IFNs, whether artificially generated by Poly-IC or 
triggered by a particular strain of Mtb, is detrimental, causing increased bacterial loads and 
decreased survival [331, 333]. We did not detect any measurable amounts of IFN- from the 
BAL fluid after vaccination, but we may have missed the critical, early time period of a rapid 
Type I IFN response (data not shown). Although apparently unfavorable for TB, the induction of 
Type I IFNs by CAF09 may be beneficial for other diseases. Although CAF01 did not cause any 
of the immediate adverse effects observed with CAF09, the vaccination of CAF01 with H56 and 
H74 did not significantly improve the protection conferred by BCG alone. 
The reduced inflammation and slightly improved disease outcomes after Mtb challenge in 
aerosol vaccinated compared to other vaccination cohorts suggested that administration of the 
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same vaccine by different routes can cause divergent outcomes, particularly in inflammation. 
The aerosol vaccinated cohort had less inflammation, granuloma dissemination, or 
extrapulmonary disease, and slightly higher frequency of sterile granulomas compared to the 
other cohorts. The marginally better outcomes of the aerosol cohort could be due to the route of 
vaccination (directly to the lungs as an aerosol), or the “prime and pull” during vaccination, 
where the NHPs were initially immunologically “primed” with H56 protein vaccine and CAF09 
adjuvant for the first two vaccinations, then the response “pulled” back to the lungs by the third 
vaccination with H56 protein vaccine only, or by a combination of both factors.   
Aerosol BCG vaccination in the guinea pig model has demonstrated the potential benefits 
of directly administering TB vaccines to the site of infection [261]. The promising effects of a 
prime and pull vaccination strategy were first shown against genital herpes simplex virus 2, 
using a parenteral vaccination to prime, followed by a local topical application of chemokines to 
pull in a local response [334]. Additional studies have had variable success with the prime and 
pull strategy, suggesting the need for optimization of combination of disease model, vaccine, and 
adjuvant [335-337]. In this study, we saw an influx of T cells immediately to the airways after 
the “pull” vaccination in the aerosol cohort, suggesting that prime and pull vaccination may be 
an important factor in improving the aerosol cohort’s response to Mtb challenge. Unfortunately, 
when we conducted further studies to enhance the effects of aerosolizing TB vaccines, we no 
longer saw any protective effects of the vaccine or the “pull” to the mucosal sites of infection. In 
the later study, we vaccinated using a heterologous prime-boost strategy, priming with 
intradermal vaccination of BCG and boosting with intramuscular vaccination of H56/H74-
CAF01, before a second boost aerosol vaccination of H56/H74. Since the previous study had 
administered H56-CAF09 by aerosol twice before the final aerosol administration pulled T cells 
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to the airway, perhaps the results differed between the two studies because of the different routes 
of the initial two vaccinations. The intradermal/intramuscular administration of priming vaccine 
may not be sufficient to pull immune responses to the airway in the context of Mtb. 
Previously, BCG has been shown to be a strong adjuvant in the context of other 
infections and in cancer treatments [338-340]. Our collaborators at SSI had shown that 
simultaneous administration of BCG and boost vaccines led to synergistic immune responses and 
reduced bacterial burden after Mtb challenge [264]. However, our results from this study showed 
no added benefit to simultaneous injection of BCG and boost vaccines. Although there were 
clear peripheral immune responses to vaccination, there was also increased inflammation, low 
immune response in the draining lymph node, and little improvement in bacterial burden or 
disease outcome above BCG alone. There were slightly higher frequencies of sterile granulomas 
in BCG&H74 IMx2 animals, but two of the eight animals in the vaccination group also met their 
humane endpoints early. Instead, animals that did not receive the boost vaccine at the same time 
as BCG (BCG, H74 IMx2) had slightly better outcomes, with slightly less inflammation, more 
stable granuloma numbers, and low bacterial load and disease pathology, comparable to BCG 
alone vaccinated animals. This suggests that if H74-CAF01 boost vaccination can confer any 
additional protection to BCG vaccination during Mtb vaccination, it may not be ideal to 
concurrently administer BCG with H74-CAF01. To our knowledge, no other studies have 
investigated simultaneous heterologous prime-boost vaccination in TB. However, in a study of 
cytomegalovirus (CMV)-based TB vaccines, rhesus macaques that were vaccinated with BCG 6 
weeks before boost CMV vaccination had less protection during Mtb challenge than those that 
were only vaccinated with the CMV-based vaccine, suggesting that BCG may have interfered 
with the immune response and protection of their vaccine [341]. Additionally, in the context of 
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tumor treatment with BCG, Yu et al. found that simultaneous injection of BCG and a VEGF 
inhibitor was worse at reducing tumors in a mouse model than administering BCG or VEGF 
independently [342]. Thus, simultaneous vaccination of BCG with boost vaccines may not 
always confer additional protection, and may interfere with BCG immune effects rather than 
serve as an adjuvant. 
The ideal combinations of local cytokine response for reducing bacterial burden in the 
granuloma are not known [68, 102]. The different vaccination groups from both parts of this 
study resulted in slightly different granuloma T cell cytokine profiles. In the first part of the 
study, the aerosol group, which had the least inflammation and disease among the H56-CAF09 
vaccinated groups, had higher frequencies of IFN--producing T cells compared to granulomas 
from unvaccinated controls. Moreover, although the intranasal and subcutaneous cohorts had 
similar disease outcomes, their local cytokine responses were different compared to the 
unvaccinated cohort. The intranasal group had higher frequencies of IFN- and TNF, and lower 
frequencies of IL-17, while the subcutaneous group only had significantly lower frequencies of 
IL-17 compared to the unvaccinated controls. In the later study with H56/H74-CAF01 
vaccination, the vaccination group with the relatively best disease parameters, BCG, H74 IMx2, 
had significantly higher proliferation, IL-2+TNF+ and TNF cytokine response and lower 
activation of T cells compared to BCG alone. In contrast, the vaccination group with the 
relatively worst disease parameters and outcomes, BCG&H74 IM AE, had significantly lower 
frequencies of pro-inflammatory cytokines (Any Th1 cytokine, IFN-+IL-2+, IL-2, IFN-, IL-17) 
and anti-inflammatory cytokine IL-10. The consistently lower frequencies of CD3 T cells 
producing IL-17 in lung granulomas of vaccinated animals with worse disease outcomes 
(intranasal and subcutaneous groups from the initial study, BCG&H74 IM AE from the later 
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study) is consistent with previous studies showing the necessity of a strong IL-17 response for 
bacterial control and may warrant further investigation [92, 93, 102]. The peripheral BAL and 
PBMC cytokine response during vaccination from both parts of this study did not predict the 
differences of the local granuloma T cell response or bacterial loads between the vaccinated 
groups. 
In summary, this study has demonstrated that the different vaccination strategies using 
subunit fusion proteins and adjuvants tested in this study are not protective against Mtb 
challenge. We can conclude that many potential vaccination strategies may not work in the 
context of Mtb in a NHP model. First, H56-CAF09, particularly without initial BCG priming 
vaccination, is not an ideal strategy for TB vaccinations, leading to adverse effects and high 
levels of inflammation after Mtb challenge. Second, aerosol vaccination of boosting vaccines 
may pull T cells to the desired mucosal site, but may need multiple administrations of 
aerosolized vaccinations to be successful. When we vaccinated NHPs with aerosol vaccinations 
multiple times of H56-CAF09, we observed a T cell influx to the airways after boost vaccination. 
However, when we primed NHPs by intradermal/intramuscular vaccination, we did not observe 
any additional influx of immune cells to the airways. Third, simultaneous vaccination of BCG 
and H56/H74-CAF01 does not seem to significantly boost immune responses or protective 
effects. Finally, although H56, H74, CAF01, and CAF09 in different combinations had 
demonstrated some protective effects in mouse and NHP models and in human studies, these 
particular combinations using these vaccination strategies did not significantly increase 
protection above BCG vaccination alone. While this study failed to produce any viable vaccines 
or vaccination strategies for TB, it demonstrated that beyond preparing and influencing the 
peripheral responses, vaccines can also alter the T cell responses at the site of infection, in TB 
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granulomas. These results may better inform the potential correlates of protection for TB 
vaccines and better inform our vaccination strategies for TB. 
4.5 METHODS 
4.5.1 Experimental animals 
For the initial H56-CAF09 study, nine cynomolgus macaques (Macaca fascicularis) between 7 
and 8 years of age, with starting weights of 6-8kg were used (Valley Biosystems, Sacramento, 
CA). For the subsequent H56/H74-CAF01 study, 36 cynomolgus macaques (Macaca 
fascicularis) between 5 and 10.5 years of age, with starting weights of 3.1-8kg were used (Valley 
Biosystems, Sacramento, CA). Animal care was in accordance with institutional guidelines, and 
all experimental manipulations, protocols, and care of the animals were approved by the 
University of Pittsburgh School of Medicine Institutional Animal Care and Use Committee 
(IACUC). Animals were examined while in quarantine as previously described to ensure animals 
were in good physical health with no previous M. tuberculosis infection [57, 291].  
4.5.2 Experimental vaccines 
Recombinant H56 protein vaccine (Ag85B-ESAT6-Rv2660c) and recombinant H74 
protein vaccine (Rv3881c-ESAT-6-Rv3614c-Rv3615c-Rv3616c-Rv3849) were purified from 
Escherichia coli [326]. CAF01 liposomes were formulated by incorporating the glycolipid ,’-
trehalose 6,6’-dibehenate (TDB) into dimethyldioctadeclyammonium (DDA) liposomal vesicles 
 185 
suspended in 10mM Tris-buffer, pH7.4 as previously described [343]. CAF09 liposomes were 
prepared with DDA, monomycoloyl glycerol (MMG)-1, and Poly(I:C) and suspended in 10mM 
Tris-buffer, pH7.4 [244]. CAF09PEG2000, a pegylated form of CAF09, was created for 
subcutaneous vaccinations. Doses used for H56-CAF09 study were 50ug H56 protein vaccine 
and 625ug CAF09 adjuvant in 0.3ml for intranasal or subcutaneous delivery, and 1ml for aerosol 
delivery, diluted in filter-sterilized 10mM Tris-buffer, pH7.4. Doses used for H56/H74-CAF01 
study were 15ug H56 protein vaccine or 15ug H74 protein vaccine and 625ug CAF09 adjuvant 
in 1ml for intramuscular delivery, diluted with 10mM Tris-buffer, pH7.4. For aerosolized 
delivery of H56 or H74 during H56/H74-CAF01 study, 50ug of H56 protein vaccine or 50ug of 
H74 protein vaccine were resuspended in 1ml of filter-sterile 10mM Tris-buffer, pH7.4. 
4.5.3 Vaccinations 
For the H56-CAF09 study, NHPs were vaccinated with H56 protein and CAF09 adjuvant 
by three routes – intranasal, subcutaneous, and aerosol, with each animal receiving 3 
vaccinations every 4-5 weeks (Table 1). As this was a pilot study, each vaccine group consisted 
of 3 macaques. The intranasal group received H56 and CAF09 by intranasal mucosal atomization 
device in the right nare (Teleflex, Morrisville, NC). The subcutaneous group was injected with 
H56 and CAF09PEG2000 (pegylated CAF09) subcutaneously above the right axillary lymph 
node. The aerosol group received H56 and CAF09 by the Investigational e-Flow Nebulizer 
System (PARI Pharma, Munich, Germany), an electronic nebulizer with vibrating membranes 
that generates aerosolized droplets of 2-8um, together with a pediatric face mask to deliver the 
aerosolized droplets to the animals. The aerosol group received only H56 protein for their third 
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vaccination because of observed adverse effects when H56 and CAF09 were administered by 
aerosol for the first two vaccinations. 
For the H56/H74-CAF01 study, NHPs were vaccinated with BCG and H56-CAF01 or 
H74-CAF01 in different combinations, with all animals receiving an initial BCG vaccination at 
Week 0, followed by boost vaccinations for animals in experimental boost vaccine groups at 
Week 14 and Week 20 (Table 2). BCG Danish (courtesy of Statens Serum Institut, Copenhagen, 
Denmark) was administered according to manufacturer’s directions by intradermal injection on 
the right quadriceps. Resuspended BCG vaccine was also plated on 7H11 agar plates to confirm 
bacterial growth was within range of manufacturer’s standards. During simultaneous 
vaccinations, H56-CAF01 or H74-CAF01 were injected intramuscularly adjacent to site of BCG 
injection. At subsequent boost vaccinations, H56-CAF01 and H74-CAF01 was injected on the 
right quadriceps adjacent to original BCG injection. The vaccine groups that received aerosol 
vaccinations had H56 or H74 aerosolized using the Investigational e-Flow Nebulizer System 
(PARI Pharma, Munich, Germany) as described above. 
4.5.4 Intracellular cytokine staining and flow cytometry 
Blood samples were collected over the course of vaccination and after infection, and peripheral 
blood mononuclear cells (PBMCs) were isolated as previously described [344]. In the H56-
CAF09 study, for each NHP, 1x106 PBMCs were stimulated with individual peptide pools of 
Mtb proteins ESAT-6, Ag85B, and Rv2660c, whole protein H56, and PDBU and ionomycin for 
1 hour at 37°C/5% CO2, then for an additional 5 hours in the presence of Brefeldin A 
(Golgiplug: BD Biosciences) at 37°C/5% CO2. PBMCs and stimulators were diluted in RPMI-
1640 containing 1% HEPES, 1% L-glutamine, and 10% human AB serum. Peptide pools and 
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protein were diluted to 10ug/ml. After stimulation, PBMCs were washed with 1xPBS and 1% 
Fetal Bovine Serum and stained as described below.  
Bronchoalveolar lavage (BAL) was also collected as previously described [344], 
centrifuged to obtain the immune cells, and live immune cells quantified by trypan blue 
exclusion. In the H56-CAF09 study, BAL cells were stimulated with individual peptide pools of 
H56 vaccine-specific proteins ESAT-6, Ag85B, and Rv2660c for 2 hours at 37°C/5% CO2, then 
for an additional 12 hours at 37°C/5% CO2. Peptide pools were diluted to 1ug/ml. PDBU and 
ionomycin was used as a positive control for stimulation whenever additional cells were 
available. After stimulation, BAL cells were washed with 1xPBS and stained as described below.  
Similarly, in the H56/H74-CAF01 study, after BAL cells were isolated, they were 
stimulated with peptide pools/proteins of H56 vaccine-specific proteins ESAT-6, Ag85B, and 
Rv2660c, or H74 vaccine-specific proteins ESAT-6, Rv3881c, Rv3614c, Rv3615c, Rv3616c, 
and Rv3849, for 2 hours at 37°C/5% CO2, then for an additional 12 hours at 37°C/5% CO2. 
Peptide pools were diluted to 1ug/ml. PDBU and ionomycin was used as a positive control for 
stimulation whenever additional cells were available, and BAL cell responses were media-
subtracted to approximate vaccine-specific responses. After stimulation, BAL cells were washed 
with 1xPBS and stained as described below.  
After stimulation and wash, BAL cells were stained for viability (Invitrogen). BAL cells 
and PBMCs were stained for surface and intracellular cytokine markers. Antibodies for cell 
surface markers included: CD3 (clone SP34-2, BD Biosciences), CD4 (clone L200, BD 
Biosciences), CD8 (RPA-T8, BD Biosciences), CD45Ra (clone 5H9, BD Biosciences), CD27 
(clone 0323, eBiosciences). Cells were fixed and permeabilized (BD Biosciences). Intracellular 
staining of cytokines and other cellular markers included: CD69 (clone TP1.55.3, Beckman 
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Coulter), IFN- (clone B27, BD Biosciences), IL-2 (clone MQ1-17H12, BD Biosciences), TNF 
(clone MAB11, BD Biosciences), IL-10 (clone JES3-9D7), Ki67 (clone B56, BD Biosciences), 
and IL-17 (clone eBio64CAP17, eBiosciences). Cells were fixed in 1% paraformaldehyde. Data 
acquisition was performed using a LSR II flow cytometer (BD Biosciences) and analyzed using 
FlowJo Software v.9.7 or v.9.9 (Treestar Inc.). BAL cytokine responses were normalized to live 
cell counts and mL of fluid obtained.  
4.5.5 PBMC ELISPOTs 
Isolated PBMCs were serially stimulated over the course of vaccination and infection with 
vaccine-specific peptides, and IFN- production captured by NHP-specific IFN- ELISPOTs 
(Mabtech) according to manufacturer’s instructions. Briefly, white membrane ELISPOT plates 
(Millipore) were coated with IFN- specific capture antibody (MT162L, Mabtech) and blocked 
with ELISPOT media (RPMI+1% L-glutamine+1% HEPES+10% human AB serum). 2ug/ml 
peptide pools of H56 proteins (ESAT-6, Ag85B, and Rv2660c) and H74 proteins (ESAT-6, 
Rv3881c, Rv3614c, Rv3615c, Rv3616c, and Rv3849), and 2ug/ml Mtb culture filtrate protein 
(CFP) were added to 2x105 PBMCs in duplicate and incubated at 37°C/5% CO2 for 40-50 hours. 
Cells were then washed, and IFN- detection antibody (7B6-biotin) was added for 2 hours at 
37°C or overnight at 4°C. After washing, streptavidin-HRP was incubated for 45 minutes at 
37°C, and ELISPOT plates were developed using AEC substrate solution. After development 
and drying, IFN- spots were enumerated by ImmunoSpot program, and results normalized by 
spot forming units per 2x105 cells. 
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4.5.6 ELISAs 
Reciprocal endpoint titer ELISAs were used to measure the H56 vaccine-specific response in the 
BAL and plasma. IgG responses were detected using a pan-monkey antibody (clone: 1B3-HRP, 
NIH NHP Resources, Mass Biologics) and IgA responses were detected using a rhesus antibody 
(clone: 10F12, NIH NHP Resources, Mass Biologics). Results were measured at OD450 on a 
spectrophotometer (SpectraMax). Antibody levels were measured by serial sample dilutions, and 
calculated using the average OD450 + 2 standard deviations of the highest dilution of the 
negative control as a cutoff. All BAL results were normalized by plasma and BAL urea levels. 
4.5.7 Animal infection 
Animals in H56-CAF01 study were infected with 12-21 colony forming units (CFUs) of Mtb 
virulent Erdman strain per monkey by bronchoscopic instillation to the lower lung lobe, as 
previously described [267]. Similarly, animals in H56/H74-CAF01 study were infected with 4-
25 CFUs of Mtb virulent Erdman strain per monkey. To reduce numbers of macaques used, 6 
unvaccinated controls for the H56-CAF01 study were from another published study [106]. 
4.5.8 PET/CT scans 
After Mtb challenge, serial 18F-fluorodeoxyglucose (FDG) PET-CT scans were performed in a 
biosafety level 3 imaging suite as previously described [269]. Scan analyses were conducted 
using OsiriX viewer as described elsewhere, with quantification of granulomas on scans and 
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summation of total 18F-FDG uptake in lungs [329]. Six of the eight unvaccinated controls only 
had a single PET CT scan prior to necropsy, while two had serial scans. 
4.5.9 Necropsy procedures, pathology scores, and bacterial burden 
Necropsy was performed as previously described [57, 291]. In summary, NHPs were humanely 
sacrificed by terminal bleed, and lesions in lungs and thoracic lymph nodes identified by PET-
CT or at necropsy were individually excised for histological analysis, and homogenized into 
single cell suspension for bacterial burden and immunological assays. Extent of disease was 
quantified using a disease pathology score that incorporates the number, size, and pattern of 
granulomas in each lung lobe, mediastinal lymph nodes, peripheral lymph nodes, and 
extrapulmonary organs, modified from our previously described version [57]. To determine the 
bacterial burden, each granuloma homogenate was plated in serial dilutions on 7H11 medium 
and incubated at 37°C/5% CO2 for 21 days before CFU enumeration. Total CFU was calculated 
from a summation of plated samples. Excised and homogenized granulomas were also analyzed 
for immunological response by intracellular staining and flow cytometry as described above after 
2.5-3.5 hours in the presence of Brefeldin A (GolgiPlug, BD Biosciences) to capture cytokine 
response. 
4.5.10 Statistical analysis 
Statistical analyses were performed using GraphPad Prism v6 and v7 (Graphpad Software). 
Kruskal-Wallis test was used with post hoc analysis Dunn’s multiple test comparisons to 
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compare vaccinated groups to unvaccinated controls. P values less than 0.05 were considered 




5.0  SUMMARY AND IMPLICATIONS 
5.1 IL-10 AND T CELL EXHAUSTION ARE NOT SIGNIFICANT MODULATORS 
OF T CELL CYTOKINE RESPONSE IN TB GRANULOMAS  
The goal of this dissertation was to determine the contributions of the immunomodulators IL-10 
and exhausted T cells on T cell cytokine response in TB granulomas. Studies in the mouse model 
of Mtb infection and other infectious disease models suggested that IL-10 may be dampening 
protective T cell cytokine responses [132-137, 345-347]. While the absence of functional IL-10 
in Mtb-infected NHPs had transient effects on the inflammation, cytokine response, and structure 
in a subset of lung granulomas, it did not affect the overall disease outcome or bacterial burden 
of the NHPs (Chapter 2). The changes in the lungs and lymph nodes in NHPs with IL-10 
neutralization were mostly nullified or reversed by 8 weeks of Mtb infection. Since the Mtb-
specific adaptive immune response is typically induced 4-6 weeks after Mtb infection in NHPs, 
the differences observed at 4 weeks may have been counteracted by the adaptive response by 8 
weeks of infection [57]. As some of the previous murine studies of Mtb infection in the absence 
of IL-10 suggested, IL-10 alone may not have a significant role in modulating the immune 
response during Mtb infection, and may be compensated by other, currently unidentified, 
immune factors [139-142]. These results also suggested that some but not all lung granulomas 
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may be modulated by IL-10. Thus, although IL-10 may modulate some of the cell responses 
during Mtb infection, it is not the only or the major contributor.  
A major limitation of this study is the short timeframe of Mtb infection. We had wanted 
to capture the effect of IL-10 during the transition from innate- to adaptive-dominated immune 
response in granulomas, thus only investigated two early, critical time points of Mtb infection. 
Administration of antibodies for long periods of time is challenging in non-human primates. 
However, in restricting our time frame, we may have missed the long-term effects of IL-10 
during Mtb infection. A previous study in Mtb infection in mice found that lack of IL-10 did not 
make a difference in the granuloma structure or bacterial burden until after at least 2 months of 
infection [136]. Additionally, neutralizing IL-10 only within the first 3 weeks of infection set the 
Mtb-infected mice up for similar granuloma structure and bacterial control during chronic 
disease compared to mice completely lacking IL-10 during the entire infection. This suggests 
that IL-10 may be critical during the first month of Mtb infection, and the changes that we 
observed after 4 weeks of IL-10 neutralization may have set the stage for increased long-term 
bacterial control that we simply did not observe because we did not extend our study long 
enough. It also confirms that blockade of IL-10 beyond the first month of Mtb infection did not 
further increase the protection. Interestingly, as in the mouse study, we also observed increased 
signs of fibrosis in the granulomas in the absence of IL-10, further suggesting that these fibrotic 
granulomas may have better chronic control of Mtb, which supports previous studies associating 
fibrotic granulomas with containment, drug treatment, and sterility [286, 287]. The timing of the 
greater effects of the IL-10 neutralization, increasing cytokine and chemokine responses and 
decreasing inflammation at 4 weeks post-infection also suggests a stronger effect of IL-10 on the 
innate immune response during Mtb infection, before a robust adaptive immune response begins 
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around 6 weeks post-infection. By 8 weeks post-infection, during the establishment of the 
adaptive immune response, Furthermore, many of the changes in cytokine response during anti-
IL-10 treatment were cytokines typically produced by innate immune cells. Thus, IL-10 may be 
more critical for innate cell response, rather than on T cells, as previously hypothesized. 
Our observations that IL-10 is not critical for bacterial control during the first two months 
of infection settles the discordant mouse studies about the role of IL-10 during early Mtb 
infection. Additionally, the absence of IL-10 does not significantly affect the T cell response. 
Thus, while therapeutics to supplement or block IL-10 have been suggested for other 
autoimmune or infectious diseases, therapeutics to reduce IL-10 and boost immune responses 
may not be prudent [348-350]. Although the research in this dissertation strongly suggests that 
IL-10 alone may not significantly affect disease outcomes early in Mtb infections, further 
research into the effects of IL-10 later on in infection should be conducted. Understanding the 
role of IL-10 during later stages of Mtb infection is especially critical because human Mtb 
infections are typically not diagnosed until months to years later. IL-10 may have a different role 
during Mtb infections by the time patients are diagnosed. Regulatory T cells, other 
immunomodulatory cytokines, such as TGF-, currently unidentified factors, or IL-10 in 
conjunction with another factor may be more critical to modulating the T cell response in TB 
granulomas. 
This dissertation also aimed to investigate whether exhaustion of T cells during Mtb 
infection influenced the T cell responses in TB granulomas. T cell exhaustion is a major 
contributor to T cell dysfunction in many chronic viral diseases and cancer [143-148]. Using our 
NHP model of TB, we did not find evidence that T cells in TB granulomas across infection time 
or pathology were definitively exhausted (Chapter 3). There were low frequencies of T cells 
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expressing the inhibitory receptors PD-1, CTLA-4, or LAG-3, and those expressing these 
inhibitory receptors still had similar or even more cytokine functionality and proliferation 
capability than those without inhibitory receptors. Our collaborators further demonstrated that 
when they manipulated levels of T cell exhaustion in a computational model of TB granulomas, 
there were much higher levels of bacterial load than observed in vivo. The low levels of T cell 
exhaustion we observed contrast with previous studies in humans, mice, and NHPs. However, 
many of those studies characterized T cell exhaustion by the expression of a single inhibitory 
receptor [159-161]. Additionally, the presence of an inhibitory marker (PD-1 or CTLA-4) in 
some studies seemed to mark T cells as activated rather than exhausted [115, 169, 179]. Thus, 
although TB is a chronic disease where Mtb and its antigens can persist in granulomas for 
extended periods of time, the T cells do not appear to be exhausted. Our collaborators’ 
computational model and observations of the compartmentalization of activated cells in 
granulomas support our hypotheses that the low levels of T cell exhaustion may be a virtue of the 
highly organized structure of granulomas preventing T cells from encountering Mtb antigens 
[179, 268, 351].  
Due to limited reliable reagents available for NHPs, our study focused only on 3 main 
inhibitory receptors, PD-1, CTLA-4, and LAG-3, as markers of T cell exhaustion. However, 
these inhibitory receptors are also the ones with blocking therapies furthest in development. 
Drugs targeting inhibitory receptors have been used in cancer immunotherapy, with anti-PD-1 
and anti-CTLA-4 drugs FDA-approved since 2014 and 2011, respectively [352]. 
Immunotherapies to block LAG-3 are also in development to treat cancer [353]. The success of 
these therapies depend on the presence of these inhibitory receptors on the T cells in the tumors 
[352]. With low levels of these inhibitory receptors on T cells in TB granulomas, these therapies 
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would not be beneficial during TB treatment. The contrast between T cell exhaustion in TB 
granulomas and tumor microenvironments, although similar in their congregations of immune 
cells, highlights the unique spatialization and organization within TB granulomas that prevent 
the chronic antigen presentation necessary for T cell exhaustion. 
IL-10 and T cell exhaustion have been long suggested as potential reasons for the low T 
cell responses and lack of bacterial control during Mtb infections. The results from this 
dissertation demonstrate that IL-10 and T cell exhaustion individually are not significant 
contributors to the modulation of T cell responses at the local site of Mtb infection, in TB 
granulomas. Understanding that IL-10 and T cell exhaustion are not immunological correlates of 
TB protection helps push TB research into different directions, so that hopefully other more 
significant contributing factors may be found. 
5.2 VACCINATION STRATEGY CAN ALTER IMMUNE RESPONSE 
By testing different vaccination strategies, this dissertation sought to alter the T cell response in 
the TB granulomas and engender greater protection than the current TB vaccine, BCG, with 
protein subunit vaccines. Although we were able to alter the immune response, and interestingly 
did so by only changing the routes or timing of vaccination, the vaccine strategies that we tested 
did not significantly improve protection above traditional BCG vaccination (Chapter 4). Initial 
results of homologous subunit vaccination suggested targeting the mucosal airways by aerosol 
vaccination may recruit lymphocytes to the airways and lead to less inflammation after Mtb 
challenge. However, when NHPs were vaccinated by BCG prime and heterologous aerosol 
subunit boosts, there were few protective benefits, with slightly increased inflammation, bacterial 
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loads, and disease pathology in aerosol boost-vaccinated NHPs compared to BCG-vaccinated 
NHPs. Additional testing of a novel vaccination strategy of simultaneous priming with BCG and 
a subunit vaccine before further subunit boosting demonstrated few benefits of simultaneous 
prime vaccinations. Instead, the NHPs that received BCG-only prime followed by subunit boosts 
did the best among the experimental vaccination groups. These NHPs also had similar to slightly 
improved protection compared to BCG-vaccinated NHPs, with slightly less inflammation, more 
stable lung granuloma numbers, and slightly lower lung bacterial burdens. Ultimately, these 
different vaccination strategies suggested that the subunit vaccines H56 and H74 with the 
liposomal adjuvants we tested, CAF01 and CAF09, did not boost much immune protection 
beyond BCG alone, although the granuloma T cell responses were different depending on the 
vaccination strategy.  
Additional boost vaccination could have resulted in minimal additional protection for a 
variety of reasons. The vaccination routes tested may not have been effective. We primarily 
targeted the lymph node priming by the simultaneous BCG-subunit vaccination and the mucosal 
airways by aerosol vaccination, but other vaccination strategies may be more effective, such as 
intravenous administration, which has shown increased protection of BCG [252-254]. The 
combination of subunit vaccine and adjuvant may not have been optimal, and may have not 
targeted the “right” immune response for protection. Current strategies design vaccines to elicit T 
cell responses, but because the correlates of protection for TB have not yet been identified, these 
T cell responses may not be sufficient to create a protective immune response to TB. Likewise, 
subunit vaccines may not be creating memory T cell responses to the necessary Mtb antigens 
[209]. 
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Although this dissertation did not identify a vaccination strategy that could improve the 
current BCG vaccine, it challenges the benefits of aerosol vaccination and simultaneous priming 
of BCG with a subunit vaccine. It has demonstrated the difficulty in designing and optimizing an 
effective subunit vaccine for TB, and the complexity in improving BCG despite its deficiencies. 
More positively, the differential T cell responses under various vaccination strategies establishes 
that vaccinations can alter the immune response in TB granulomas, and may eventually improve 
understanding of the protective T cell responses necessary in the local environment of Mtb. 
5.3 FUTURE DIRECTIONS IN TB RESEARCH 
This dissertation highlighted the difficulty in pinpointing a single modulator of T cell responses 
or correlate of protection within TB granulomas. TB is an intricate disease with many moving 
parts, and TB granulomas are dynamic structures that involve many different cell types and are 
heterogeneous in nature. Studying granulomas within NHPs, which are heterogeneous with 
complex immune systems, further complicate matters. However, because of their similarity to 
human disease, the ability to track TB disease from the moment of infection, and the ability to 
analyze the individual granulomas, NHPs are an accessible and accurate representation of the 
elaborate local response to Mtb in humans. Beyond the complexities of the host immune 
response to Mtb, the bacteria can also exert its own pressures on the immune response. 
Understanding the interactions between Mtb and host will continue to be a pressing question. 
The results from this dissertation confirm that the protective immune response to Mtb infection is 
not simple and likely cannot be reduced to a single factor. 
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How can we build upon the results presented in this dissertation? Although these data 
demonstrated IL-10 does not have a significant role in the outcome of pathology and bacterial 
load early in Mtb infection, it had transient effects on the immune response in the granulomas. 
To understand the role of IL-10 during the course of Mtb infection, future studies should 
investigate whether the role of IL-10 may change depending on the stage of Mtb infection and 
whether the observed early effects of IL-10 may change disease outcome during longer 
infections. This work has also described the low frequencies of T cell exhaustion in TB 
granulomas. Although there may be conditions in which T cell exhaustion may occur during Mtb 
infections, these data suggest that it is not a common or critical component of TB granuloma 
outcomes. Until further evidence of high levels of functionally exhausted T cells in the 
granulomas of TB patients, it may be reasonable to consider alternate modulators of T cell 
responses in TB granulomas. Namely, the inhibitory cytokine TGF- was outside of the scope of 
this dissertation, but as a main mechanism of regulatory T cells to modulate immune responses, 
it may have additional regulatory effects on the immune response in TB granulomas. In this 
study, another anti-inflammatory cytokine, IL-13, was also observed to increase TB granulomas 
in the absence of IL-10, which may contribute to the observed increased fibrosis and warrants 
further investigation. Other factors that may modulate other immune cells in addition to T cells, 
such as mesenchymal stem cells and myeloid-derived suppressor cells, may also be critical in the 
immune response during Mtb infections.  
Furthermore, this study investigated the roles of IL-10 and T cell exhaustion within Mtb 
infection separately. However, IL-10 and T cell exhaustion have been shown to be associated in 
other disease models, and concurrent targeting during experimental immunotherapies are 
increasingly recognized to have synergistic effects. As previously mentioned, the host response 
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to TB is complex, and the modulation of the immune response is not likely by a single 
modulator. Thus, despite the results of this dissertation suggesting the low individual 
contributions of IL-10 and T cell exhaustion to the control of TB, future studies should still 
investigate the synergistic effects of these factors, and of the other previously suggested immune 
modulators. While the research in this dissertation indicates few benefits of treating with anti-IL-
10 or anti-inhibitory receptor therapies, it does not eliminate the potential of combinatorial 
therapies to enhance the effects of antibiotic treatments. 
Finally, the absence of protection observed after testing multiple vaccination strategies 
using subunit proteins as a boost to BCG reminds us that producing a vaccine or vaccination 
strategy for a complicated disease like TB, which has evolved with the human immune system 
for millennia, will take much more research and innovation. Besides designing a vaccine to 
better elicit a protective immune response, future vaccination research will also need to optimize 
delivery strategies and consider vaccine/adjuvant combinations, prime/boost combinations, and 
routes of vaccination. The results of this study also demonstrated that despite the problems with 
BCG, it continues to confer some level of protection, supporting its continued use as 
improvements are researched. Boosting BCG with a protein subunit vaccine in a liposomal 
adjuvant such as those tested in this dissertation may not provide sufficient lasting immune 
responses to protect from Mtb challenge. Although the liposomal adjuvant was designed and 
tested to create a vaccine depot, slower clearance of a live vaccine, such as BCG or a viral 
vector, may be necessary to create a sustained or larger immune response against Mtb. However, 
since these experimental boost vaccination strategies were able to increase the T cell cytokine 
response within TB granulomas without improving the granuloma or overall disease outcomes, 
this suggests that more research into understanding the correlates of protection for TB is still 
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needed. The cytokines classically associated with improved disease outcomes, such as IFN- and 
TNF, may continue to be critical for control of Mtb, but are likely not sufficient for complete 
protection from Mtb. In order to identify these factors that may improve host outcomes during 
Mtb infection, future studies should continue to dissect the immune responses of hosts protected 
vs. unprotected from Mtb and granulomas that are sterile vs. nonsterile. With improvements in 
techniques for multi-parameter immune research down to even a single cell from a TB 
granuloma, the identification of the correlates of protection and protective balance of Mtb-
specific immune response may be possible in future research. 
Much work remains to be done, but I expect that the results of this dissertation will help 
move the field of TB research forward by focusing the understanding of potential significant 
modulators of T cell response in TB granulomas away from IL-10 or T cell exhaustion. This 
study also establishes the ability of vaccination routes and strategies to affect the local immune 
response during Mtb challenge, suggesting important considerations during future TB vaccine 
studies. I am confident that these dissertation results, when combined with the results of the 
many ongoing TB studies around the world, will help to one day identify the correlates of 
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